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Evidence suggests that engagement in care (EIC) may be worse in young people with perinatal HIV 
(PHIV) than in adults or children living with HIV. However, there is no consensus on how best to 
measure EIC; and most studies use a simplistic definition based on number of clinic visits attended 
per year and examine limited predictors of EIC.  
In this thesis, I took an existing EIC algorithm for adults living with HIV in England, and adapted it 
to young people with PHIV in the Adolescent and Adults Living with Perinatal HIV cohort (AALPHI), 
using data from 2013-2015. A wide range of potential predictors of EIC from the AALPHI dataset 
were explored in logistic regression models (allowing for clustered data). Predictors of EIC 
identified in the quantitative analysis were then explored in focus groups with young people with 
PHIV to help contextualise the findings and to explore if they resonated with the experiences of 
young people themselves. 
Of 3,585 months of total follow-up in 306 young people, 3,126 (87%) person-months were 
classified as engaged in care. Multivariable predictors associated with poorer odds of being 
engaged in care were: baseline viral load >50c/mL vs. viral load ≤50c/mL; Asian/mixed ethnicity 
vs. black ethnicity; ever self-harmed vs. not; self-assessed adherence as bad/not so good/not on 
ART vs. good/excellent. Findings from the focus groups support and expand the quantitative 
results. Young people described actively choosing when to and when not to attend clinic 
depending on what they thought their viral load was or to hide non-adherence and self-harm.  
My adapted algorithm provides a more sensitive method to measure EIC in young people with 
PHIV. Identifying which young people are less likely to engage in care may allow targeted 
interventions to support young people to attend clinic and optimise their health outcomes. 
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Chapter 1. Introduction 
Engagement in care (EIC) is increasingly being recognised as a crucial step in improving the 
outcomes of patients with human immunodeficiency virus (HIV) (1–4) and lowering healthcare 
costs (4) and is therefore a desirable public health goal. Between 2000-2015, people living with 
HIV aged 10-19 years were the only age group whose mortality increased.(5,6)  Therefore, 
improving engagement in care in this group, and health outcomes, is a priority.  
This thesis describes my doctoral work on EIC in young people with perinatal HIV (PHIV), in which 
I took both quantitative and qualitative approaches.  The quantitative data for this analysis was 
from the Adolescents and Adults Living with Perinatal HIV (AALPHI) cohort. AALPHI was a 
prospective cohort study of young people with PHIV, and HIV negative but HIV-affected young 
people, and it investigated the impact of life-long antiretroviral therapy (ART) on a range of health 
areas. The rich dataset available in AALPHI enabled me to investigate a wide range of exposures 
potentially affecting EIC. Given some of the unique difficulties many young people in this 
population subgroup face compared to other young people in the UK, it is crucial these factors are 
taken into consideration when examining EIC. Having access to data from the AALPHI study has 
therefore been a key strength of my approach. 
I complemented these quantitative data by employing a qualitative approach, with the aim being 
to examine EIC in young people through qualitative understanding of the cohort themselves. 
Combining the quantitative results from the rich AALPHI dataset with qualitative research has 
ensured that the thesis is focused on the young people themselves and provides contextual 
analysis to the findings.  
In this chapter, to set the scene for the focus of my PhD, I give overviews of: 
• HIV clinical science and antiretroviral therapy  
• the clinical epidemiology of HIV in children 
• survival into adolescence and transition to adult care 
• complexities of clinical management of young people with perinatal HIV  
• engagement in care, 
all with a focus on high and high middle income countries. 
I then introduce: 
• the data sources for my PhD 
• the aim and objectives of my PhD 
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• the thesis overview and structure 
• my role as the PhD candidate 
• ethics and funding.   
EIC in young people is not reviewed in detail here as it is the focus of the literature review. 
 HIV clinical science and epidemiology 
HIV was first identified it the early 1980s when small clusters of previously healthy men started 
presenting with rare infections such as Pneumocystis carinii pneumonia (now known as 
Pneumocystis jirovecii)  and Karposi sarcoma in the USA.(7,8) These initial cases were noteworthy 
due to the rarity of the infections, that they only occurred in men who had sex with men, and 
because mortality was so high. In the following months, cases began to be reported in other 
population groups such as people who inject drugs,(9) blood product recipients (10) and 
children.(11) 
HIV is a retrovirus that is transmissible through blood and other bodily fluids, and modes of 
acquisition include sexual contact, parenternally, perinatally or through breast milk. All 
retroviruses need a host cell in order to replicate, and in the case of HIV, these are primarily CD4 
lymphocyte cells, also called CD4 cells. These CD4 cells are an essential part of the immune system 
coordinating the body’s response to infection. Once HIV integrates itself into the host CD4 cell, 
the virus then uses the CD4 cell to replicate more copies of HIV and eventually causes the 
destruction of the host CD4 cell.(12)  
The natural history of HIV in adults is shown in Figure 1.1. Not long after primary infection,  




there is a rapid rise in HIV plasma viremia during which individuals can have a seroconversion 
illness (acute HIV syndrome) with flu-like symptoms.(14) During this time, viral reservoirs are also 
established. This is when HIV infects cells that are more stable and inactive compared with the 
main replicating virus.(15) After the initial peak in which the viral load (the term used to describe 
the number of copies of HIV per millilitre of blood, copies/mL) can rise to over 1 million copies/mL, 
the viral load slowly declines to a steady set point probably after specific antibody has 
developed.(14) This period of ‘clinical latency’ can last for a number of years, and is generally 
characterised by asymptomatic disease. However, over time, there is a steady depletion of CD4 
cells, weakening the individual’s immune system and leaving them susceptible to infections.(16)  
Once the CD4 cell count drops to <200 cells/µL, opportunistic infections (such as Pneumocystis 
jirovecii pneumonia, cerebral toxoplasmosis, cryptosporidium/microsporidial diarrhoea, 
oesophageal candidiasis) or HIV malignancies (Kaposi sarcoma, aggressive B-cell non-Hodgkin 
lymphoma, and cervical cancer) can develop.(16,17)   
For adults and children, CD4 cell counts and plasma viral load are used as markers of the 
effectiveness of ART. CD4 cell count is used as an indicator of the risk of developing acquired 
immune deficiency syndrome (AIDS) defining illnesses. (16,18,19) The amount of virus in the 
plasma is not only a contributing factor to CD4 cell decline,(16) but it is also an independent 
predictor of morbidity and mortality.(20)  The goal of all antiretroviral therapy is to reduce the HIV 
viral load to a level at which it is ’undetectable’ on an assay measurement. A viral load is commonly 
considered to be undetectable when it is ≤50 copies/mL (c/mL), despite recent developments that 
mean many current assays used are more sensitive and can detect virus below this cut-off.  
This reduction in viral load and subsequent CD4 cell count improvement is achieved with 
combination ART (cART). ART is used to prevent the replication of HIV in the CD4 cell and reduce 
the amount of virus circulating in the blood. Although ART can reduce the virus in the blood, viral 
reservoirs are more persistent and so ART therapy cannot cure HIV.(15) However, the reduction 
in viral load to ≤50c/mL delays disease progression by preventing further damage to the immune 
system and allowing immune reconstitution. It also prevents transmission of the virus to other 
people.(21) 
There are now 30 HIV treatments in six major drug classes. Different HIV drug classes prevent viral 
replication at different stages of the replication cycle. The first drug to be licensed by the US Food 
and Drug Administration (FDA) in 1987 was zidovudine, from the nucleoside reverse transcriptase 
inhibitors (NRTIs) class.(22) Zidovudine works by inhibiting the synthesis of viral RNA to DNA by 
blocking the reverse transcriptase enzyme. Zidovudine was initially given as monotherapy, and 
soon after other NRTIs were developed, enabling dual therapy, which was more effective at 
27 
 
suppressing virus. However, despite initial optimism it soon became apparent that monotherapy 
and dual therapy were insufficient. Due to high viral replication, HIV has a high rate of genetic 
error and subsequent high genetic heterogeneity. The virus responds to the host environment and 
selects the quasispecies that can dominate and survive. Therefore, a sufficiently potent drug 
combination is required to quickly stop replication so that the virus cannot mutate and select a 
strain that can survive in the presence of those drugs, thus causing drug resistance.(23)  
The development of two new classes of drugs, protease inhibitors (PIs) and non-nucleotide 
reverse transcriptase inhibitors (NNRTIs) in the late 1990s meant that potent combinations of ART 
were available, now called “cART”. Initial combinations included a backbone of two NRTI drugs 
with a choice of third agent from the PI or NNRTI drug classes. Three more classes of drugs have 
been developed in recent years: entry inhibitors (EIs); integrase inhibitors (IIs); and CCR5 
inhibitors. More recent guidelines still recommend an NRTI backbone, and the preferred third 
agent is now either an II,  boosted PI or NNRTI, for adults and children.(24–27)   
The initiation of treatment was previously based on immunological and clinical criteria. Then in 
2013 findings from the Children with HIV Early Antiretroviral Therapy (CHER) trial in South Africa 
(28) of infants with HIV changed HIV treatment guidelines, and now rapid initiation of cART is 
recommended for all infants and children at diagnosis.  Following this, in 2015, treatment 
guidelines for adults worldwide were changed based on the results of the Strategic Timing of 
AntiRetroviral Treatment (START) and the Early Antiretroviral Treatment and/or Early Isoniazid 
Prophylaxis Against Tuberculosis in HIV-infected Adults (TEMPRANO ANRS 12136) trials.  These 
established that there were substantial benefits to starting cART immediately after diagnosis 
rather than based on immune markers.(29,30)  Due to these advances in the treatment of HIV, 
adults who start ART with a CD4 >350 cells/µL have a life expectancy similar to that of the general 
population.(31)  
There are three main paediatric HIV guidelines used globally. The Paediatric European Network 
for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection are used in 
Europe;(27,32) the U.S. Department of Health and Human Services Guidelines for Use of 
Antiretroviral Agents in Pediatric HIV Infection are used in the USA;(26) and World Health 
Organization Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and 




Table 1.1: Licensed antiretroviral drugs in 2020 
Drug class Drug Year of 
approval 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)   
NRTIs inhibit the synthesis of viral RNA 
to DNA by blocking the reverse 
transcriptase enzyme 
Zidovudine (AZT) 1987 
Didanosine (ddI) 1991 
Zalcitabine (ddC) 1992 
Stavudine (D4T) 1994 
Lamivudine (3TC) 1995 
Abacavir (ABC) 1998 
Tenofovir disoproxil fumarate 
(TDF) 
2001 
Emtricitabine (FTC) 2003 
Tenofovir alafanamide fumerate 
(TAF) 
2016 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)  
NNRTIs inhibit the synthesis of viral RNA 
to DNA by binding to and altering the 
reverse transcriptase enzyme  
Nevirapine (NVP) 1996 
Efavirenz (EFV) 1998 
Etravirine (ETR) 2008 
Rilpivirine  2011 
Doravirine (DOR) 2018 
Protease inhibitors (PIs)   
PIs bind to the vial protease enzyme 
preventing the processing of viral 
proteins  
Saquinavir hard gel (SQV) 1995 
Indinavir (IDV) 1996 
Ritonavir (RTV) 1996 
Saquinavir soft gel (SQV) 1997 
Nelfinavir (NFV) 1997 
Amprenavir 1999 
Lopinavir/ritonavir (LPV/r) 2000 
Atazanavir (ATZ) 2003 
Fosamprenavir  2003 
Tipranavir (TPV) 2005 
Darunavir (DRV)  2007 
Entry inhibitors (EIs)   
Entry inhibitors block HIV from entering 
the CD4 cells of the immune system. 
Enfuvirtide (T20) 2003 
Integrase inhibitors (IIs)   
Integrase inhibitors bind to the viral 
enzyme integrase, interfering with the 
incorporation of reverse-transcribed 
HIV DNA into the host cell 
Raltegravir (RAL) 2007 
Dolutegravir (DTG) 2013 
CCR5 inhibitor s   
CCR5 inhibitors prevent the entry of HIV 






 Clinical epidemiology of HIV in children  
1.2.1. Clinical epidemiology of HIV in children in low and middle income countries 
In 2019, the global total number of children living with HIV aged 0-14 years of age was estimated 
to be 1.8 million.(34) The vast majority of children and young people with HIV are living in low-
and middle-income countries, with 88% in sub-Saharan Africa.  
The predominant mode of HIV acquisition for most children is vertical transmission either in utero, 
intrapartum or through breastfeeding.  Without ART, the risk of HIV vertical transmission is 
between 15-30%, with an additional risk of 10-25% from breastfeeding, depending on 
duration.(35) The roll out of ART to pregnant and breastfeeding women living with HIV has seen 
the global annual number of children with HIV halve since 2010.(36). However, there were still an 
estimated 150,000 new annual infections in children in 2019.(34) 
Disease progression is much more rapid in children than adults. In sub-Saharan Africa around 50% 
of infants who acquire HIV perinatally and 25% of infants who acquire HIV during breastfeeding 
will die before the age of two years if they do not receive ART.(37) Mortality can be reduced by 
75% if cART is started in the first three months of life, making early diagnosis and timely initiation 
of ART in infants crucial.(38,39) 
Due to this very high mortality risk in infancy and childhood, prevention of vertical transmission 
of HIV has been a focus of many global health programmes.  In 2011, the Global Plan Towards the 
Elimination of New HIV Infections was launched, and included the goals to eliminate new 
infections in children to <5% in countries where women breastfeed, and <2% in countries where 
women do not breastfeed, and focusing efforts on 22 countries that together accounted for 90% 
of new paediatric infections.(40) In the 2015 Progress Report on the Global Plan,(41) it was 
reported that there was a 48% decrease in the number of new HIV infections in children between 
2009-2014, compared to a decrease of 13% between 2000-2008. However, although vertical 
transmission fell from 28% in 2009 to 15% in 2014, this was still much higher than the goal of <5%.  
A recent Joint United Nations Programme on HIV/AIDS (UNAIDS) review of 56 countries, which 
together accounted for 87.5% of the global burden of HIV, and 87% of new infections, compared 
vertical transmission in higher prevalence (≥4.5%) and lower prevalence (<4.5%) countries.(42) 
Vertical transmission rates were higher in countries classified as low prevalence compared to high 
prevalence. Many high prevalence countries have been the focus of targeted support, which may 
account for their greater reductions.  
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In 2019, only 53% of the estimated 1.8 million infants and children aged 0-14 years of age living 
with HIV were diagnosed and on cART.(34) A major problem for children with HIV globally, and 
especially in low and middle income countries, is the research and development time lag for 
paediatric formulations compared to adults.(43,44) For infants under two years of age, only a 
quarter of the antiretroviral products approved by the FDA or European Medicines Agency (EMA) 
for adults are available for children.(44)  
Treatment in children is more complicated than in adults because children are continually 
growing, and their metabolism changing, and therefore dosage needs regular revision. Children 
also need to take ART for longer than adults. Historically there were huge problems with the 
palatability of ART and practical issues for families who had to carry large quantities of liquids for 
long distances, if they lived far away from their HIV clinic.(36) Improvements in drug formulations 
have been made more recently, with some fixed dosed tablet and dispersible sprinkles 
formulations becoming more commonly, which facilitates transportation, storage and 
administration.(36)  
Overall, annual HIV related deaths in children have fallen from 300,000 in 2000 to 95,000 in 2019,  
largely due to prevention of vertical transmission.(45) However the burden of HIV remains 
significant and globally HIV is the 14th cause of Disability Adjusted Life Years (DALY, the sum of 
years of potential life lost due to premature mortality and the years of productive life lost due to 
disability) in children aged 0-9 years.(46) Furthermore, estimates of both infant diagnosis and the 
number of infants and children on ART fall short of the UNAIDS 90-90-90 treatment targets for 
2020 that aimed to achieve 90% of people living with HIV to be aware of their status, 90% of all 
diagnosed people to be on ART and 90% people on ART to be virally suppressed.(47) Although 
there have been many successes in the fight against HIV for infants and children, infant diagnosis 
and access to ART among infants and children remains a huge challenge in low and middle income 
countries.  
1.2.2. Clinical epidemiology of HIV in children in high income countries 
Prevention of vertical transmission of HIV has been a success story in Europe, and in 2018, less 
than 1% of new infections were due to vertical transmission.(48) In the UK, vertical transmission 
rates have continued to fall and by 2015-2016 had declined to 0.28% among a total of 20,111 live 
births (Figure 1.2).(49) In the USA, vertical transmission has declined from 2.6 per 100,000 in 2010 
to 1.3 per 100,000 in 2015.(50) However, this varies by ethnicity, with 5.4 per 100,000 in 
black/African American women to 0.4 per 100,000 in white women.  
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Figure 1.2: Vertical transmission in UK/Ireland, 2000-2016(49) 
 
Early studies from Europe and the USA described substantial health improvements following the 
introduction of cART regimens in children living with HIV. In 2001, the Pediatric AIDS Clinical Trials 
Group Protocol 219 (PACTG 219) cohort reported findings from 1,028 children and young people 
with perinatal HIV (PHIV) aged <20 years, of whom 73% were receiving cART. There was a 67% 
reduction in mortality irrespective of sociodemographic factors or CD4 cell count. Similarly, in 
2003, an analysis from the CHIPS cohort in the UK reported on health outcomes of 944 children, 
with median age 5.7 (range 0.0-18.6) years. Since the introduction of cART mortality had fallen 
80%, progression to AIDS 50%, and hospital admission 80%.(51) 
Long-term trends in mortality and AIDS defining events have also been investigated in cohorts in 
high income countries.  A pooled analysis of 3,526 children and young people from Europe and 
Thailand,(52) all of whom had initiated cART, reported outcomes a median of 5.6 (2.9, 8.7) years 
after cART start. Although mortality rates initially declined rapidly when cART was introduced in 
1996, since 2006 mortality rates remained low but unchanged. Five year survival was 97.6%, 
however mortality rates for 0-14 year old PHIV living in Europe were 3-12 times higher than in the 
general European paediatric population. Half of the deaths (46%) occurred in the first 6 months 
of commencing cART, highlighting the importance of early diagnosis and timely cART 
initiation.(52) 
1.2.3. Epidemiology of HIV in children in the UK 
In the UK, children diagnosed with PHIV are followed throughout paediatric care in the 
Collaborative HIV Paediatric Study (CHIPS), a cohort with almost complete national coverage. To 
the end of March 2020, 2,210 children had been reported to CHIPS.(53) Of the 547 children and 
young people still alive and in active follow-up in 2020, half (57%) were female, 52% were born in 
the UK or Ireland, and 74% were black African.(54) In total, 124 children were known to have died 
32 
 
(104 prior to 2008) and 1,324 (60%) had left paediatric care and transitioned to adult care.(53) In 
the UK, almost all children and young people with perinatal HIV initially receive their HIV care in 
paediatric HIV services and then transition to adult HIV services (adolescent-specific or HIV in 
Genitourinary Medicine (GUM)) at a median age of 17 years.(55)  
Of children with follow-up data available since January 2018 (n=514), 1% were ART naive, all of 
whom were ≥10 years of age, 97% were on a ≥3 drug regimen of whom 78% were on a fixed dose 
combination, and 47% were on an integrase-based regimen. Immunologically, 80% had a CD4% 
≥25% and 81% had a viral load <50c/mL.(54) 
 Survival into adolescence and transition to adult care 
The availability and extensive use of ART and success in the prevention of vertical transmission in 
high income countries has changed the epidemiology of paediatric HIV, with increasing numbers 
of children with perinatal HIV surviving in to adolescence and young adulthood.(56) This has 
resulted in an ageing paediatric cohort with more than half of the perinatal HIV population now 
in adolescence and transitioning to adult care.(54,57,58) However, transition to adult care is a 
vulnerable time for young people with HIV, who are not only transferring their healthcare but also 
becoming young adults. Rapid brain development that occurs during adolescence is characterised 
by considerable behavioural and psychosocial change.(59,60) This dynamic process is especially 
challenging due to the substantial social and economic transformations young people experience 
in the same period as they transition from childhood to adulthood.(60,61)  
There is now considerable recognition at a global policy level of the importance of investment and 
support in young people in order for them to achieve their full potential in adulthood.(62–64) 
Ensuring that young people are appropriately supported during adolescence is crucial to 
encourage the establishment of good habits of self-management that underpin health and 
wellbeing in adulthood in general,(62,65) but even more so when they are growing up with a 
chronic condition such as HIV. Long-term follow up in this vulnerable group is crucial but 
hampered by a number of factors. Very few national surveillance studies exist and of the studies 
that do exist, they do not always span paediatric as well as adult care, or stratify data by age or 
mode of HIV acquisition.(5) These programmatic changes are essential steps to facilitate 
monitoring of outcomes for young people, so that appropriate interventions and support can then 
be put in place to help them thrive into adulthood.(5) 
33 
 
 Complexities of clinical management of young people with PHIV 
Increased survival of children with PHIV has changed the nature of problems faced by this group 
as they age.  New and interrelated issues result from complications of long-term management of 
HIV, as well as psychosocial factors. 
1.4.1. HIV-related clinical outcomes 
Studies from the USA and Europe have found that as children with PHIV age into adulthood, they 
are at increased risk of unsuppressed viral load and immunosuppression,(66) with CD4 declining 
even before transition to adult care.(67)  Associated with this, while the incidence of HIV-related 
opportunistic and bacterial infections has generally declined in the cART era, non-infectious 
conditions related to long-term HIV and cART have emerged in young people. Metabolic 
complications (dyslipidaemia and insulin resistance) and changes in fat distribution (lipoatrophy 
and lipohypertrophy) associated with ART toxicities have been reported in children and young 
people with PHIV on cART.(32,68) 
There is increasing evidence that like adults, children with HIV experience ongoing immune 
activation even when fully suppressed on cART.(32) Although it is not clear what the consequences 
of this will be long-term, there are concerns that it may result in cardiovascular risk, 
neuroinflammation and increased risk of malignancy in adulthood.(32,69) Chronic bone disease is 
also an increased risk in children with PHIV, possibly resulting in premature osteoporosis and 
fractures. It is thought that this risk is from ART toxicities (in particular TDF) and low grade immune 
activation(69). Chronic renal disease risk is increased in children with PHIV even without 
traditional risks such as hypertension and type 2 diabetes.(68,69) Chronic renal disease has been 
associated with TDF use and some protease inhibitors but HIV-induced immune activation may 
also play a part. As children with PHIV  transition to adolescence it is essential that they continue 
to be monitored for risks of non-communicable diseases, comorbidities and complications.(69)  
There is growing awareness of the increasing number of deaths in young people with PHIV.  Data 
from the PACTG 219C and International Maternal Pediatric Adolescent AIDS Clinical Trials Network 
(IMPAACT) P1074 cohorts in the USA were combined to assess the effect of long-term cART on 
young people with HIV (87% PHIV) between 2004 -2007.(70) In total 1,201 young people were 
included in the analysis with a mean age of 20.9 (SD 5.4) years at last interview. Although mortality 
in this time period was lower than in the pre-cART era, excess mortality remained at 31.5 times 
that of the USA general population, and similar findings have been reported in other studies from 
the USA and the UK.(66,71)  While HIV associated opportunistic infections were uncommon, most 
deaths (86%) remained HIV related. Deaths were associated with poor HIV control and were more 
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likely to occur in older patients who were off cART with a lower CD4 cell count and higher viral 
load.(70)  
1.4.2. Family 
Growing up with PHIV is different to many other chronic conditions because of the 
multigenerational context, with a child with HIV usually having acquired it from their mother. This 
can pose problems around the stigma of both horizontal and vertical transmission within the 
family,(72) and it also means that children may grow up in a household with parents who have 
previously been unwell or are still suffering physical or mental health disabilities and/or ill-health 
related to HIV.(73,74) Furthermore, many young people have experienced the death of one or 
both parents, and subsequent multiple transitions between different carers.(75,76) In the USA, 
many children living with PHIV are born into families affected by parental psychiatric and 
substance abuse disorder, violence and neighbourhood disruption;(73,77,78) in contrast, children 
in Europe are commonly from ethnic minority migrant families, some with immigration concerns, 
and often residing in disadvantaged areas.(32) 
1.4.3. HIV naming, stigma, secrecy, and onward disclosure  
HIV naming to children (the first step in a process in which a child is told that they have HIV) is 
recognised as a process that occurs overtime. Recommendations on how this is carried out have 
also changed over time. When paediatric HIV was first discovered, children had very high 
morbidity and mortality, and parents/carers and healthcare staff were understandably concerned 
about talking to children about their HIV.(79) In addition, many children were too young to engage 
in discussion about HIV, so conversations were delayed until they were older. However, since 
prognosis in children living with HIV has improved, the importance of knowing their HIV status has 
changed, and the focus around HIV naming is now framed around a child’s right to know their 
status.(80) In light of these developments, it is now advised that children are given accurate 
information about their health from an early age, and that this knowledge is incrementally built 
upon so that HIV is named when children are of school age (defined as between 6 and 12).(81) 
In the past, many parents/carers had an understandable but misplaced concern that HIV 
disclosure would cause distress in their child.(81,82) Parents/carers also reported feeling ill-
equipped for the consequences of naming HIV to their child, and in some instances also revealing 
their own HIV status, and this led to a desire to delay the disclosure process.(82–84) However, 
there is little evidence of harm from talking to children and naming HIV.(81) Furthermore, delayed 
disclosure has also been associated with negative psychological consequences for young people; 
when asked about HIV disclosure, some report  that they were already aware that they had HIV 
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before it was named; others may construct their own narratives in the absence of open 
discussion.(80,85,86)    
Unfortunately, the complexities of HIV disclosure and stigma often continue beyond the naming 
of HIV. Children and young people’s experience of stigma within their family and the wider world 
is unique because it is experienced through silence.(87) Following disclosure of their HIV diagnosis, 
there is often very limited discussion of HIV within the family.(80) Attempts to ask questions about 
HIV can be closed down and conversations limited to medicalised talk around ART and previous 
illness stories, which are used to incentivise treatment adherence.(88,89) Children and young 
people therefore may experience HIV naming as a single event rather than an ongoing supportive 
process.  
As young people move into adolescence and young adulthood, it can be very challenging for them 
to negotiate independent friendships and sexual relationships. Young people with PHIV may go to 
great lengths to keep their diagnosis secret.(90,91) Onward disclosure could have a number of 
potential benefits such as improved adherence, more frequent condom use, and improved 
wellbeing.(92)  However, there are also barriers to onward disclosure. One of the concerns for 
young people when considering onward disclosure of HIV status is the risk of inadvertently 
revealing their mother’s or the wider family’s HIV status at the same time, and equally they may 
also face resistance about disclosing their status to others from their parents.(91) Young people 
also may choose to continue to keep their HIV status a secret for fear of isolation and rejection 
from peer groups and partners.(91) 
In the AALPHI cohort in the UK, of 261 young people with PHIV with a median age of 16 [IQR 15, 
18] years, 22% of the participants had told no one about their HIV and 31% had only told one or 
two people.(93) In a study from the USA examining sexual risk behaviour in young people with 
PHIV, of 67 active young people with information about their disclosure to sexual partners, 33% 
told their first partner their HIV status.(94)  
1.4.4. Adherence to ART 
Children face decades, if not a lifetime of taking cART. Adherence to these medications poses 
multiple challenges for young people. Adherence to cART may be complicated by young people’s 
lack of autonomy and importance of the child-caregiver relationship for their medication 
adherence.(95)  Suboptimal adherence in adolescence is not a unique problem to HIV and there 
are reports that adherence declines during adolescence across other chronic infections.(90,96,97) 
However, adherence in young people with PHIV is even more complex with research suggesting a 
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complicated interplay of individual,(93,98,99) familial,(73,74) structural (100) and ART (90,93,99) 
related factors. 
Despite the discrepancy in adherence prevalence, a number of studies have consistently reported 
lower adherence in young people compared to adults and children (99,101–103) which is 
particularly concerning due to the extra years of treatment young people with PHIV face. A recent 
study analysed 1,190 self-reported adherence questionnaires completed by 379 young people 
aged 8-22 years, with a median of 3.3 years follow-up.(99) Prevalence of adherence declined with 
age with 69% adherence in 8-12 year olds and 50% in 18-22 year olds (p=<0.001).  
An important aspect of adherence that emerges from qualitative studies is around patient 
experiences of managing long term ART and dialogue about adherence to ART in the clinic 
environment. In two large longitudinal qualitative studies, 147 children and young people with 
PHIV were interviewed as part of two large clinical trials. The interviews took place with children 
from Uganda, Zimbabwe, the UK and the USA.(104) Young people reported being frustrated about 
how little recognition there was from healthcare staff about the complexity of taking medication.  
When young people did report missed doses they were often scolded, and they felt that 
adherence was presented to them as a ‘choice’.  Consequently, young people described that they 
often withheld information about missed doses. This then results in lost opportunities for advice 
and support to be given to young people to help overcome adherence problems. An 
acknowledgment of how HIV disrupts adolescence is needed to provide young people with 
appropriate support.(104,105) 
1.4.5. Mental health 
Young people with PHIV may face an increased burden of mental health problems compared to 
other adolescents due to the complex mix of psychosocial issues and biomedical factors already 
described. Despite the reduction in severe cognitive complications since the advent of cART, many 
children may still experience mild cognitive deficits that can affect their quality of life, social 
relations and educational and employment outcomes.(106,107) Most of the earlier research 
examining mental health was from larger studies in the USA. There is a large range in prevalence 
of mental health issues reported across the studies, between 25-70%.(78,108–111) This broad 
range is likely to be due to between-study variation, with different ages at which young people 
were recruited, differences in scales used to measure different aspects of mental health problems, 
and differences in the person completing the assessment (young person or child vs caregiver). 
Studies predominantly found higher prevalence of mental health problems in young people with 
PHIV than the general population or other vulnerable populations, but similar levels to HIV 
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negative but HIV affected comparators.(73,109,111–113) Additionally, many studies’ findings 
highlighted the important effect of contextual factors, such as age, gender, cognitive function, 
parent physical and mental health, and life stressors, on mental health, rather than HIV clinical 
factors such as viral load and CD4.(109,113–115) 
However, it is important to note that many of these studies may include the first generation of 
survivors of PHIV who may be more likely have complex treatment histories. Furthermore, many 
of these studies have been carried out in the USA, where young people are exposed to different 
socioeconomic problems, such as parental drug use,(116) and with very different health and 
support provision compared to Europe and the UK.  
 Engagement in HIV care 
1.5.1. Importance of engagement in care  
As has been shown, cART has substantially improved mortality and morbidity in adults and 
children living with PHIV.  However, for these benefits to be realised, people need to first be 
diagnosed with HIV, and secondly engaged in care. These steps form the first part of most HIV 
cascades of care. The cascade of care is a tool used for local, national and international 
benchmarking of treatment progress, tracking the sequential stages of healthcare that people 
with HIV need to go through between diagnosis of HIV and achievement of viral suppression.(117) 
Studies have found increased viral suppression and improved CD4 cell count in patients who have 
higher EIC.(118,119) Similarly missed visits have been associated with higher viral load.(120) In 
addition, studies have found that transmission of HIV is more frequent in people who are not 
engaged in care,(121) and higher EIC has been associated with lower healthcare costs.(4,122,123) 
While younger children and older adults with HIV continue to see improved mortality on the cART 
era, young people are the only age group to be experiencing increasing HIV mortality.(5,119,124–
132) A number of studies have found that young people have worse EIC when compared to adults 
and children.(118,133,134) A UK population study of 72,218 adults with HIV, including an 
undefined number of young people with PHIV, examined loss to follow-up in patients attending 
adult HIV services. Patients most likely to lost to follow-up, defined as no further follow-up or 
presence of a death certificate, were black African, aged 15-34 years, not on ART, and having 
acquired HIV outside the UK.(135) In a study of 87,146 people living with HIV from all age groups 
in New York, a u-shaped relationship between age and EIC was shown, with young people aged 
20-29 years with the lowest EIC across the whole age spectrum.(133) 
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Thus, EIC results add to the evidence that young people living with HIV should be considered a 
vulnerable group. Findings point to the need for investment in research and interventions, to find 
sustainable ways of improving EIC in this group, to that they can fully benefit from HIV treatment 
programs.   
1.5.2. Definition of engagement in care 
Measuring EIC is complex, and there is no standard definition of this indicator, resulting in EIC 
being measured differently across different studies. The most common EIC measures are 
appointment adherence, gaps in care, visit constancy (visits at define intervals), and hybrids of 
these methods.(136–138) However, there is huge inconsistency in these definitions, in terms of 
the types of visits to be considered as either missed or attended (e.g. appointments with the 
doctor, nurse, psychologist or phlebotomist), the minimum amount of time considered between 
appointments (e.g. 1 visit in 6 months or 1 visit in 1 year).(136) There is also no consensus on what 
level of EIC is good enough, and further research is needed to understand the relationship 
between different EIC thresholds and clinical outcomes.(132) Ultimately, many methodological 
decisions when measuring EIC are pragmatic and based on the clinical and appointment 
information available to researchers. However, as this relatively new area of research continues 
to develop, greater consensus in definitions will help build a more robust evidence base. Further 
review of engagement in care definitions and papers is the focus of my literature review in Chapter 
2. 
 Data sources for my PhD 
In this section, I detail the quantitative data sources for this thesis. Data from two UK based HIV 
cohorts were used in this analysis: 
• the Collaborative HIV Paediatric Study (CHIPS) 
• the Adolescents and Adults Living with Perinatal HIV (AALPHI) cohort  
The majority of the data used for this PhD thesis has come from the AALPHI study. However, I will 
first present an overview of paediatric surveillance in the UK (the CHIPS study) to better 
contextualise the AALPHI study. Both the AALPHI and CHIPS studies are coordinated at the Medical 
Research Council (MRC) Clinical Trials Unit at University College London (UCL). 
1.6.1. Collaborative HIV Paediatric Study (CHIPS) 
CHIPS, which started in April 2000, and is the national surveillance system for paediatric HIV in the 
UK and Ireland and includes all children diagnosed with HIV in the UK. There are very few national 
cohorts of children living with perinatal HIV globally.(5) Two important factors facilitated CHIPS 
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gaining complete national coverage. Firstly, when CHIPS was set up there were concerns that if 
consent were sought to collect data there could be serious ascertainment bias undermining the 
understanding of PHIV at a population level, particularly as it relates to vulnerable groups. 
Therefore, CHIPS was given ethics approval, and subsequently, PHE Regulation 3 approval1 to 
collect and process patient identifiable information without consent.  
Secondly, CHIPS is possible due to the existence of the UK’s National Health Service that facilitates 
national surveillance in many disease areas. CHIPS is also unique because it benefits from a long 
duration of follow-up.  
The main objectives of CHIPS are to describe clinical, laboratory and treatment outcomes for 
children with PHIV. All children diagnosed with HIV or born to women living with HIV in the UK are 
reported to the Integrated Screening Outcomes Surveillance Service (ISOSS) either via obstetric or 
paediatric reporting schemes. All PHIV children and young people are then followed through 
paediatric care in the CHIPS study (Figure 1.3). 
Figure 1.3: Reporting and surveillance of infants born to women living with HIV and children 
with PHIV in the UK 
 
 
1 Patient data are collected under legal permissions granted to PHE under Regulation 3 of The Health Service 
(Control of Patient Information) Regulations 2002). The PHE Caldicott Advisory Panel has granted CHIPS 
permission to process patient identifiable information without consent (PHE reference CAP-EX-2019-04). 
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Following reporting of a new diagnosis of HIV in a child from ISOSS to CHIPS, baseline forms are 
sent to the reporting clinic and prospective follow-up forms are then sent on an annual basis until 
the patient leaves paediatric care. All data are abstracted from the medical notes onto a form by 
trained clinical staff.  There are currently 37 study sites actively providing data to the study across 
England, Scotland, Wales, and Northern Ireland.  
The inclusion criteria are as follows: 
• Diagnosed with HIV 
• Receiving care in England, Scotland, Wales, or Northern Ireland 
• Receiving care in a paediatric HIV clinic aged <16 years 
CHIPS forms include the data item shown in Table 1.2. All data are extracted from patient notes 
by clinic staff. 
Table 1.2: CHIPS data items 
Category Data collected 
Demographic Sex, DOB, partial postcode 
Clinical data  
 
CDC B or C events, inpatient stays, hepatitis B and C co-
infection tests, immune function (CD4 / total lymphocytes), 
HIV viral load, medication adverse events, clinician-reported 
lipodystrophy, lipids (cholesterol, triglycerides, HDL/LDL) 
ART details  ART drug, doses, and frequency, start and stop dates, reasons 
for change in ART, and ART-associated serious adverse events 
(grade 2 or above)  
Sexual health Date of menarche and pregnancy details 
Physical assessments Blood pressure, height/weight 
HIV resistance Date of request for resistance testing 
Clinic details Clinic attended, name of paediatrician, hospital number, last 
date seen, shared care details 
 
1.6.2. Adolescents and Adults Living with Perinatal HIV (AALPHI) cohort 
AALPHI was a prospective cohort study which commenced in 2012. AALPHI was set up to answer 
a number of broader questions about the outcomes of young people living with PHIV, including 
the cognitive and psychosocial effects of having life-long HIV and long-term exposure to ART to 
improve the evidence base in this area.  AALPHI recruited two groups of young people, PHIV, and 
an HIV negative but HIV-affected comparison group. Having an appropriate comparison group is 
important because young people growing up in families affected by HIV are likely have different 
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psychosocial and socioeconomic experiences compared to families from not affected by HIV.  For 
AALPHI this was relevant as the study aimed to ascertain whether any additional ill health in the 
HIV positive group was due to having HIV, versus background factors. 
A wide range of data were collected to describe the impact of life-long HIV and long-term ART on 
the following domains: cognitive function and psychosocial issues; cardiac function; metabolic 
function; sexual and reproductive health; and body composition.  The aim was for findings to 
inform HIV treatment and care strategies for this group in the UK. At the time that AALPHI was set 
up, the only other large study including both PHIV young people and HIV negative young people 
was in the USA.(139)  
The AALPHI inclusion criteria are listed in Table 1.3: 
Table 1.3: AALPHI inclusion criteria 
Young people living with PHIV HIV negative young people 
• Aged 13-21 years • Aged 13-23 years 
• Previously or currently receiving 
paediatric care in England  
• Aware of their HIV status for at least 6 
months 
 
• HIV negative on a point-of-care test at 
the interview and aware of HIV in the 
family for at least 6 months 
• Living in the same household as a 
PHIV participant or having an HIV 
positive parent, sibling, friend or 
partner 
• In UK for > 6 months 
• Able to give informed consent/assent 
• Able to understand English 
• Willing to give a blood sample 
• In UK for > 6 months 
• Able to give informed consent/assent 
• Able to understand English 
 
 
AALPHI was coordinated by research nurses with a background in either paediatric or adult HIV. A 
psychologist trained the research nurses in cognitive testing techniques before carrying out 
interviews and recap sessions were held where any problems could be discussed at regular 
intervals throughout the study.  
Participants were recruited from 16 NHS paediatric and adult HIV clinics and six voluntary sector 
organisations. Thirteen of the clinics and organisations were located in London and nine outside 
London. The NHS clinics were selected because they had the largest numbers of PHIV young 
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people attending from across England. Voluntary sector organisations were selected based on 
providing services for both PHIV young people and HIV negative young people affected by HIV.  
Interviews took around two hours to complete and study participants were given vouchers to 
compensate for their time (£30).  Interviews were conducted in a wide range of settings, including 
NHS clinics, voluntary sector organisations, participants’ homes, and the study’s offices, and at a 
variety of different times, including evenings and weekends.  
Two interviews were conducted over 5 years. Details are only presented here for the first 
interview because data from the second interview were not used in this thesis. 
The AALPHI interviews comprised of: 
- face-to-face structured questions  
- cognitive computer and paper tests 
- computer-assisted self-interviewing (CASI) questions  
- physical assessments  
- rapid HIV diagnostic test for HIV negative participants 
- blood samples.  
Sensitive questions, including questions on sexual health, drug and alcohol use and mental health, 
were completed by the young people themselves using CASI, and other questions were completed 
face-to-face. One of the main components of the interview in both years was cognitive testing 
which was carried out using a combination of online and paper assessments. In addition to data 
collected in the interviews, clinical data were abstracted for all young people living with PHIV in 
AALPHI who had left paediatric care and thus were no longer in CHIPS. This data abstraction was 
carried out by clinic nurses and AALPHI research nurses. Table 1.4 describes the data collected and 




Table 1.4: Data collected in interview 1 
Category Data collected Data collection 
method 
Demographic Sex, age, country of birth, language spoken at home, ethnicity Face-to-face 
structured 
questions  
Social factors Marital status, number of children, 
accommodation/living circumstances, 
parent/carers’ employment, biological parents’ country of 
residence and vital status, contact with social service/youth 
offenders/education system, education history, employment 




Medical history Prematurity, birth weight, medical history, 
non-ART medications, bone fracture history, 




Quality of life 
and mental 
health 
Pediatric Quality of Life Inventory (PedsQL)TM,(140) 
communication with family, Rosenberg Self-esteem 
Scale,(141) self-harm and suicidal ideation (adapted from the 
Avon Longitudinal Study of Parents and Children (ALSPAC), 
(142) Hospital Anxiety and Depression Scale (HADS),(143) 
psychology / mental health service contacts, major life events 





The Alcohol Use Disorders Identification Test (AUDIT),(145) 




Body image satisfaction (from the Manchester Quality of Life 
Instrument),(146) referral for anorexia/obesity, tanner self-
assessment, menstrual pattern/history, HPV and HBV 
vaccination history, sexual health history, contraception use, 





Age told HIV status, how told and by whom, feelings about 





Frequency of medicines, missed doses, self-assessment of 
adherence, reasons for any missed doses 
CASI 
Cognition Executive function (CogState(147) and Color Trails Test 
(148)), speed of information processing (CogState(147) and 
Color Trails Test(148)), attention/ working memory 
(CogState(147) and Wechsler Adult Intelligence Scale – 
Fourth Edition(149)), learning (CogState(147)), memory 





Samples EDTA plasma, SST serum, Lithium heparin plasma 
HIV negative only: HIV point of care test 
Research nurse 
or clinic nurse1 
Physical 
assessments 
Blood pressure, height/weight measurements, hip/waist 
measurements, face changes  
Research Nurse 
assessment 
Clinical data  
(PHIV who were 
in adult care 
only) 
CDC B or C events, inpatient stays, hepatitis B and C co-
infection test results, immune function (CD4 / CD8 / total 
lymphocytes), HIV viral load results, medication adverse 




1 The research nurse always carried out the HIV point of care test but blood tests where possible were carried out at the same time as 




Data from paper case report forms (CRFs) were entered onto a secure database and 10% checks 
were conducted on all entered data. Data from the CASI and cognition tests were stored on 
separate secure databases and regular data downloads were accessed by the study statistician. 
The study statistician created data analysis files combing all the data on a regular basis. Further 
checks were carried out on these analysis files.   
 Aim and objectives of my PhD 
The aim of this doctoral project was to describe engagement in HIV care in young people with 
perinatal HIV in England and to assess whether psychosocial factors predicted engagement in care.  
Specific objectives were: 
• To develop a sensitive measure of EIC in order to take into account changes over time in 
treatment and health status for young people with perinatal HIV in England 
• To apply the measure to describe EIC in young people with perinatal HIV in England 
through quantitative analysis of the AALPHI cohort dataset 
• To describe the characteristics of AALPHI participants  
• To compare findings from analysis of AALPHI participants’ data to the national HIV cohort 
or the wider general population where comparisons are available 
• To investigate the relationship between a broad range of potential exposures and EIC in 
AALPHI participants, through quantitative analysis 
• To take the results from the quantitative analyses, and explore them through focus group 
discussions with young people with PHIV 
• To assess the whether the quantitative results of this study resonated with young peoples’ 
own experiences and to enhance our understanding of them. 
In this thesis, I hypothesised that psychosocial issues were more important in influencing EIC than 
clinical aspects of living with HIV. Therefore, gaining views of young people living with PHIV 
gathered via both the AALPHI study and the qualitative data collection methods are a pertinent 
component of understanding the psychosocial dimensions of EIC.  
 Thesis overview and structure 
In this thesis, I used an epidemiological and sociological, mixed methods approach to answer my 
aim and objectives. This thesis has seven chapters. The first two chapters, the introduction and 
the literature review, follow the normal structure of a PhD. Chapters 3, 5 and 6 are structured so 
that each chapter has distinct introduction, methods, results and discussion sections. This 
structure was chosen due to the discrete nature of the sections of analysis, but also to aid 
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publishing post-submission. Chapter 4 is also a discrete chapter, however the format is slightly 
different. The introduction and methods are presented and then the results and discussion are 
presented together for eight specified domains of exposure variables. The overall discussion 
therefore pulls together the discussions from the preceding chapters. Below is an overview of the 
chapters in the thesis. 
In Chapter 2, I review the literature to date on EIC in young people living with perinatal HIV in high 
and high middle income settings. In the identified papers, I describe how EIC is measured, 
summarise prevalence across the studies and describe any predictors, facilitators or barriers of 
EIC.   
In Chapter 3, I present the quantitative methods used to adapt an existing algorithm by Howarth 
et al (151) that measured EIC in adults with HIV in the UK for use in young people with PHIV. The 
resultant flowcharts where then used to measure EIC using data on 306 young people with PHIV 
in the UK based Adolescents and Adults Living with Perinatal HIV (AALPHI) cohort study. 
In Chapter 4, I present the quantitative methods by which the potential risk factors were derived. 
I then report analysis results of the potential risk factors using descriptive statistics and compare 
the findings to data from relevant studies and populations to contextualise the AALPHI cohort.  
In Chapter 5, I take the exposure variables assembled and described in Chapter 4 and the EIC 
outcome variable detailed in Chapter 3 and put them together to investigate whether the 
exposure variables predict EIC in multivariable methods. I first describe the statistical methods 
outlining the multiple stages of variable investigation and the four stages of multivariable logistic 
regression modelling. Then in the results, I present descriptive results for each exposure variable 
within each of the domains and the four stages of multivariable logistic regression analyses 
examining the effect of the variables on the EIC outcome of EIC.  
In Chapter 6, I present qualitative findings from focus groups discussions with young people with 
PHIV. There were two main topics. The first topic was use of clinical markers as a proxy for clinic 
visit attendance in the flowcharts. I explored with young people their reasons for clinic visits and 
regularity of tests and measurements to analyse the strengths and limitations of using clinical 
markers as proxies in the flowcharts. The second topic was the quantitative exposure variables 
found to be associated with EIC. I presented and discussed these with young people to elucidate 




In Chapter 7, I summarise the key findings from each of my results chapters. I then offer some 
concluding remarks, which encompass a description of my findings’ relevance, the main strengths 
and limitations of my work and its generalisability. Finally, I explore future possible uses for the 
EIC flowcharts and for improvements to EIC. 
In November 2020, I presented the findings from Chapter 5 in a poster at the International 
Workshop on HIV Pediatrics. After submission of the thesis, I plan to publish papers from Chapter 
3, Chapter 5 and Chapter 6.  
 My role as the PhD candidate 
I am a paediatric HIV nurse with over 20 years of clinical and research experience working with 
children, young people and families living with HIV. I am currently a Research Fellow at the MRC 
Clinical Trials Unit and the co-ordinator of the CHIPS cohort. I first joined the MRC Clinical Trials 
Unit in 2011 to work on the AALPHI cohort. My role on AALPHI was to coordinate the study, lead 
the development of the study interviews, organise the research nurse training and carry out 
participant interviews. I undertook an MSC in Medical Anthropology in 2002, however this PhD 
study is my first training in epidemiology. 
For the purposes of this thesis, I was responsible for the overall design of the doctoral project, and 
for the methods and analysis of the quantitative data. I am also responsible for the methods, data 
collection and analysis of the qualitative data. 
 Ethics 
This thesis was approved by the East Midlands – Leicester Central Health Research Authority as a 
sub study of AALPHI and has university ethics approval from the London School of Hygiene and 
Tropical Medicine. 
 Funding  
I received a Medical Research Council studentship to carry out this part-time PhD. In addition, I 




Chapter 2. Literature review 
 Introduction 
In this chapter, I review the literature to date on EIC in young people living with PHIV in high and 
high middle income settings. In the identified papers, I describe how EIC is measured, summarise 
prevalence across the studies and describe any predictors, facilitators or barriers of EIC.   
 Methods 
For the literature review, the following inclusion criteria were used: 
• Written in English language 
• Containing original research findings 
• Published from 2000 onwards  
• Originating from high and upper-middle income countries (based on the World Bank 
country classification by income level list (152)) 
• Describing measures of EIC (as opposed to loss to follow-up or missed appointments) 
• >50% of study population including young people aged 13-24 years with PHIV, or, where 
young people were <50% of the study population, EIC estimates (proportion EIC or 
predictors of EIC) were stratified by mode of HIV acquisition. 
Although review papers were excluded, their reference lists were scanned for additional relevant 
papers. Papers were only included from 2000 onwards because issues affecting EIC were likely to 
be very different in the pre-ART era. Papers were restricted to those describing high income and 
upper-middle income settings. This is because the model of healthcare and resources available 
are very different in many lower and lower-middle income countries.  In those settings, young 
people with HIV often attend appointments in large primary care clinics, while in contrast in many 
upper-middle and high income countries (including young people in my study), the majority of 
young people attend specialist paediatric or adolescent clinics although some older young people 
do attend generic adult HIV clinics.(58) Papers that were measuring loss to follow-up or missed 
appointments were not included as these outcomes are different to my outcome which is engaged 
in care. Finally, ideally I would have only included papers where all participants had PHIV, 
however, there were only a small number of such papers so the definition was widened to include 




In a few papers, the mode of HIV acquisition was not specified, most probably because the data 
were not available. In these instances, proxy markers for perinatal HIV status were used. Papers 
were included if age at diagnosis (or age at recruitment into a study) was <13 years,(153) or, as in 
one paper,(154) issues that are specific to PHIV, for example knowledge of HIV status, were 
discussed and included as variables in the analysis.  
PubMed was the only search tool employed for the review of published papers, and search terms 
are listed in Table 2.1. Search terms were built by reviewing the titles of existing collated papers 
on EIC for relevant terms.  Additionally, abstracts from relevant HIV conferences were searched 
using the terms “retention” and “engagement”. Abstracts from the previous three years were 
searched for the following conferences: International Workshop on HIV Pediatrics (2017, 2018 and 
2019) and the alternating International AIDS Conference (2018 only as 2020 abstracts were not 
yet available for when the literature review was conducted) and International AIDS Society 
Conference on HIV Science (2017 only as 2019 abstracts were not yet available). 
The findings of the review were organised thematically into three key areas: methods to measure 
EIC; prevalence of EIC; and predictors, barriers and facilitators associated with EIC. In the third 
theme, variables included in the study analysis were grouped into domains to aid comparison. 
Domains and example variables were: Sociodemographic (age, ethnicity, rural/urban, 
socioeconomic status); risk behaviour practices (alcohol and substance abuse); mental health 
(internalisation); clinic (youth friendliness); HIV experience and management (discrimination, time 
to linkage); and HIV markers (HIV acquisition, viral load, CD4 count, calendar year of diagnosis, 
AIDS diagnosis and ART). 
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Table 2.1: PubMed search terms 
Search terms 
(HIV[TI] OR "Acquired immunodeficiency syndrome"[TI] OR AIDS[TI] OR "human immunodeficiency"[TI] OR hiv[MH] OR "acquired 
immunodeficiency syndrome"[MH]) 
AND 
("lost to follow up"[MH] OR "retention in care"[MH] OR retain*[TI] OR retention[TI] OR engag*[TI] OR continuum[TI] OR cascade[TI] OR 
attend*[TI] OR "loss to follow up"[TI] OR "lost to follow up"[TI] OR “losses to follow up[TI]” OR attrition[TI] OR "patient engagement"[TI] OR 
"self-management"[TI] OR disengage*[TI]) 
AND 
(adolescent[MH] OR pediatrics[MH] OR child[MH] OR "young adult"[MH] OR paediatr*[TI] OR pediatr*[TI] OR adolescen*[TI] OR child*[TI] OR 




(Nigeria*[TI] OR Zimbabwe[TI] OR Rwanda[TI]  OR India[TI] OR sub Sahara*[TI] OR Uganda*[TI] OR Kenya*[TI] OR Zambia[TI] OR Tanzania[TI] 
OR South Africa[TI] OR Southern Africa[TI] OR Mozambique[TI] OR Malawi[TI] OR Ethiopia[TI] OR Botswana[TI] OR Indonesia[TI] OR East 





Seven hundred and six papers were initially identified in the literature search (Figure 1). 
Following screening of the titles and abstracts, 136 papers remained for full paper review. Of 
the full papers reviewed, 103 were excluded because they did not contain participants who 
had PHIV, and 22 were excluded for other reasons, leaving a total of 11 papers for inclusion. 
A further six papers were identified from the references of included papers or from the 









2.3.1. Summary of included papers 
Table 2.2 summarises key characteristics of the 17 eligible papers. All of the papers were 
published in the last five years. Three papers were from Europe,(155–157) with one from 
each of the UK,(155) Italy (157) and Romania.(156) Five papers were from sub-Saharan 
Africa,(153,154,158–160) of which four were from South Africa (153,158–160) and one from 
Namibia.(154) Nine papers were from North America,(123,161–168) of which eight were 
from the USA.(123,161–166,168) Fifteen of the papers used quantitative methods (123,153–
158,161–168) and two qualitative.(159,160) The number of patients in the papers ranged 
from 24 to 9,562. All of the papers included estimates of EIC of which 16 (123,153–162,164–
168) were specifically for young people living with PHIV. Ten papers conducted modelling 
and presented predictors associated with EIC, or presented barriers and facilitators from 




Table 2.2: Summary of 17 papers included  












of EIC (Y/N) 
PHIV-specific 
predictors/barriers 
or facilitators of EIC 
(Y/N) 
Europe      
Chappell, 2019 
(155) 
UK Quantitative n=905 (100%) Y -1 
Gingaras, 2019 
(156) 
Romania Quantitative n=545 (100%) Y Y 
Izzo, 2018 (157) Italy Quantitative n=24 (100%) Y - 
Sub-Saharan Africa      
Davies, 2017 (153) South 
Africa 
Quantitative n=460 (90%) Y - 
Munyayi, 2020 
(154) 
Namibia Quantitative n=385 (100%) Y - 
Pantelic 2020 (158) South 
Africa 
Quantitative n=1,059 (79%) Y Y 
Zanoni, 2018 (159) South 
Africa 
Qualitative n=28 (100%) Y Y 
Zanoni, 2020 (160) South 
Africa 
Qualitative n=59 (100%) y Y 
North America      
Gebrezgi, 2019 
(161) 
USA Quantitative n=2,872 (28%) Y N 
Gray, 2019 (162) USA Quantitative n=9,562 
(100%) 
Y Y 
Griffith, 2019 (168) USA Quantitative n=89 (57%) Y Y 
Hussen, 2017 (163) USA Quantitative n=72 (15%) N N 
Kakkar, 2016  Canada Quantitative n=25 (100%) Y - 
Lee, 2016 (164) USA Quantitative n=680 (35%) Y N 
Ryscavage, 2016 
(165) 







USA Quantitative n=124 (100%) Y Y 
Xia, 2016 (123) USA Quantitative n=1,535 
(100%) 
Y - 
1  “-“: no predictors/barriers or facilitators associated with EIC were presented in these papers 
2.3.2. Measures of engagement in care 
There was wide variability in the definitions of EIC used in the literature. Across 17 papers, 
there were eight different definitions used with one paper (157) stating no definition at all 
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(Table 2.3). Almost all of the studies used an EIC measure that combined appointment 
constancy and gap in care.(1) The three most commonly used definitions were ≥1 clinic visit 
within six months, which was used in four papers (159,160,166,167), ≥1 clinic visit within one 
year, which was also used in four papers (123,155,162) and ≥2 visits with ≥3 months apart 
within one year which was used in five papers.(123,162–164,168) Two studies, one from the 
USA and one from South Africa measured EIC using ≥2 clinic visits within one year, with ≥1 
clinic visit in each six month.(153,165) In addition, two papers (123,162) from the USA used 
both ≥1 clinic visit within one year and ≥2 visits with ≥3 months apart within one year. One 
paper from Europe measured EIC longitudinally in person months.(156) Four of the eight 
definitions were used by only one paper each.(154,156,158,161) None of the papers 
considered different follow-up appointment times for patients based on their clinical status. 
Of the eight different definitions of EIC used across the 16 papers, three definitions measured 
EIC with ≥1 clinic visit, four used multiple visits, one was a longitudinal measure and one 
measured self-reported appointment attendance combined with self-reported adherence. 
Three of the definitions were broadly comparable because they all measured two or more 
visits within one year (≥2 visits with ≥30 days apart within one year, ≥2 visits with ≥6 months 
apart within one year, and ≥2 visits within one year with ≥1 visit in each six months). 
However, apart from this example, the definitions were too variable to compare, such as ≥1 
clinic visit in 24 months and ≥1 clinic visits in six months. It is important to note that despite 
the fact that all of the papers had longitudinal data, measuring visits over time, all but 
Gingaras et al (156), measured EIC as prevalence in a given period, usually a calendar year, 
following classical cascade of care approaches. Two thirds of the papers (6/9) from North 
America justified or referenced their choice of measure based on national guidelines or 
recommendations.(123,163–166,168) Four of these papers used the same measure 
(123,163,164,168) while the other two papers used easily comparable measures.(165,166)  
Outside of North America, the only paper to reference their choice of EIC definition across 
Europe and sub-Saharan Africa was Pantelic et al (158), who followed WHO 




Table 2.3: Summary of engagement in care definitions and proportion of participants engaged in care 
EIC definition Author, Year 
(country)reference 
Time period  No. of 
visits  
Start point of EIC 
period  
N (% PHIV) EIC prevalence 
≥1 clinic visit definition      
≥1 visit in 6 months 
Tassiopoulos, 2019  
(USA)(166) 
6 months ≥1 6 months prior to 
participant 
interview 
124 (100%) 80% 
Zanoni, 2018  
(South Africa)(159) 
6 months ≥1 6 months prior to 
participant 
interview 
41 (100%) 98% 
Zanoni, 2020  
(South Africa)(160) 
6 months ≥1 6 months prior to 
participant 
interview 
28 total (16 adolescent 
clinic, 12 paediatric) 
(100%) 
94% adolescent clinic 
83% paediatric clinic 
Kakkar, 2016  
(Canada)(167) 
6 months ≥1 6 months prior to 
participant 
interview 
25 (100%) 76% 




1 year ≥1  Calendar year  9,562 (100%) Overall 73% 
13-17 80%, 18-25 73% 
Xia, 2016 (USA)(123) 1 year ≥1 & ≥2 Calendar year 1,596 (100%) Overall 96%  
99% aged 13-19 years 
95% aged 20-29 years 
Chappell, 2019 
(UK)(155) 
1 year ≥1 Calendar year  905 (100%) 98% 




2 years ≥1 Within 2 year 
study period 
385 (100%) 
(78 in intervention) 
91% in intervention vs. 90% 
in SOC 
Multiple visit definition      
≥2 clinic visits with 
≥30 days apart 
within 1 year 
Gebrezgi, 2019 
(USA)(161) 
1 year ≥2 Calendar year 2,872 (28%) Overall 65% (73% 
perinatal) 
85% in 13-17 years 
82% in 18-20 years 
61% in 21-24 years 
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EIC definition Author, Year 
(country)reference 
Time period  No. of 
visits  
Start point of EIC 
period  
N (% PHIV) EIC prevalence 
≥2 clinic visits with 
≥3 months apart 
within 1 year 
Gray, 2019 
(USA)(162) 
1 year ≥2 Calendar year  9,562 (100%) Overall 61% 
68% in 13-17 years 
57% in 18-25 years 
Xia, 2016 (USA)(123) 1 year ≥1 & ≥2 Calendar year 1,535 (100%) Overall 80%  
89% in 13-19 years 
76% in 20-29 years 
Lee, 2016 (USA)(164) 1 year ≥2 Calendar year  680 (35%) 85% of total (93% of 
perinatal) 
94% in 15-19 years 
82% in 20-24 years 
Griffith, 2019 
(USA)(168) 
1 year ≥2 1 year post 
transition 
89  (57%) 89% of total 
Hussen, 2017 
(USA)(163) 
1 year ≥2 Pre transition, 1 




93% last year of paediatrics  
Post transition to adult 
care: 
89% 1st year, 56% 2nd year 
(p= <0.001)  
≥2 clinic visits within 
1 year, with ≥1 clinic 
visit in each 6 month 
Davies, 2017  
(South Africa)(153) 
1 year ≥2 1, 2, and 3 years 
post transfer 
460 (90%) Post transfer: 90% 1st year, 
88% 2nd year post, 84% 3rd 
year post 
1st year: 93% 10-14, 81% 
15-19 
2nd year: 90% 10-14, 85% 
15-19 
3rd year: 85% 10-14, 85% 
15-19 
Ryscavage, 2016  
(USA)(165) 
1 year ≥2 Year post linkage 
to adult care 
50 pre transition (35%) 
43 post transition (37%) 
50% of total at 1st year post 
transition, 60% of perinatal 
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EIC definition Author, Year 
(country)reference 
Time period  No. of 
visits  
Start point of EIC 
period  
N (% PHIV) EIC prevalence 
Other definitions       
Attended all clinic 
visits within last 
year & >85% 
adherence 
Pantelic, 2020 (South 
Africa)(158) 
1 year All visits Calendar year 
(baseline and 
follow-up) 
1,059 baseline (79%) 38%  over 2 years 
Total months 
engaged in care 
Gingaras, 2019 
(Romania)(156) 
Longitudinal  ≥1 visit 
previous 
year 
Previous year at 
ages 15, 20, 25 
545 (100%) 4,775 person-years,  
92% aged 15 years 
84% aged 20 years 
74% aged 25 years 
Not defined Izzo, 2018 (Italy)(157) n/a n/a n/a 24 (100%) 80% 
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A key aspect of measurement that complicates comparisons across papers is the starting 
point of the EIC period. A number of papers investigated EIC across a single calendar year 
(123,155,158,161,162,164) and one paper analysed data across two consecutive calendar 
years.(154) Other papers started the EIC period at a particular visit. This was either related 
to the point of transfer to another clinic (153) or from the first appointment (linkage) in adult 
care (163,165,167,168) or a time period prior to an interview date. Finally, one paper 
investigated EIC longitudinally focusing on three specific ages.(156)  
Additionally, the timing of measuring EIC varied across the papers. A number of the papers 
compared EIC pre- or post-transition to adult care. There are additional challenges for young 
people transitioning to a new adult or adolescent clinic that are likely to pose different 
problems to maintaining EIC compared to young people in a stable clinic environment, for 
example leaving their long term paediatric health care provider (170) and issues around 
increased self-management expectations,(171,172). Further complicating comparison, 
young people transition much earlier in Europe, at around 18 years of age, compared to 
young people in the USA who transition by 25 years.(58) In the sub-Saharan African studies, 
many children were seen from diagnosis in a general primary care clinic spanning paediatric 
and adult care.(58,153) However, transfer did occur for some patients who were initiated on 
ART in a specialist paediatric clinic and were then transferred to their local primary care clinic, 
and this largely happened when patients were in their early teens.(153)  
In terms of the way visits were measured, six (154,157,164,165,167,168) gave no 
information, presumably because actual visit dates were recorded in their datasets.  Eight 
papers (123,153,155,156,159–162) used clinic visits or proxy markers (laboratory test, ART 
changes or record of a pharamcy refill). Of the remaining three, one paper (163) used 
scheduled appointments as opposed to attended appointments, because attendance was 
not documented. Two papers (158,166) used self-reported attendance, because 
documented attendance and proxy markers were not available, of which one (158) validated 
self-reports in a subset of patients who did have dates for viral load results.  
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2.3.3. Prevalence of engagement in care  
Among the studies measuring EIC, a number measured EIC using a definition of at least one 
clinic visit. Four papers, two using quantitative methods (166,167) and two qualitative 
methods,(159,160) used ≥1 clinic visit within 6 months as their measure, all of which 
measured EIC around the time of transition to adult care (Table 2.3).(159,160,166,167) In the 
largest of these four papers, Tassiopoulos et al (166) investigated young people who were 
either about to transition or had already transitioned to adult care, within an existing 
longitudinal, multisite cohort study across the USA.(166) Of 455 participants, 27% (n=124) 
transitioned to adult care at a mean age of 22 (SD 2.9) years and 80% were engaged in care 
within the six months preceding the study interview (self-reported). Kakkar et al (167) 
approached all young people living with PHIV who had transferred from paediatric to adult 
care within one hospital in Montreal, Canada, between 1999 and 2012. Of 45 patients, 25 
consented to the study. Young people had a mean age of 22 (range 19-25) years, and 
comparably to Tassiopoulos et al (166), 76% remained engaged in care post transition.  
The two papers using qualitative methods were conducted in young people with PHIV in 
different hospitals in Kwa-Zulu Natal in South Africa. In the first paper, Zanoni et al (2018) 
(159) performed in-depth interviews with 12 young people in routine paediatric care and 16 
young people in an adolescent-friendly clinic in a single hospital. In the paediatric clinic, 75% 
of the participants (n=9) were >15 years old and 83% were engaged in care, in the adolescent 
friendly clinic 94% of the participants (n=15) were >15 years old and 95% were engaged in 
care. In the second paper, Zanoni et al (2020) (159) undertook in-depth interviews with 41 
young people living with PHIV prior to transition to adult services in a single centre in to 
explore aspects of care that could improve EIC. Paediatricians identified participants for the 
study based on them being ready to transition to adult care. Across the 41 participants with 
median age of 15 (range 14-16) years, EIC was 98%. Participants in the Tassiopoulos and 
Kakkar papers (166,167) were interviewed outside of the clinic setting which may account 
for the lower EIC than in these two South African papers (159,160) where participants were 
recruited in the clinic setting, so were likely to be a largely treated and engaged population. 
In addition, the two qualitative papers were design to explore why adolescent friendly 
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services had better EIC and what interventions could be put in place to improve EIC, and so 
did not set out to measure EIC as their main purpose.  
All three papers using ≥1 clinic visit within a year as their measure, examined EIC in multiple 
clinics (5,12,17) two of which were national cohorts.(155,162) In the largest of the studies 
and the first of two from the USA, Gray et al (162) analysed data reported to the National 
HIV Surveillance System (NHSS) on all persons diagnosed with PHIV across the USA by the 
end of 2014 and still alive by the end of 2015. Overall, 9,562 young people were included in 
the analyses and the proportion engaged in care was 75%. Patients aged 13-17 years had 
higher EIC (80%) compared to 18-25 year olds (73%). In the second study from the USA, Xia 
et al (123) included 1,596 children and adults living with PHIV in New York City.  Prevalence 
of EIC was 96% overall, 99% in 13-19 year olds, and 95% in 20-29 year olds. Chappell et al 
(155) described prevalence of EIC in children with PHIV in paediatric care across the UK. To 
be included patients had an appointment in the preceding year and were aged ≤21 years. Of 
905 patients with a median age of 14 [IQR 11, 16] years, 98% were engaged in care in 2016.  
Using this definition of at least one clinic visit within one year, two of the studies reported 
EIC to be high at 90% and above.(123,155) In addition, all three of the studies compared EIC 
stratified by age and reported that EIC was higher in young patients.(138,153,162)  
One further paper used a measure with ≥1 clinic visit, but within 24 months as opposed to 
six or 12 months.(154) In this single centre study from Namibia, 385 PHIV young people who 
were aged 10-19 years between 2015 and 2017 were enrolled. Of these, 307 young people 
attended a paediatric clinic and 78 a ‘Teen Club’. No difference was found in EIC between 
these groups (90% vs. 91% respectively, p=0.93), however the young people in the paediatric 
clinic were younger than those in the teen club (44% 15-19 years in the paediatric clinic vs. 
67% in the Teen Club).   
Eight papers measured EIC using multiple visit definitions, (123,153,161–165,168) two of 
which compared these multiple clinic visit measures to a measure of at least one clinic 
visit.(123,162) Unsurprisingly both of these papers reported that EIC was lower using a 
multiple clinic visit definition. Gray et al (162) reported, when using the multiple visit 
measure, 61% of young people living with PHIV were engaged in care, although younger 
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patients aged 13-17 years had higher engagement (68%) when compared to 18-25 year olds 
(57%). Using the less strict definition (≥1 clinic visit) in the same study EIC was 73% overall, 
and 80% in 13-17 year olds and 73% in 18-25 year olds. Likewise in Xia et al’s (123) analysis, 
when using the multiple visit measure, overall EIC was 80% and did not vary by age (13-19 
years old 89%, 20-29 years old 76%). Using the alternative definition of at least once clinic 
visit, EIC was 96% overall, and 99% in 13-19 year olds and 95% in 20-29 year olds. 
Two further papers from the USA examined young people with PHIV alongside young people 
with BHIV and reported that young people with PHIV had higher prevalence of EIC.(161,164) 
Both were large studies, with around a third of patients with PHIV. Lee et al (164) assessed 
the effect of youth friendliness on 680 patients in 15 clinics who had a visit in 2011. Overall 
EIC was high at 85%, but with a potential decline with age (94% 15-19, 82% 20-24). Young 
people living with PHIV had the highest EIC (PHIV 93%, heterosexual 82%, MSM 80%, 
p=<0.001). Likewise, a large analysis by Gebrezgi et al (161) included all young people aged 
13-24 diagnosed across Florida between 1993 and 2014 (n=2,872). EIC declined with age, 
from 85% in those aged 13-17 years, 82% in age 18-20 years and 61% in age 21-24 years.(161) 
Only 28% of the cohort had PHIV, but similarly to Lee et al (164), EIC was highest in this group 
compared to other HIV acquisition categories (PHIV 73%, MSM 66%, PWID 58%, heterosexual 
58%).  
Three of the 8 papers using a multiple visit measure, measured engagement in care in singe 
clinic studies during transition to adult care. Griffith et al (168) examined the electronic 
records of 89 patients (57% PHIV) who had transitioned from one paediatric clinic to two 
adult clinics in Maryland and New York, USA, between 2009 and 2015 (median age BHIV 25 
years, PHIV 22 years). Overall 89% of young people were engaged in care at one year post 
transition. Hussen et al (163) evaluated EIC pre and post transition in 72 patients within a 
single hospital in Georgia, USA. In the year leading up to transition, 95% of young people 
were engaged in care (aged 24 years [IQR 22, 25]) which was slightly higher than 85% of 
young people who were engaged in care at one year post transition. EIC did significantly 
decline from the first to the second year post-transition, from 89% to 56% (p=<0.001). 
However, only 15% of the participants in this study had PHIV and results were not stratified 
by mode of HIV acquisition. The final study using multiple visits to measure EIC around the 
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time of transition was Ryscavage et al (165). In this study EIC in 50 young people (of whom 
35% were PHIV) pre-transfer was compared to 43 different young people (37% PHIV) post 
transition. The study included young people who had attended a single paediatric clinic and 
followed them as they transitioned to three adult clinics in Maryland, USA from 2004 to 2012. 
The median age at transition was 21.8 (range 19.2, 26.9) years in the PHIV group compared 
to 25 (19.1, 28.2) years in the BHIV group. No statistical difference was found between the 
proportion in each of these groups who remained engaged in care (60% vs. 50% 
respectively). 
Finally, Davies et al (153) used multiple visits to measure EIC in a retrospective study 
examining EIC at three time points following transfer of care across four cohort studies in 
Cape Town, South Africa. Transfer in this context is different to transition in Europe and 
North America and was defined as the movement of patients from a tertiary to primary care 
centre. However, in some cases this did coincide with a transition from a usually paediatric 
tertiary care service to an adult primary care service.(153) A total of 460 young people (90% 
PHIV) aged 10-19 years at transfer (72% 10-14 years), on ART, and with a Department of 
Health number, were included. EIC declined with increasing time from transfer, with 90% 
engaged in care one year after transfer, 88% at two years, and 84% after three years. EIC was 
higher at one and two years post-transfer in those aged 10-14 years at transfer, compared 
to 15-19 years olds (year 1: 93% vs. 81%,. year 2: 90% vs. 85%, respectively), but similar at 
three years (85% vs. 84%).  
The stricter definitions of EIC employed in these eight papers (123,153,161–165,168) led to 
lower estimates of EIC prevalence when compared to studies using a measure of at least one 
visit.(123,154–156,159,160,162,166,167) In addition, the two studies that compared EIC 
between young people with PHIV and BHIV reported higher EIC in those with PHIV.(161,164) 
Furthermore, two studies measured EIC post transition to adult or primary services and both 
reported EIC declined with time post transfer.(153,163) Finally, all five papers that measured 
EIC by age,(123,153,161,162,164) report decreasing EIC with older age. Two of these studies 
had already show this pattern using an alternative EIC measure.(123,162)  
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Finally three of the 17 papers reviewed used alternative ways of measuring EIC, of which one 
was not defined. In a large study from sub-Saharan Africa, Pantelic et al (158) measured EIC 
in young people aged 10-19 years (79% PHIV) who had ever initiated ART treatment across 
53 clinics (n=1,059). EIC was measured as a combination of self-reported attendance at all 
clinic visits within the last year as well as >85% ART adherence over the last week. Using this 
definition, 37% of young people over 2 years were engaged in care. In the second study, 
Gingaras et al (156) measured EIC longitudinally in 545 patients in a single clinic in Romania 
92% of young people were EIC at 15 years, 84% at 20 years and 74% at 25 years using a 
definition of EIC of at least one visit in the previous year.(156)  
Lastly, Izzo et al (157) describe the characteristics of 24 young people who had transferred 
to adult care at age ≈18 years in a single centre in Italy between 2004 and 2016.  Of these, 
80% were retained in care at the end of follow up, a median of 52 months later, though the 
definition of what constituted “retained in care” was not specified.  
In summary, there was heterogeneity in the way EIC was measured across the 17 papers in 
my review. Eight different definitions were used to measure EIC. Three studies compared 
young people with PHIV and BHIV, (161,164,165) of which two reported that young people 
with PHIV had higher EIC.(161,165) Of five studies that stratified EIC by age, four reported 
that EIC declined with increasing age.(75,123,156,162) Finally, eight studies used a definition 
with at least one measurement over six months,(159,160,166,167) one year (123,155,162) 




2.3.3.1. Predictors, barriers and facilitators associated with engagement in care 
Finally, eight quantitative (156,158,161–164,166,168) and two qualitative papers (159,160) 
identified predictors of, or facilitators and barriers to, EIC (Table 2.4). Across the ten papers, 
exposure variables included could be grouped into six domains: sociodemographic; risk 
behaviour practices; mental health; clinic; HIV experience and management; and HIV 
markers. Here I present study findings first by study and then by domain. 
Only one European study, from Romania, and one Sub-Saharan African paper, from South 
Africa, reported predictors of EIC from quantitative analyses. In Gingaras et al’s (156) analysis 
of EIC in 545 young people with PHIV in a paediatric HIV clinic, included predictors of EIC 
were from the sociodemographic and HIV marker domains. Only viral load and CD4 count 
were associated with disengagement in care. Young people with a viral load ≥400c/mL were 
more likely to be not engaged in care (15.1%) than young people with a viral load <400c/mL 
(10.5%, p=<0.001). In addition, severe immunosuppression was associated with having 
higher proportion of disengagement (not engaged in care: CD4 <200 cells/µL, 15.1%; CD4 
200-349 cells/µL, 15.6%; CD4 350-499 cells/µL, 11.9%; CD4 ≥500 cells/µL, 11.6%, p=<0.001).  
Pantelic et al (158) also reported an association between viral load from the HIV markers 
domain and EIC in their study of 979 young people (79% PHIV) aged 10-19 years of age in the 
Eastern Cape, South Africa. Viral load was not included in the main model, and was instead 
used to validate the self-reported EIC outcome variable in a subset of 514 young people who 
had available viral load data. After adjusting for sociodemographic factors and HIV 
acquisition (HIV marker domain), EIC was associated with lower odds of VL>1000c/mL (OR 
0.37, 95%CI 0.22, 0.61). In the main model, Pantelic et al (158) examined the impact of four 
different types of discrimination (HIV experience and management and clinic domains) and 
internalised HIV stigma (mental health domain) on EIC in young people. These were 
discrimination due to the young person’s HIV status (being teased/losing friends); 
discrimination due to a family members HIV status (being gossiped about or treated badly 
due to a family members HIV status); discrimination by clinic staff (frequency of being 
shouted at by clinic staff). In a multivariable logistic regression model adjusted for 
sociodemographic and HIV markers factors, discrimination in by clinic staff was associated 
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with reduced EIC (OR 0.54, 95%CI 0.37, 0.78) as was internalised stigma (OR 0.81, 95%CI 0.71, 
0.94). 
Six studies from the USA reported predictors of EIC. In the first study, Gebrezgi et al (161) 
investigated the effect of neighbourhood factors on EIC including socioeconomic status, non-
Hispanic black density (a proxy for segregation) and rural/urban status in a population study 
of 2,872 young people in Florida (sociodemographic domain). After adjusting for individual 
and neighbourhood factors, a number of exposures were identified to be associated with 
EIC, from the sociodemographic and HIV markers domains. From the sociodemographic 
domain, males were less likely to be engaged in care than females (PR 0.86, 95%CI 0.79, 
0.93). Those aged 13-17 years had better EIC than 18-20 year olds (PR 0.85, 95%CI 0.78, 0.92) 
and 21-24 year olds (PR 0.74, 95%CI 0.68, 0.80). Young people living in low socioeconomic 
areas had better EIC than young people in higher socioeconomic areas (PR 1.15, 95%CI 1.02, 
1.20). Hispanics were less likely to be engaged in care than people of non-Hispanic white 
ethnicity (PR 0,88, 95%CI 0.81, 0.95) and areas with a high density of people of non-Hispanic 
black ethnicity were less likely to be engaged in care than areas of lower density (PR 0.90, 
95%CI 0.83, 0.98). From the HIV markers domain, calendar year of diagnosis was associated 
with EIC, with young people diagnosed in 2005-2009 being less likely to be engaged in care 
(PR 0.88, 95%CI 0.81, 0.95) than people diagnosed between 2010-2014. Compared to young 
people with heterosexual acquisition of HIV, young people living with PHIV (PR 1.17, 95%CI 
1.03, 1.33) and MSM (PR 1.26, 95%CI 1.15, 1.49) were more likely to be engaged in care. 
Finally, young people who had a previous diagnosis of AIDS (defined as AIDS <2016) were 
more likely to be engaged in care than young people who had not had a previous diagnosis 
of AIDS (PR 1.22, 95%CI 1.16, 1.30). However, young people living with PHIV only made up 
28% of the participants in this study.  
In the second study, Gray et al (162) analysed data from 9,562 young people living with PHIV 
across the USA. . Only variables from the sociodemographic domain were included in the 
analysis. In unadjusted analysis, female participants were more likely to be engaged in care 
than males (PR 1.1, 95%CI 1.1, 1.2). Young people aged 13-17 years had a higher prevalence 
of EIC that 18-25 year olds (prevalence ratio (PR) 1.2, 95%CI 1.1, 1.2). In addition, 
Hispanics/Latinos were more likely to be engaged in care than white participants (PR 1.1, 
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95%CI 1.1, 1.2). Finally, young people born outside the USA were more likely to be engaged 
in care than young people born in the USA (PR, 1.1, 95%CI 1.1, 1.2).   
In their retrospective cohort study of 89 young people living with HIV (57% PHIV) in the USA, 
Griffith et al (168) investigated variables from the sociodemographic, risk behaviour 
practices, mental health and HIV markers domains in an adjusted analysis for EIC.  The only 
variable found to be associated with EIC was HIV acquisition (HIV markers domain).  Young 
people with PHIV were found to be more likely to be engaged in care post transition to adult 
care (OR 14.95, 95%CI 1.38, 161.68 p=0.03) compared to young MSM. 
In the fourth study from the USA, Hussen et al (163) measured EIC in 72 young people post 
transition to adult care. Variables from the sociodemographic, HIV experience and 
management domains and HIV markers were investigated in multivariable models for EIC. 
Increased time between final paediatric and first adult appointment (HIV management and 
experience domain) was reported to be associated with worse engagement in adult care 
after two years (Relative Risk (RR) 0.92, 95%CI 0.85, 0.99, p=0.03 per three month increase). 
Older age at transition from paediatric to adult care was associated with better EIC (Relative 
Risk (RR) 1.16 per year older, 95%CI 1.00, 1.35, p=0.047).  
In Lee et al’s (164) study including 680 15-25 year olds in the USA, clinics were assessed on 
five youth friendly structures (clinic domain) based on the WHO youth friendly framework. 
After adjusting for sociodemographic and HIV marker factors, three of the five youth friendly 
structures were reported to be associated with EIC: youth friendly space (aOR2.47, 95%CI 
1.11, 5.52); evening clinic hours (OR 1.94, 1.13, 3.33); and providers with adolescent training 
(OR 1.98, 95%CI 1.01, 3.86). In addition, Lee et al (164), reported young people who had been 
prescribed ART were more likely to be engaged in care than young people who were not on 
ART (OR 4.96, 95%CI 3.08, 8.01). The model did not include viral load and it is possible that 
ART acted as a proxy for viral load to some extent.  
In the final paper from USA, Tassiopoulos et al (166) compared sociodemographic, HIV 
markers and self-reported perceived social support (mental health domain) and self-
management (HIV experience and management domain) by transition status in 455 young 
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people. Higher perceived social support was associated with higher EIC (OR 1.05, 95%CI 1.01, 
1.10) as was increased ability to self-manage (OR 3.40, 95%CI 1.33, 9.12).   
Two qualitative papers from South Africa reported facilitators and barriers to EIC. Following 
content analysis on data from interviews with 16 young people from the adolescent clinic 
and 12 from the paediatric clinic, Zanoni et al (2018) (159) reported  a number of the barriers 
and facilitators to EIC that were related to clinic environment and clinic staff (clinic domain).  
Young people in the paediatric clinic identified appointments scheduled during the school 
day as a barrier to EIC because young people felt the need to balance their health and 
educational needs. Not only did this put their health at risk, but it also created tension with 
staff that then became an additional barrier to EIC. In addition, participants attending the 
paediatric clinic who reported difficulty disclosing their HIV status to others, felt subsequent 
increased internalised stigma and social isolation both of which were described as decreasing 
EIC. The importance of the timing of clinics was reiterated by young people attending the 
specialist adolescent clinic. They reported that there were several benefits to running after 
school clinics that acted as facilitators to EIC. Not only could young people access the support 
and health benefits of attending clinic more regularly but also it reduced the stigma of 
missing school and the negative impact on schoolwork. Improved EIC provided more regular 
contact with peers providing social support which further improved EIC. In addition, young 
people reported that more regular contact with clinic staff, meant that they developed a 
more positive relationships with the staff in the adolescent clinic compared to the 
relationship they had with the same staff in the paediatric clinic.  
Finally, in the second qualitative paper from South Africa, Zanoni et al (2020) (160) conducted 
in-depth interviews with 41 young people and 18 of their caregivers to identify factors to 
improve EIC prior to transition to adult care. Young people who understood their HIV 
diagnosis at an earlier age (defined as before 12 years of age) described minimal internalized 
stigma and higher self-esteem with a subsequent improvement in EIC. Conversely, young 
people relayed negative consequences for their self-identity when their HIV was disclosed to 
them later, or when others had lied to them or they had a traumatic disclosure. All of these 
factors impacted on their relationships with clinic staff and subsequent EIC. The paper also 
describe a third group of young people who despite carers reporting a full disclosure process, 
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the young people remained in denial about their HIV which compromised their ability to fully 
engage in HIV care. Finally, young people who were orphaned and had frequent changes in 
carers, had reduced support to manage their HIV in general, but specifically in travelling to 
and attending to clinic.  
2.3.3.2. Summary 
Across the ten studies reporting predictors (156,158,161–164,166,168) or facilitators and 
barriers (159,160) to EIC, factors found to be associated with EIC came under five out of the 
six domains (sociodemographic, HIV markers, clinic, HIV experiences and management and 
mental health). Most variables found to be associated with EIC were in the sociodemographic 
and HIV markers domain. There was very little consistency across the 10 papers, with most 
of the variables found to be associated with EIC each being from a single study. Eight 
variables were found by more than one study. Two studies found female sex, younger age, 
and Hispanic/ Latino ethnicity (vs, white young people) from the sociodemographic domain 
to be associated with higher EIC.(161,162) In the mental health domain, reduced internalised 
stigma (158,159) and higher perceived social support.(159,166) In the clinic domain, two 
studies reported that evening clinic appointments helped improved EIC.(159,164) Finally, in 
the HIV markers domain, two studies reported that young people with PHIV were more likely 
to be engaged in care compared to young people with BHIV (161,168) and two studies found 
young people who had an undetectable viral load (<400c/mL) were more likely to be engaged 
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In this literature review, I have summarised the methodology and presented the findings 
from 17 papers on EIC in young people with PHIV in high and high middle income countries. 
All papers were published in the last five years showing the recent recognition of the 
importance of EIC in HIV care. 
There was high variation in estimates of prevalence of EIC across the included studies making 
comparison and generalisation difficult. There are likely to be a number of reasons for this. 
Firstly, high variation in estimates may be largely due to the different definitions used. 
Secondly, comparing young people in the process of transferring to adult care to either young 
people in stable paediatric or adult care is problematic due to the additional complexities of 
transitioning care. Finally, healthcare provision and geographical settings vary hugely across 
the papers. 
The majority of the studies were from the USA, of which most were multicentre studies, 
although despite the studies being multicentre, five of the nine studies had a sample size of 
less than 150 participants each. Of the smaller number of studies from sub-Saharan Africa 
and Europe, most were single centre.  
A wide range of predictors and barriers of EIC were identified, with little consensus between 
studies. The majority of predictors fell into the sociodemographic and HIV markers domains, 
and perhaps unsurprisingly variables from these domains were most commonly included in 
these analyses, as these variables are often available from routine healthcare records. Very 
few studies investigated factors within the risk behaviours, mental health domains and HIV 
experiences and management domains that may have great impact on young people’s EIC. 
As national cohorts, Chappell et al (155) and Gray et al (162) are the two studies that are 
most likely to most accurately capture engagement in care across a population. This is 
because the risk from regional and especially single clinic studies is that patients could be 
erroneously classified as disengaged when they have actually decided to attend an 
alternative HIV clinics, transitioned to adult care or moved out of the area. National cohorts 
should have mechanisms to track these patients and identify such situations. Chappell et al 
(155) reported a much higher prevalence of EIC (98%) in the UK compared to Grey et al (75%) 
in the USA, but there were key methodological differences. To be included in the UK analyses, 
patients had to be in care in the previous year, whereas in the USA analyses, they included 
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all patients diagnosed and alive (through linkage with national mortality records) at the end 
of 2015. In addition, within the Gray et al (162) study, two definitions of EIC were compared, 
and lower prevalence of EIC (61%) was found with a stricter definition. It is therefore hard to 
know whether the differences between the estimates of EIC in the two national cohorts are 
real or not.  
One of the major questions when investigating EIC in young people with PHIV is whether 
young people drop out of care because they have PHIV or because they are adolescents. 
From the literature reviewed in this chapter, it may be that both factors have a role. There 
was the suggestion of a trend of decreasing prevalence of EIC with increasing age across all 
of the studies that stratified EIC by age, including the studies that only included young people 
with PHIV as well as the studies that also included young people with BHIV. Furthermore, 
two studies found age was a predictor of EIC in multivariable analysis, similarly reporting that 
EIC reduced with increasing age.  Additionally, of the four studies that compared EIC between 
young people with PHIV and BHIV, three reported that young people with BHIV had worse 
EIC, two of these in multivariable analyses. The most compelling evidence that both age and 
HIV acquisition are relevant is from Gebrezgi et al.(161) In their large study they measured 
EIC using a multiple visit definition of EIC (≥2 clinic visits with ≥30 days apart within 1 year), 
and in multivariable analysis, found that both younger age and PHIV acquisition of HIV were 
associated with better EIC. However, this is just one study and so needs corroboration from 
further research.     
Another possible limitation of the studies included in this analysis, is that most of the studies 
defined the denominator (for example in care in last year or appointment pre transition), 
and then they followed up the cohort. In these studies, it means that the population at the 
beginning was in care. In addition, none of the studies looked at changes in EIC over time. 
Most studies defined their measure of EIC in response to the data available. Ideally, in a 
cohort of young people, maturing into adulthood and transitioning to adult/adolescent care, 
it would be useful to be able to track them over time to see their patterns of EIC, when they 
drop out and reconnect into care and what variables affect their EIC at what time points. 
However, this is more complicated to measure and few national datasets exist to enable this 
level of scrutiny.  
Finally, all of the studies in this literature review used the same definition to measure EIC 
across all of the participants in their studies, irrespective of the young person’s age or clinical 
status. Setting the same standard for how often a patient should be seen is inevitably not 
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going to be appropriate for a whole cohort of patients,(136) especially one as heterogeneous 
at young people living with PHIV. Some patients may have very well managed HIV and less 
need for very regular appointments, whilst others may have health issues which require 
regular visits.  Arguably, these studies are therefore measuring EIC at a basic public health 
level,(138) but not providing enough detail to know whether patients are attending clinic as 
their individual health care needs necessitate. 
In conclusion, there is an urgent need to both characterise engagement in HIV care during 
adolescence and young adulthood, and crucially, to understanding what factors support or 
prevent young people from attending HIV care. Studies in this literature review used a wide 
range of measures of EIC and there was little consistency in identified predictors. 
Importantly, studies were cross sectional and took no account of individual health care status 
in deciding when the next appointment should occur. Further investigation is needed to 




Chapter 3. Defining the engagement in care outcome 
measure 
 Introduction 
The first stage of this PhD project was to decide what was the most appropriate measure of 
EIC for use in young people with PHIV. Management of young people living with PHIV is 
complicated as they receive HIV care in adult as well as paediatric HIV services. Whilst many 
young people receiving HIV care in paediatric clinics routinely have clinic visits every three to 
four months,(173) older participants and those attending university quite regularly have 
clinic visits every 6 months, in accordance with adult HIV guidelines.(174) Basing this analysis 
on one of the commonly used EIC definitions from the literature with universal expected 
gaps between clinic visits would not pick up these nuances. In addition, neither scheduled 
nor attended visits are collected in the datasets used for this analysis which meant missed 
visits and appointment adherence could not be used for this analysis. At the outset of my 
PhD, I discussed potential definitions of EIC for this thesis with members of the AALPHI 
Steering Committee. Clinicians reported that they did not use a “standard” follow-up for 
young people with PHIV because their decisions about when next to see patients were more 
individualised, dependant on clinical and psychosocial characteristics. Based on these 
factors, I decided to use a sensitive visit constancy measure of EIC that could pick up changes 
in the health status and treatment of young people who received clinical care in paediatric 
and adult HIV care. The AALPHI Steering Committee recommended I adapt a novel EIC 
algorithm for adults developed by Howarth et al (151) due to its consideration of clinical 
factors in the decision on the timing of the next clinic appointment.  
In this chapter, I detail the methods that I used to adapt the Howarth et al’s (151) EIC 
algorithm. Due to the increased number of considerations for managing young people with 
PHIV compared to adults with HIV, I developed three EIC flowcharts that classified clinical 
management  (using a decision tree approach(175)) from the Howarth et al algorithm for use 
in young people. I describe how I assembled and prepared the dataset for this analysis, how 
the data were cleaned, and how I managed missing data. Finally, I describe how the 




• To develop a sensitive measure of EIC in order to take into account changes over 
time in treatment and health status for young people with perinatal HIV in England. 
• To apply the measure to describe EIC in young people with perinatal HIV in England 
through quantitative analysis of the AALPHI cohort dataset. 
 Methods 
3.3.1. Definitions 
For clarity, a few of the main terms used through this chapter are defined in Table 3.1. 
Table 3.1: Chapter definitions 
Phrase Definition 
engagement in care (EIC) The spectrum of engagement in care  
in care Engaged in care 
time to next scheduled 
appointment 
Time to participants next scheduled 
appointment as defined by the 
flowcharts (not an actual visit) 
visit/visit date Actual visit or visit date attended by 
participant  
 
3.3.2. The Howarth et al algorithm 
3.3.2.1. Clinical criteria for use in adults 
Howarth et al (2016) developed the EIC algorithm for adults with HIV by carrying out semi-
structured interviews with HIV clinicians.(151) Their rationale for developing this new 
algorithm was that standard EIC measures do not take into account how the frequency of 
clinic attendance is based on individual patients’ health and treatment status and that this 
changes over time. Howarth et al interviewed eight adult HIV clinicians in 2013 and 2014 and 
the reasons for time to next appointment for 66 patients were discussed. Content analysis 
was conducted on interview transcripts identifying factors determining the scheduling of the 
next appointment, and time frames for the next scheduled appointment were identified to 
develop the algorithm. The clinicians reported that while they did follow guidelines for 
appointment scheduling, individual psychosocial and physical comorbidities and clinical 
factors made scheduling more individualised. However, although psychosocial comorbidities 
about mental health and social support needs were cited as a common reason for adjusting 
“standard” appointment scheduling, Howarth et al commented that these factors were 
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difficult to include in EIC analyses. This is because these factors are often not recorded 
electronically in hospitals or reported routinely in cohort studies, and likewise in my case 
they were not available in the CHIPS and AALPHI datasets. As a result, the Howarth et al EIC 
algorithm used clinical factors alone to predict when patients should next be seen in clinic 
(i.e. the expected next appointment date) and thus the algorithm developed for my analysis 
also only used clinical factors.  
Table 3.2 presents the clinical factors and the corresponding scheduling of the next 
appointment according to the Howarth et al EIC algorithm. So for example, an adult patient 
who is not on ART, and has a CD4 cell count ≤350 cells/µL or any drop in CD4 cell count will 
be classified to be seen in 2 months. If more than one set of clinical factors applies at the 




Table 3.2: Clinical factors predicting the time to next scheduled appointment date in 
Howarth et al’s engagement in care algorithm (1) 
Clinical factors at the current clinic visit 
Time to next  
scheduled appointment: 
Less than 1 month since HIV diagnosis 2 months 
AIDS diagnosis 2 months 
Started ART 2 months 
Started new ART combination 2 months 
Not on ART 
CD4 cell count ≤350 cells/µL or 
any drop in CD4 cell count 
2 months 
CD4 cell count ≤350 cells/µL and 
no drop in CD4 cell count 
4 months 
CD4 cell count 351-499 cells/µL 4 months 
CD4 cell count ≥500 cells/µL and 
CD4 cell count drop ≥100 cells/µL 
4 months 
CD4 cell count ≥500 cells/µL and 
CD4 cell count drop <100 cells/µL and 
viral load ≥100,000c/mL 
4 months 
CD4 cell count ≥500 cells/µL and 
CD4 cell count drop <100 cells/µL and 
viral load <100,000c/mL 
6 months 
Already started ART 
Viral load >200c/mL 2 months 
Viral load 51-200c/mL and 
does not appear to be a blip1 
2 months 
Viral load 51-200c/mL and 
appears to be a blip 
4 months 
Viral load ≤50c/mL and 
CD4 cell count ≤200 cells/µL  
4 months 
Viral load ≤50c/mL and 
CD4 cell count >200 cells/µL  
6 months 




3.3.2.2. Management of multiple visits in the Howarth et al algorithm 
Howarth et al (151) reported that patients often had multiple measures of different clinical 
factors (e.g. CD4, viral load) within very short time periods. On examination, these episodes 
were considered likely to be linked to the same clinic visit, and so clinic visits were grouped 
within month-long time periods.(151) For each month the lowest CD4 cell count and highest 
viral load were chosen, and, together with the other clinical factors detailed in Table 3.2, 
were used to calculate the date of the next scheduled clinic appointment.  
3.3.2.3. Measuring ‘in care’ 
For the Howarth et al (151) algorithm (and this analysis) the outcome is a binary classification 
of ‘in care’, coded as either ‘yes’ (i.e. engaged in care) or ‘no’ (i.e. not engaged in care) for 
each month of follow-up. The next scheduled appointment date was compared to the next 
observed visit date, and participants were classified as in care if their observed visit occurred 
on or before the scheduled appointment date.  However if the observed visit occurred after 
the scheduled appointment date, the period of time between the previous visit and the 
scheduled next appointment was classified as in care, and the period of time following the 
scheduled appointment until the observed visit was classified as out of care. Table 3.3 
presents an example of how a single patient’s time following a clinic visit would be measured, 
using the Howarth et al algorithm. In this example a patient makes a clinic visit on 16 July 
2008, and, based on their clinical characteristics (not shown), the time to their next 
scheduled appointment is two months later, on 16 September 2008.  However, they do not 
attend until 16 October 2008. Therefore, months one and two would be classified as “in 
care”, as the periods of follow-up time both precede the next scheduled appointment date 
of 16 September 2008.  However, month three, the time following the next scheduled 
appointment date (16 September 2008) and preceding the next observed visit date (16 
October 2008) would be classified as out of care. In this way, each person month of follow-
up is ether in care of out of care. Once Howarth et al had developed the algorithm, they then 
applied It to data from the UK Collaborative HIV Cohort (UK CHIC) study.  
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Table 3.3: An example of a single participant classified in or out of care between two 











In care  
(Y / N) 
1 16 Jul 2008 16 Sept 2008 16 Jul 2008 15 Aug 2008 Y 
2   16 Aug 2008 15 Sept 2008 Y 
3   16 Sept 2008 15 Oct 2008 N 
4 16 Oct 2008     
3.3.3. Adapting the clinical criteria and developing the flowcharts for use in young 
people 
Howarth et al’s EIC algorithm was originally developed for use in adults living with HIV and 
so required adaptation for use in PHIV young people. To assist in this process I met with two 
clinicians caring for young people living with PHIV in large London clinics and discussed the 
key aspects of the algorithm and how it should be adapted.  
3.3.3.1. Clinical criteria for use in young people 
The first step was to update Howarth et al’s algorithm in line with the most recent British 
HIV Association (BHIVA) clinical monitoring guidelines, which had been published after 
Howarth et al’s algorithm had been developed.(174) This provided a foundation to ensure 
that any later adaptations that I made to the Howarth et al algorithm were never more 
lenient than the follow-up recommendations made for adults living with HIV. The next step 
was for me to incorporate maximum appointment times for patients still in paediatric care 
based on the PENTA paediatric HIV guidelines,(173) which suggest more regular monitoring 
than for adults, due to some additional complexities of paediatric patients. For example, 
BHIVA monitoring guidelines for adults (174) recommend that if a participant is established 
on ART with two consecutive viral loads >50c/mL over one year apart, they do not require a 
subsequent CD4 measure (unless there is subsequent viral load failure or symptoms). The 
PENTA guidelines for children,(173) however, recommend that CD4 cell counts are measured 
every three to four months, regardless of viral load. Another example of an additional 
complexity in the paediatric population is weight. Young people who weigh <40kg may still 
be on weight-adjusted doses of ART (rather than fixed adult doses) and so require more 
regular appointments (minimum every three months) to ensure that they are still on the 
correct dose for their weight as they grow.   
Initially, I categorised viral loads as in the Howarth et al algorithm (151) and BHIVA 




- 51-200 c/mL 
- >200 c/mL 
However, my discussions with the two clinicians revealed that they would react differently 
to a viral load >50c/mL for a patient on a NNRTI compared to those on a PI with greater 
urgency in following up a patient on NNRTIs. Therefore, the focus of scheduling the next 
appointment was the combination of ART regimen (PI vs NNRTI), rather than whether the 
amount of virus >50c/mL was considered a viral load blip or not. On this basis, I changed viral 
load categorisation to a binary ≤50 or >50c/mL variable.  
For the purposes of this analysis, ‘ART’ means mono, dual or cART unless otherwise specified, 
and a cART regimen is defined as ≥3 ART drugs, including regimens containing a NNRTI, or a 
PI regimen with a booster. 
3.3.3.2. Development of three flowcharts for young people 
Through the conversations with clinicians, it also became evident to me that three main 
groupings of PHIV young people (based on ART status and viral load) were employed in 
clinical decision making to determine scheduled appointment dates.   
1) Flowchart A: young people living with PHIV on ART with viral load ≤50c/mL  
2) Flowchart B: young people living with PHIV on ART or starting/restarting ART with 
viral load >50c/mL 
3) Flowchart C: young people living with PHIV off ART 
Additionally within each of these groupings, there were a series of steps, in which different 
criteria were applied before the next scheduled appointment date could be estimated.  Thus, 
I developed separate flowcharts for each of the three main groupings, based on a decision 
tree approach, in order to visually show each step.  These were for the following groups of 
patients, at their “current” visit: 
I presented the EIC flowcharts for young people living with PHIV to the CHIPS Steering 
Committee in September 2017.  Many of the clinicians from the larger UK clinics treating 
children and young people living with PHIV were members of the Steering Committee and 
attended this meeting, and so it was an ideal opportunity to discuss the draft flowcharts with 
a wider group of clinicians as they were being developed. The draft versions presented are 
in Appendix A. The consensus from the Steering Committee was that the flowcharts were 
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clinically valid. However, some alterations were suggested, which I made (changes are 
summarised in Appendix B. Additionally I made final refinements during the statistical 
analysis programming stage, when minor inconsistencies were uncovered. 
3.3.3.3. Engagement in care flowcharts for use in young people living with PHIV 
The final three flowcharts developed after consultation with the clinicians are shown in the 
following figures: Figure 3.1 presents Flowchart A, Figure 3.2 Flowchart B, and Figure 3.3 
Flowchart C. To note, the coloured boxes in my flowcharts are the terminal nodes and 
indicate the ends of decision making, with the colour itself indicating the timing of the next 
follow-up appointment.  
Figure 3.1 shows how a patient on ART with a viral load ≤50c/mL at the current visit should 
be managed in relation to the scheduling of their next appointment. As an example, if a 
patient has had no CDC C event in the preceding three months, was not on a new ART 
regimen, was on cART, had a CD4 cell count >350 cells/µL, and was in adult care with a weight 
≥40kg, their next scheduled appointment would be in six months’ time. 
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Figure 3.1 : Flowchart A: Young people living with PHIV on ART with viral load ≤50c/mL 
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Figure 3.2 shows how a participant either already on ART, or starting or restarting ART, and with 
a VL >50c/mL, at the current visit should be managed in relation to the scheduling of their next 
appointment. As an example, if a participant had no CDC C events in the preceding three months, 
had been on an ART regimen for more than 6 months, was on a PI-based regimen, and this was 
their first VL >50c/mL, their next scheduled appointment would be in one month’s time. 
Figure 3.2: Flowchart B: Young people living with PHIV on ART or starting/restarting ART with 
viral load >50c/mL 
 
Figure 3.3 shows how a participant not taking ART at the current visit should be managed in 
relation to the scheduling of their next appointment. As an example, if a participant had no CDC 
C event in the preceding three months, and had a CD4 cell count ≥500 cells/µL, their next 
scheduled appointment would be in four months’ time. 
* In line with guidelines during the time period covered by this analysis (2012-2015) integrase inhibitors (including dolutegravir) 
are treated the same as NNRTIs in regard to time to switch regimen
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Figure 3.3: Flowchart C: Young people living with PHIV off ART 
 
3.3.3.4. Comparison of engagement in care measures for adults and young people 
My adaptation process of Howarth et al’s algorithm changed the clinical factors and subsequent 
time to next scheduled appointment used in the adult criteria to this more complex picture for 
young people with HIV. Table 3.4 summarises the additional considerations and more 
conservative appointment scheduling in the flowcharts for young people living with PHIV 
compared to the criteria used for appointment scheduling for adults in the Howarth et al 
algorithm. This table is the same as Table 3.2 but has a new column with ‘My amended criteria 





Next appointment in 1 month
Off ART
No CDC C 
in the last 
3 months
CDC C 






drop <50 in  
CD4 since 
last visit
















drop ≥50 in  
CD4 
Next appointment in 2 months
Next appointment in 3 months
Next appointment in 4 months
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Table 3.4: Adaptations to the Howarth et al algorithm for young people living with PHIV 
Howarth et al’s clinical 
factors at current visit 
Time to next  
scheduled 
appointment 
My amended criteria for young 
people living with PHIV 
Less than 1 month since HIV 
diagnosis 2 months 
Not applicable as have to be aware of 




1 month (and monthly for first 3 
month)  
Started ART 2 months 1 month 
Started new ART 
combination 
2 months 1 month 
Not on ART   
CD4 cell count ≤350 cells/µL 
and any drop in CD4 cell 
count 
2 months 
Dependant on size of CD4 cell count 
change: 
- If increase, no change or drop 
of <50, next appt in 2 months 
- If CD4 cell count drop of ≥50, 
next appt in 1 month 
CD4 cell count ≤350 cells/µL 
and  
no drop in CD4 cell count 
4 months 2 months 
CD4 cell count 351-499 
cells/µL  
4 months 
Dependent on CD4 cell count change:  
- If increase, no change or drop 
of <50, next appt in 3 months 
- If single drop of ≥50, next 
appt in 3 months  
- If a consecutive drop ≥50, 
next appt in 2 months 
CD4 cell count ≥500 cells/µL 
and  
CD4 cell count drop ≥100 
cells/µL 
4 months No change – 4 months 
CD4 cell count ≥500 cells/µL 
and 
CD4 cell count drop <100 
cells/µL and 
viral load ≥100,000c/mL 
4 months No change – 4 months 
CD4 cell count ≥500 cells/µL 
and 
CD4 cell count drop <100 
cells/µL and 
viral load <100,000c/mL 
6 months 4 months 
Already started ART   
Viral load >200c/mL 2 months Cut-off set at ≤50 or >50 (not ≤200). 
Management would depend on a 
number of factors: 
- how recently started cART 
- on PI or not 




Howarth et al’s clinical 
factors at current visit 
Time to next  
scheduled 
appointment 
My amended criteria for young 
people living with PHIV 
- if first VL >50  
- CD4 cell count and CD4 cell 
count drop 
Management may be more lenient or 
more conservative 
Viral load 51-200c/mL and 
does not appear to be a blip 
2 months Dependent on whether first VL is >50 
or not: 
- If this is the first VL >50 would 
need appt irrespective of VL 
- If not first VL >50, would 
depend on the size of VL 
increase, CD4 cell count and 
CD4 cell count drop 
Management may be more lenient or 
more conservative 
Viral load 51-200 c/mL and 
appears to be a blip 
4 months As above. Blip not treated differently 
Viral load ≤50c/mL and 
CD4 cell count ≤200 cells/µL 
4 months Dependent on a number of combined 
factors: 
- Number and class of ART 
drugs 
- length of time CD4 cell count  
≤200 
- weight or ART dosing 
- whether in paediatric or 
adult care  
Management may be more lenient or 
more conservative 
Viral load ≤50c/mL and 
CD4 cell count >200 cells/µL 
6 months Dependent on a number of combined 
factors: 
- number and class of ART 
drugs 
- CD4 cell count 
- weight or ART dosing 
- whether in paediatric or 
adult care 
Management may be more lenient or 
more conservative 
 
Howarth et al’s EIC algorithm grouped the possible clinical factors into 15 different pathways to 
determine the time to next scheduled appointment for adults (2, 4, or 6 months). In my EIC 
flowcharts for young people, the terminal nodes illustrate the 37 different pathways that result 
in the time to next scheduled appointment classification. Appendix C lists all of the clinical 
factors used in each stage of my flowcharts and the source/reference for each stage. 
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3.3.4. Assembling the dataset 
I conducted data manipulation, cleaning and analysis in STATA version 15.(176)  
3.3.4.1. Data linkage 
Datasets from two UK-based HIV cohort studies were used in this analysis: 
• the AALPHI cohort, and  
• the CHIPS cohort. 
All AALPHI participants were in the CHIPS cohort as this was one of the AALPHI eligibility criteria, 
and the CHIPS study number was common to both datasets. AALPHI data were linked to five 
CHIPS datasets (CD4 cell count dataset, viral load dataset, weight/height dataset, ART dataset 
and summary dataset (for date of last clinic visit)) which contained the clinical data required for 
this analysis, using the CHIPS study number. All of the CHIPS datasets, apart from the summary 
dataset, were in long format (multiple rows per patient) in contrast to the AALPHI datasets (and 
the CHIPS summary dataset) which were in wide format (one row per patient). Therefore, the 
relevant data from CHIPS datasets in long format were converted into wide format prior to the 
datasets being combined into one dataset.  
3.3.4.2. Inclusion criteria 
Clinical data (CD4 cell count, viral load etc.) were an essential component of this analysis.  
Therefore, participants who had no clinical data in the CHIPS dataset following their AALPHI 
interview date were excluded from the analysis. 
3.3.4.3. Follow-up time 
The in care outcome measure was defined using data on young people’s attendance at their HIV 
clinic. For this analysis, follow-up for each AALPHI participant was for one year following their 
first AALPHI interview date. 
3.3.4.4. Proxy visit dates 
As actual clinic visit dates were not collected in the CHIPS or AALPHI studies, dates of clinical 
markers were used as proxy clinic visit dates. This is based on the assumption that participants 
would have to attend the clinic for these measurements to be taken. This is a common strategy 
used to estimate visit dates in many cohort study analyses.(151,177)  
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Creating proxy clinic visit dates 
For the first stage of manipulation, I used multiple proxy markers to increase the chance of 
capturing true attendance in each clinic (CD4, viral load, weight, and height, ART start, switch or 
end). As an example of the sorts of data that I was manipulating, Table 3.5 presents how 
reported clinical data might have appeared for one participant during one week of follow-up. 


















Height CD4  VL    
Weight       
 
It is unlikely that the example participant depicted in Table 3.5 attended their clinic on three 
different days within the same week. It is much more likely that they attended the clinic on 15 
January 2014 when they had their height and weight recorded, and a blood sample was taken 
on this date. The CD4 result came back to the clinic the next day, and the viral load two days 
after that, and these results were then recorded on the CHIPS CRF and entered into the 
database. 
In order to manage these multiple proxy markers and not overestimate the number of actual 
clinic visits, I dropped all visit dates within 7 days of an earlier visit and collapsed the data to 
contain multiple markers in one row grouped by CHIPS study number and visit date. This is 
shown for a hypothetical participant in Table 3.6 and Table 3.7. Prior to collapsing the data, I 
first examined the data for any repeated clinical measures of the same type (so for example two 
different viral loads within the same week) which may indicate a true repeat visit. 
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123456 Clinic A 01/01/2013 01/01/1997 Male 01/01/2013 CD4 41    
123456 Clinic A 01/01/2013 01/01/1997 Male 01/01/2013 Weight  25.2   
123456 Clinic A 01/01/2013 01/01/1997 Male 03/01/2013 VL   1435000  
123456 Clinic A 01/01/2013 01/01/1997 Male 15/02/2013 CD4 91    
123456 Clinic A 01/01/2013 01/01/1997 Male 15/02/2013 ART    15/02/2013 
123456 Clinic A 01/01/2013 01/01/1997 Male 16/02/2013 VL   4033028  
1 Date can be for ART start, switch or end 
 

















123456 Clinic A 01/01/2013 01/01/1997 Male 01/01/2013 1 41 25.2 1435000  





Handling duplicate CD4 cell counts, viral loads and weights 
I individually examined all CD4 cell counts, viral loads and weights for which there was a 
subsequent measure within the next 7 days.  For the majority of the subsequent measures, the 
same value of the clinical indicator had been reported, and so I dropped them, assuming the 
same value had erroneously been entered twice. Where any of the following criteria were met 
for the subsequent measure, I then checked the CHIPS paper CRF: 
- CD4 cell count difference >100cells/µL 
- Viral load difference >1 log 
- Weight difference >3kg 
In total, the CRFs of seven participants with repeated CD4 cell count or viral load measurements 
were checked. Three participants had CRF data entered incorrectly, so the data for these 
participants were corrected. For two participants the data reported on the CRF may have been 
completed incorrectly, for example in one case a total lymphocyte count was reported as a CD4 
cell count. In these instances, the measurement that appeared most probable in relation to the 
previous trend was used. In the two remaining participants, there were no apparent data entry 
errors, but it was decided it was unlikely they were two genuine visits and so the worst result 
(lowest CD4 cell count or highest viral load) was entered. There were no repeat height or weight 
measurements that required checking. 
In a small number of instances, the subsequent measure was not exactly the same value but was 
similar and did not meet the criteria outlined above, in which case the worst of the two 
measurements was taken. 
3.3.5. Preparing the dataset to apply the engagement in care criteria  
Once the dataset was prepared, a number of stages of manipulation were performed, and 
management of multiple visits, the outcome, start date and re-engaged in care classifications 
were defined.  
3.3.5.1. Coding the data in accordance with the engagement in care criteria 
For the first stage of data manipulation to apply the EIC flowcharts to the dataset, I coded the 
data so that time to next scheduled appointment could be classified correctly for each 
participant at each visit. For each visit, clinical data were used to predict the time to next 
scheduled appointment. This method assumes that all of the clinical variables were available to 
the clinician at the time of the current visit, and were used to predict the next appointment date. 
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In reality, however, and demonstrated in Table 3.5, blood tests may only be available after the 
current appointment has ended. In these cases clinicians would use previous results to 
determine the timing of the next appointment.  However, subsequent test results available a 
few days later could prompt a rescheduling of the next appointment, if clinical measurements 
should change, and patients would be contacted by the clinic and the appointment rescheduled 
accordingly.  Therefore, the approach I took here should approximate what actually happens in 
clinics.  
I then derived individual variables for each of the decision tree questions set out in the boxes of 
the EIC flowcharts, so that I could calculate time (one, two, three, four or six months) to the next 
scheduled appointment. I coded each flowchart separately to ensure that every pathway ending 
in a terminal node was included, and that participants were only categorised within one 
pathway. For example, using Figure 3.3 for pathways requiring one or two months’ follow-up 
time, participants were coded for the next appointment to be scheduled in one month if: 
- They were off ART and had a CDC C event in the last three months 
or 
- They were off ART, had no CDC C event in the last three months, had a CD4 cell count 
≤350 cells/µL and had a drop in CD4 cell count ≥50 cells/µL since the last visit 
Similarly, participants were coded for the next appointment in two months if: 
- They were off ART, had no CDC C event in the last three months, had a CD4 cell count 
≤350 cells/µL and had an increase or no change or drop <50 cells/µL in CD4 count since 
the last visit 
or  
- They were off ART, had no CDC C event in the last 3 months, had a CD4 cell count 351-
499 cells/µL and had a second consecutive drop of ≥50 cells/µL. 
Once I had coded all the pathways in the three flowcharts, individual visit rows that had no time 
to next scheduled appointment date defined in this process were examined. A few minor 
inconsistencies were found in the coding at this stage, which I corrected. My management of 
rows with missing data are described in section 3.3.6.1 new patient. My checks indicated that 
no participants were categorised into two different pathways. 
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3.3.5.2. Splitting the data into month time frames 
For this second stage of data manipulation, I recoded the data from representing one row per 
clinic visit date for each patient, to month time periods, so that I could then calculate the number 
of months in and out of care. This manipulation enabled me to calculate the time to next 
scheduled appointment. The date of the AALPHI interview was treated as the start date for the 
analysis. I created a new dataset with data organised so each row contained the month number 
and the date at the beginning of the month (the AALPHI interview date for month one) and the 
end of the month, so that visit dates (and the associated clinical data) could be merged into the 
corresponding rows.  All months were retained even if there was no visit. If two visits occurred 
within a month, two rows were created for this month. A new variable was created for the date 
of next scheduled appointment, based on the current visit date and the time to next scheduled 
visit as determined by the flowcharts. Fifteen days were added to this variable to add some 
leniency into the analyses to make it more applicable in actual clinics, for two reasons.  Firstly, 
it is plausible that there was no clinic availability at the exact time of the next scheduled clinic 
appointment date, so a slightly later appointment date may have been arranged. Secondly, a 
patient may be sent an appointment letter for their next visit, and subsequently rescheduled it 
slightly due to calendar conflicts. 
3.3.5.3. Management of multiple visits 
In the Howarth et al analysis, clinic visits were grouped into month episodes, and the lowest CD4 
cell count and the highest viral load measurements were established for each visit. I manipulated 
my data slightly differently for my analysis of young people living with PHIV. Once proxy visits 
within seven days were collapsed, all visits were kept in the dataset (including multiple visits 
within a month). In the year of analysis, there were 81/3,873 (2%) instances in 59 participants 
of more than one visit in a month. Where multiple visits occurred, all visits were classified for 
time to next scheduled appointment, but the visit that occurred later in the month was 
prioritised over the previous visit(s) and so the earlier visit in the month was dropped.  Table 3.8 
presents a participant with two visits in one month. The second row (visit date 08/07/2013) is 
prioritised. 
Table 3.8: Management of multiple visits in a month 
Month Visit date 
Time to next 
scheduled 
appt 





Month end In care 
11 10/06/2013 1 month 25/07/2013 10/06/2013 09/07/2013 Yes 
11 08/07/2013 3 months 23/10/2013 10/06/2013 09/07/2013 Yes 
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1 Date of scheduled appointment is visit date plus time to next scheduled appointment, plus 15 days. 15 days is added to each month 
to make more applicable to what happens in clinic 
3.3.5.4. Defining months as in or out of care 
I then classified each month in the 12 months following the AALPHI interview date (start date) 
as in or out of care. For months where the next scheduled visits was due, participants were 
considered in care if (i) they attended clinic prior to the start of the month; or (ii) they attended 
clinic within the month. Those who attended after the month end were considered out of care 
for that month. For participants who attended their appointment early, the date of their next 
scheduled appointment was reset and based on their most recent appointment date. Figure 3.4 
gives an example for a hypothetical participant in paediatric care.  
Figure 3.4: Months in and out of care for a hypothetical participant in paediatric care 
 
This participant had a clinic visit on the day of their AALPHI interview, with a viral load ≤50c/mL 
and CD4 cell count 380 cells/µL (Figure 3.4) and they are therefore classified in Flowchart A 
(Figure 3.1). The participant had no CDC C event in the last 3 months or ART changes, and was 
on three or more cART drugs,  CD4 >350 cells/µL, they were in paediatric care and they were on 
adult cART doses, so their next scheduled appointment was four months later. They did not 
attend clinic until six months later, so were considered in care for the first four months and then 
out of care for the following two months past their scheduled appointment date. At the clinic 
visit in month seven, the participant had a viral load 1,200c/mL and their CD4 cell count 
decreased to 325 cells/µL (Figure 3.4) and they are therefore classified based on Flowchart B 
(Figure 3.2). The participant had no CDC C event, had been on their ART regimen for >6 months 
and was on a PI-based regimen. It was their first viral load >50c/mL, so the time to their next 
scheduled appointment was in one month. The participant attended clinic after two months so 
Key
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Expected date of next appointment




















































was considered in care for the first month (month seven) and out of care the next month (month 
eight). The participant attended in month nine, and had a viral load ≤50c/mL again (and they are 
therefore classified in Flowchart A again, Figure 3.1) with no CDC, no new ART, on ≥3 drugs and 
their CD4 count increased to 360 cells/µL. The participant was still in paediatric care and was on 
adult doses and was therefore due to be seen in four months so was considered in care for the 
last four months (months 9-12). Overall, this participant had nine months in care and three 
months out of care. 
For this analysis, I chose the AALPHI interview date as the start of the year’s follow-up for all 
participants. Seven days leniency was allowed so that 18 participants (6% of total) who had a 
clinic visit within seven days after their AALPHI interview date were considered to have their 
interview at the same time as a clinic visit.  I decided not to consider visits in the 7 days before 
the AALPHI interview as the same time as the AALPHI interview date because then the exposures 
measured during the AALPHI interview predicted the outcome measure, in care from the past. 
Participants with an interview date at the same time as their clinic visit had the time to their 
next scheduled clinic appointment based on clinical data taken at the same time as their AALPHI 
interview. However, only 43% of participants in AALPHI were interviewed in clinic in the same 
week as their clinic visit (including the 6% described above). For participants without a clinic visit 
in the same week as their AALPHI interview, I based time to next scheduled appointment on the 
visit prior to the AALPHI interview. Figure 3.5 shows how this effects different groups of 
participants. Participants with a clinic visit and AALPHI interview on the same day can only start 
the analysis year in care (Figure 3.5 example (a)). Conversely, participants with no observed visit 
on the day of their AALPHI interview whose scheduled appointment falls before the AALPHI 




Figure 3.5: AALPHI analysis start date scenarios 
 
To assess the effect of this choice of start date on exposure variables, I conducted a sensitivity 
analysis, to examine using an alternative start date to the AALPHI interview date. This sensitivity 
analysis is detailed in Chapter 5 because it was performed on the final logistic regression model 




 = out of care = in care
(a) Indicates a participant who had their AALPHI interview at the same time as a clinic visit. The next expected visit date is based on data taken at the same 
time as their interview and therefore this patient starts the analysis period in care.
(b) Indicates a participant whose AALPHI interview is NOT at the same time as a clinic visit. The next expected visit date is based on data taken at the visit
prior to AALPHI. The next expected visit is after AALPHI interview date and therefore this patient starts the analysis period in care.
(c) Indicates a participant whose AALPHI interview is NOT at the same time as a clinic visit. The next expected visit date is based on data taken at the visit
prior to the AALPHI date, AND the next expected visit is before the AALPHI interview date. If this patient doesn't attend they start the analysis period out
of care.
AALPHI interview  
& observed  visit 
date on same date
Data from observed visit prior to analysis year used 















Data from start of analysis year used to 
predict time to next expected visit
Data from observed visit prior to analysis year used to 
















3.3.5.5. Classifying participants in or out of care:  issues resulting from moving from 
continuous to discrete time 
Moving from continuous time to monthly intervals introduced some assumptions. Since 15 days 
was added to the calculated scheduled appointment date, a participant for whom a scheduled 
appointment fell towards the end of a month, still had time allowed to attend (minimum 15 
days), before being classified as out of care in that month.  
Classifying a participant as in care in any month they attended a visit was adopted. Other options 
were considered around classification of the visit month as in or out of care based on time since 
scheduled appointment or days into the month (late/early in the month). Using a strict cut off 
based on the end of the 15 days leeway was problematic, as if for example, a participant on 
monthly follow-ups was classified as out of care when they attended a visit on the third day into 
the month as they were due (including the 15 day leeway) on the first day of the month and 
then they did not return in the following month, they would be classified as out of care for two 
months despite having attended clinic. Carrying forward ‘in care’ was also problematic due to 
covariates being updated at the beginning of each month and the impact on the subsequent 
appointment schedule. Splitting the month by days into the month seemed arbitrary and also 
led to similar problems if ‘in care’ were carried forward.  
However, classifying a participant in care for a visit month did mean participants for whom a 
scheduled appointment fell towards the beginning of the month were allowed more leeway in 
addition to the 15 days added to the initial calculated scheduled appointment date, as they were 
classified as in care, irrespective of how late they attended in the month. This may have led to 
some patients being classified as in care when they had in fact missed a scheduled appointment. 
To explore this, I considered all the visits that were attended late where the participant was in 
care in the preceding month; 103/183 (58%) visits were attended within the intended 15 days 
leeway and the median (Interquartile Range (IQR)) time from calculated visit to attended visit 
was 11 days [5, 25]. 
3.3.6. Missing data and data cleaning/checking  
3.3.6.1. Missing data 
For missing data, I had three primary considerations.  The first was to manage missing clinical 
data when creating the proxy clinic visit dates. The second was to manage missing data so that 
time to next scheduled appointment could be classified correctly at each visit. The third was to 
apply data cleaning and consistency checks. Missing AALPHI data are discussed in Chapter 5. Any 
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errors identified or additional data obtained were reported to the CHIPS or AALPHI statisticians 
so that changes could be made to the relevant source dataset. 
In my analysis dataset, each row represented a month of follow-up and was classified as either 
in or out of care.  Figure 3.6 presents all of the rows/months (I will use these terms 
interchangeably) with and without a visit that were dropped from the analysis due to missing 
data and the total number of participants at each stage.  
Rows were dropped for four reasons: 
- A: Multiple visits in one month (section 3.3.5.3) 
- B: Participants with missing proxy clinic dates 
- C: Participants with partially missing proxy clinic dates 
- D: Participants with proxy visits dates for whom next scheduled appointment date 
cannot be estimated 
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Figure 3.6: Number of rows dropped from the analysis 
 
When the data were initially split into 12 rows (one per month of follow-up) for each participant 
there were 3,873 rows included in the analysis. Once the 81 visit months were dropped due to 
multiple visits in a month, there were 3,792 rows remaining, of which 1,204 (32%) had a clinic 
visit, across 316 participants.   
Participants with missing proxy clinic dates (B) 
Some participants had missing proxy clinic dates for the whole year covered in my analysis 
















Number of months 
dropped / reason
Total number of 
rows/months 
(visit months)
A: 81 (2%) visit 
months dropped 
because >1 visit in 
month
B: 120 (3%) rows/ 
months dropped 
due to no CHIPS 
data for follow-up 
year
D: 46 (1%) months 
dropped due to 
missing clinical 
data at a visit 
C: 41 (1%) 
rows/months 
dropped due to 
partial CHIPS data 




Identifying these participants was important to make sure that they were not categorised as out 
of care in error when in fact there was simply no CHIPS form.  All participants whose last clinic 
visit (as recorded on the CHIPS form) was before the end of the follow-up year were examined. 
The last clinic visit date was compared to the date of form completion and follow-up status as 
recorded on the CHIPS database to ensure correct identification of participants with missing 
CHIPS forms.  
The CHIPS Data Manager assisted me in trying to obtain missing data from clinics. Participants 
whose clinical data remained missing were included in my analysis of descriptive characteristics. 
However, for the subsequent analysis of predictors of EIC (Chapter 5) participants with no clinical 
data for the whole year were dropped completely. In total, I dropped 10 participants completely 
(accounting together for 120 months/ rows) which left 3,672 rows, of which 1,204 were visit 
months, in 306 participants.  
Participants with partially missing proxy dates (C) 
In addition, a number of participants had missing proxy clinic date for part of the follow-up year 
because clinical data were not collected for the entire year of analysis. The affected months 
where I had no clinical data were dropped. In total, I dropped 41 rows in eight participants (one 
of whom died halfway through follow-up).  This left 3,631 rows with 1,204 clinic visits in 306 
participants.   
Participants with proxy visits dates for whom next scheduled appointment date cannot be 
estimated (D) 
Where proxy visit dates existed but clinical data (viral loads and CD4 cell counts) were not 
complete enough to estimate the time to next scheduled appointment, the last count (VL or 
CD4) was carried forward for a maximum of six months to correspond to the longest time 
between appointments in the flowcharts. Once I had calculated the time to next scheduled 
appointment for every appointment, I examined all rows where the time to next scheduled 
appointment remained unclassified (i.e. did not have the necessary data to fit into a terminal 
node). I then checked the CHIPS database and paper CRFs for all participants with missing data 
(or an ‘unclassified row’) in the analysis year to check if any data were available and had not 
been entered into the database in error. Where data were found to be actually missing, the 
CHIPS Data Manager tried to contact clinics to ask them to report it.   
This process revealed that time to next scheduled visit remained unclassified for 84 of the 1,204 
visit months (7%), due to viral load and CD4 data being missing for more than six months. In 
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some instances, CD4 cell count and viral load measurements were present for a particular visit, 
but a missing CD4 cell count or viral load from the previous visit resulted in variables requiring 
consecutive measures, such as ‘consecutive drop in CD4 cell count’ or ‘VL compared to last VL’, 
being incalculable. I then reviewed all participants who still had gaps in their data, and defined 
imputation criteria to carry data forward for longer than 6 months in stable participants (Table 
3.9). The imputation criteria detailed are only in relation to the data in this analysis rather than 
all possible situations that could occur using a different dataset. 
Table 3.9: Missing data imputation rules 
Rule 
no. 
Missing value Imputation criteria 
Imputed value based 





1 CD4 cell count VL ≤50c/mL >1 year and CD4 
351-499 cells/µL within last 
year 
CD4 351-499 cells/µL 
3 
2 CD4 cell count VL ≤50c/mL >1 year and CD4 
≥500 cells/µL within last 2 
years 
CD4 cell count  ≥500 
cells/µL 26 
3 CD4 cell count VL ≤50c/mL <1 year and CD4 
≥500 cells/µL within last year 
CD4 cell count ≥500 
cells/µL 
5 
4 CD4 cell count  VL ≤50c/mL <1 year, 351-499 
cells/µL within last 9 months 
CD4 351-499 cells/µL 
1 
5 CD4 cell count ART naïve and previous CD4 
≥500 cells/µL within the last 
6 months 
CD4 cell count ≥500 
cells/µL 1 
6 Consecutive 





Previous CD4 >350 cells/µL 
and within 6 months 
No 
3 




On ART >12 months, 
VL>50c/mL, and last viral 
load (irrespective of date) < 
than current viral load  
Higher than previous 
3 
8 VL VL ≤50c/mL >1 year and last 




9 VL VL ≤50c/mL <1 year and last 




   Total 46 
 
Time to next scheduled visit was classified in 46/84 clinic visits after I had applied the nine 
imputation rules, leaving 38 visits still unclassified (Table 3.9). The remaining 38 unclassified visit 
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months were coded as in care for one month (the minimum time to next scheduled 
appointment). If the participant did not attend again by the time of the next scheduled 
appointment, based on this month, then subsequent months (or rows) without a visit were 
dropped until the participant attended again. Forty-six months without a visit in 17 participants 
were subsequently dropped until the next visit occurred. In all of these cases, unclassified visits 
were due to missing data (e.g. CD4 cell count or viral load) rather than an omission in the 
flowchart coding.  This resulted in a total of 3,585 months, where 1,204 were visit months across 
306 participants. 
3.3.6.2. Data cleaning/checking  
The AALPHI and CHIPS datasets that I used for my analysis had already been cleaned by the 
respective studies’ statisticians prior to this analysis, to check for inconsistencies and errors. In 
addition, I conducted the following checks for my analysis.  
ART data 
For a few patients the ART start date fell between two visit dates, probably due to a drug being 
prescribed on the visit date, followed by a short delay in starting or switching to the drug, or a 
data error. In these cases, I recoded the ART start date so that it was the same as the preceding 
visit date. When examined, the difference between the ART start date and the visit date was no 
larger than 14 days and therefore no further investigations were considered necessary. 
Mono/dual therapy 
Participants with evidence of multi-drug resistance may be prescribed mono or dual therapy due 
to a lack of other viable options, but cART is the recommended standard treatment approach 
for HIV.(178,179) During my data cleaning process I identified a small number of participants 
who appeared to be prescribed mono or dual therapy in the CHIPS database. As this is contrary 
to the recommended treatment approach, I checked the CHIPS paper CRFs for these participants 
to make sure that their ART data had been entered correctly. Errors were found in a small 
number of participants which were corrected in my analysis dataset.  
Shared care visits 
A possible source of missing data was from participants who are in “shared care”. All paediatric 
HIV patients should have access to and review by a multidisciplinary team. Due to the small 
number of children with HIV, a formal paediatric clinical care network was established across 
the UK to allow patients in more remote areas to attend their local clinic for most appointments, 
as well as to have regular review from, and possibly occasionally attend, a multidisciplinary 
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specialist paediatric HIV clinic.(180) Due to a range of different established so called “shared 
care” pathways, reporting to CHIPS is sometimes by both “shared care” clinics, while in other 
instances only one or other clinic reports to CHIPS. Subsequently, one clinic may not be fully 
aware of the visits at the other clinic and so reporting omissions might happen. There is also 
potentially an increased chance of this cohort being in shared care due to their age. Young 
people at University may receive local care while at University and attend their routine clinic 
when home in the holidays. Therefore, the number of participants in shared care was examined 
and the median number of visits over the year follow-up for this analysis compared in 
participants in shared care vs. participants not in shared care. 
Newly diagnosed patients 
Howarth et al (151) categorised patients in the adult algorithm to be followed-up sooner if they 
had been diagnosed with HIV in the last month. This was not relevant for this analysis because 
to be eligible for AALPHI, patients had to be aware of their HIV diagnosis for at least 6 months. 
However, follow-up in the first year of diagnosis may be more regular, especially if the patient 
is off ART. The different requirements for new patients were not taken into account when 
classifying time to next scheduled appointment for these flowcharts, therefore, the number of 
AALPHI participants diagnosed in the last year was examined.   
Early attendance for appointments  
My analysis categorised patients who attended their visits as either on time, or early (both of 
which would be considered in care) or late (out of care).  However if too many participants were 
classified as attending visits early, this could indicate that parts of the flowcharts are not 
representative of clinical practice. To check how frequently this occurred I created a variable 
describing the actual number of months between visits, and compared this to the scheduled 
next appointment time frame. The last appointment for all participants within the 12 month 
period was dropped because it was not possible to assess if participants attended early or not 
for this appointment because this visit could have occurred after the follow-up period. 
I then classified all participants as being ‘not early’ (which included both participants who 
attended on time and those who attended late) or ‘early’. Participants cannot come early to a 
scheduled appointment classified as one month, so scheduled appointments of one month were 
not examined here. To allow for the reality of booking appointments in busy NHS clinics, some 
leniency was added into the time frames, so that any participant attending one month early for 
a visit was considered ‘not early’. For this reason, time to next scheduled appointments of two 
months were also not examined any further here.  
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Two analyses were undertaken to investigate the potential effect of early attenders for 6, 4 or 3 
month appointments on the results of my analyses.  Firstly, I wanted to be assured that early 
attenders were no different in characteristics to those who attended on time or late.  If early 
attenders were different in some way, this might point to my flowchart criteria being wrong and 
the need for additional decision boxes to incorporate the characteristic which was different. 
Therefore, I compared key characteristics (e.g. age group, sex, ethnicity, clinic type, on adult 
doses) of participants who attended early to those who were not early.  I also changed 
definitions of flowchart classifications (e.g. CD4 groupings, consecutive CD4 drop to single CD4 
change, viral load log increase from 0.5 log to 1.0 and 0.25 log changes) in the flowchart to see 
if this highlighted a difference between participants who attended early vs. not early to their 
visit. Secondly, to understand the effect of early attenders in more detail, the actual time to the 
next visit was then cross tabulated with all the possible terminal nodes for each of the three EIC 
flowcharts. If the proportion of early visits out of the total visits in each terminal node was a 
gross departure (e.g. more than half of the participants came early) it might indicate that the 
scheduling for the next appointment for that terminal node was not reflective of actual clinical 
practice, and might need to be shortened.  
3.3.7. Summary across the three flowcharts 
The flowcharts were summarised in three ways. Firstly, total time ‘in care’ for this analysis was 
examined by calculating the total number of months in the analysis classified as in care. 
Secondly, to understand overall frequency of time to next scheduled appointment over the 
three flowcharts, I examined distribution within the three flowcharts and across the whole 
cohort. Finally, I looked at the frequency of time to next scheduled appointment across all 
participants (as opposed to frequency across flowcharts). The median (and IQR) number of 
attended visits per participant was calculated. Then, I examined the number of participants with 
at least one visit within each scheduled next appointment time (1, 2, 3, 4, 6 months) across the 
follow-up year. Finally, I looked at all patients in month 7 (selected arbitrarily) and checked what 
appointment schedule they were predicted to be on at that time (either based on the month 7 
attended visit or the most recent attended visit prior to month 7) for all participants in care’. 
This was to look at the distribution of predicted appointment intervals, which could not be done 
across all months, as for example a patient scheduled to be on one-monthly appointments 
would contribute 12 observations in a year, while a patient on 6-monthly visit would contribute 
two observations in the same time period. Month 1 was not selected because participants could 




In the year starting on the date of the AALPHI interview for each participant, there were 3,585 
months of follow-up across 306 participants. Across these 3,585 months, there were 1,204 (34%) 
months with a clinic visit. Of the 1,204 visit months, 38 were not classified due to missing data. 
Of the remaining 1,166 visit months, the number and proportion of visit months were 
distributed across the three flowcharts as follows: 
- Flowchart A (young people living with PHIV on ART with viral load ≤50c/mL): 734/1,204 
(61%) 
- Flowchart B (young people living with PHIV on ART or starting/restarting ART with viral 
load >50c/mL): 320/1,204 (27%) 
- Flowchart C (young people living with PHIV off ART): 112/1,204 (9%) 
3.4.1. Flowchart A: Young people living with PHIV on ART with viral load ≤50c/mL 
For all of the 734 visit months in 235 participants on ART with a viral load ≤50c/mL (Figure 3.7) 
there were no CDC C event in the last 3 months (734/734), and the majority (718/734) had no 
new ART regimen at this visit. 
Of the 718 visit months where no new ART regimen was started, 666 were in participants on 
three or more drugs, of whom 620 had a CD4 cell count >350 cells/µL. Of these 620 visit months: 
161 were in participants who weighed ≥40kg or were on adult doses and who had already 
transferred to adult care; 448 were in participants who weighed ≥40kg or were on adult doses 
but were in paediatric care; and the remaining 11 visit months were in participants weighing 
<40kg and not on adult doses, who were in either paediatric or adult care.  
Only seven of 666 visit months in participants with a viral load ≤50c/mL on three or more drugs 
were in those with a CD4 cell count ≤200 cells/µL. In six of these visit months, participants had 
a CD4 count ≤200 cells/µL for less than a year, and in one visit month a participant had a CD4 
cell count ≤200 cells/µL for over a year.  
Of the 718 with no new ART regimen at the visit, 52 were on mono or dual therapy, and most of 
these (34) had been on this regimen for at least a year.
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Figure 3.7: Results for Flowchart A: Visits in young people living with PHIV on ART with viral load ≤50c/mL (734 visits in 235 participants) 
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3.4.2. Flowchart B: Young people living with PHIV on ART or starting/restarting ART 
with viral load >50c/mL 
Three hundred and twenty visit months were in 112 participants who were on ART with a 
detectable viral load (>50cmL) (Figure 3.8). Almost all of these visit months (318/320) were in 
participants with no CDC C event in the last three months.  Of these 318, 266 were in participants 
who had been on the same ART regimen for >6 months, and the regimens were mainly PI-based 
(241/266). In half (130/266) of these visit months, participants had a previous viral load >50c/mL 
but their viral load had not substantially increased (either had decreased, not changed or 
increased <0.5 log) since last visit. Of these 130 visit months: 52/130 visit months were in 
participants with a CD4 cell count ≤350 cells/µL and an increase or no change in CD4 cell count 
since their last visit; 40/130 of these visit months were in participants who had a CD4 cell count 
between 351-499 cells/µL and again either an increase or no change in CD4 cell count since their 
last visits (34/40) or it was their first drop in CD4 cell count (6/40); in 38/130 visit months, 
participants had a CD4 cell count ≥500 c/mL. 
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Figure 3.8: Results for Flowchart B: Young people living with PHIV on ART or starting/restarting 
ART with viral load >50c/mL (320 visits in 112 participants) 
 
3.4.3. Flowchart C: Young people living with PHIV off ART 
A total of 112 visit months were in 35 participants who were off ART (Figure 3.9). Reassuringly, 
none of the visit months were in participants who had a CDC C diagnosis in the last three months. 
In a third (33/112) of the visit months, participants had a CD4 count ≤350 cells/µL of which 23/33 
of the visit months were in participants where their CD4 count had increased/ not changed or 
dropped <50 cells/µL and 10/33 of the visit months were in participants who had a drop in CD4 
count ≥50 cells/µL. A further third (37/112) of visit months were in participants with a CD4 cell 
count 351-499 cells/µL. Of these 37 visit months: 28/37 visit months were in participants with 
an increase/no change or drop of <50 cells/µL; 7/37 visit months were in participants who had 
a single drop ≥50 cells/µL; and 2/37 visit months were in participants who had a second 
consecutive drop in CD4 cell count ≥50 cells/µL. The final third of visit months (42/112) were in 
participants with a CD4 cell count ≥500 cells/µL. 
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Figure 3.9: Results for Flowchart C: Young people living with PHIV off ART (112 visits in 35 
participants) 
 
In summary across the 1,204 visits represented in Flowcharts A, B and C, the largest number of 
visit months fell into the following categories: 
• 609 (51%) for participants on ART with a viral load ≤50c/mL, who were stable on cART 
with a CD4 cell count >350c/µL (Flowchart A); 
• 241 (20%) for participants on ART with a viral load >50c/mL, who had been on a PI-
based regimen for >6 months (Flowchart B); 
• and 112 (9%) for participants off ART (Flowchart C). 
3.4.4. Shared care visits 
In total, 41 (13%) of the 306 participants in the AALPHI cohort were in shared care at the time 
of their AALPHI interview. The medium number of visits over the follow-up year for my analysis 
was four, for both participants who were in shared care [interquartile range (IQR) 3, 4] and 
participants who were not in shared care [IQR 3, 5] suggesting that “shared care” visits were 
reasonably well captured.  
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3.4.5. Newly diagnosed patients 
Four (1%) of the 306 participants in the AALPHI cohort were diagnosed with HIV in the UK in the 
last year, and together accounted for 14 visit months. All four of these participants were 
previously diagnosed abroad. Three of the four spent the entire year of follow-up with a viral 
load ≤50c/mL, and one participant had a VL ≤50c/mL at baseline and then rebounded and 
supressed again over the 1 year follow-up. None of the ART naive participants classified in 
flowchart C were diagnosed in the UK in the last year.  
3.4.6. Early attendance for appointments 
The number of visits that participants attended earlier than their next scheduled appointment 
date as well as a summary of months attended early or not early are shown in Table 3.10, 
stratified by the time frame of the next scheduled appointment. A total of 262 (39%) visit months 
were earlier than originally scheduled, and 416 (61%) not early.  For participants whose next 
scheduled appointment was at 3 months’ time or 4 months’ time, around a third of visits were 
early.  However, for participants whose time to next scheduled appointment was in 6 months’ 





Table 3.10: Number of visits attended early by time frame of next scheduled appointments 
 Time to next scheduled 
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3 months (n=185) 
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4 months (n=383) 
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6 months (n=110) 
Total 
(n=678) 
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The comparisons across appointment schedules should be viewed with caution because there 
was greater opportunity for participants to be early for a six month appointment than a three 
or four month appointment. To see if there was a difference in the characteristics of those who 
attended on time or late, key characteristics and slightly altered definitions of flowchart 
classifications were compared for participants who attended on time at 3, 4, and 6 month 
appointments, and participants attending before the scheduled appointment dates. Results are 




Table 3.11: Comparison of key characteristics of participants who were early for their 3 month 
appointment compared to those who were not early 
 










Participant characteristic      
Age group      
≤15 years of age 47 (39%) 24 (37%) 
0.93 
16-18 years of age 52 (43%) 30 (46%) 
19-21 years of age 21 (18%) 11 (17%)  
Sex      
Male 48 (40%) 35 (54%) 
0.07 
Female 72 (60%) 30 (46%) 
Ethnicity      
Black 105 (87%) 59 (91%) 
0.54 Asian/mixed/prefer not to say 13 (11%) 6   (9%) 
White 2   (2%) 0   (0%) 
On all adult ART doses       
Yes 146 (54%) 50 (45%) 
0.08 
No 114 (42%) 58 (52%) 
Missing 10   (4%) 4   (3%)  
Re-categorised flowchart definitions      
CD4 category1      
≥600 cells/μL 24 (20%) 11 (17%) 
0.25 
500-599 cells/μL 13 (11%) 5   (8%) 
400-499 cells/μL 19 (24%) 10 (15%) 
<400 cells/μL 54 (45%) 39 (60%) 
CD4 change        
≥50 cells/μL lower than previous 37 (31%) 12 (19%) 
0.10 Same as previous 69 (59%) 47 (75%) 
≥50 cells/μL higher than previous 12 (10%) 4   (6%) 
VL change      
>1.0 log lower than previous 41 (35%) 22 (65%)  
Same as previous 74 (42%) 41 (35%) 0.31 
>1.0 log higher than previous 4 (3%) 0   (0%)  
VL change       
>0.25 log lower than previous 55 (46%) 30 (48%) 
0.95 Same as previous 55 (46%) 29 (46%) 
>0.25 log higher than previous 9   (8%) 4   (6%) 




Table 3.12: Comparison of key characteristics of participants who were early for their 4 month 
appointment compared to those who were not early 
 










Age group       
≤15 years of age 163 (60%) 70 (62%) 
0.42 
16-18 years of age 92 (34%) 39 (35%) 
19-21 years of age 16   (6%) 3   (3%)  
Sex      
Male 111 (41%) 48 (43%) 
0.73 
Female 160 (59%) 64 (57%) 
Ethnicity      
Black 232 (86%) 99 (88%) 
0.76 Asian/mixed/prefer not to say 28 (10%) 9   (8%) 
White 11   (4%) 4   (4%) 
On all adult ART doses       
Yes 146 (54%) 50 (45%) 
0.08 
No 114 (42%) 58 (52%) 
Missing 10   (4%) 4   (3%)  
Re-categorised flowchart definitions 
CD4 category1      
≥600 cells/μL 175 (64%) 74 (66%) 
0.84 
500-599 cells/μL 51 (19%) 17 (15%) 
400-499 cells/μL 34 (13%) 15 (14%) 
<400 cells/μL 12   (4%) 6   (5%) 
CD4 change       
≥50 cells/μL lower than previous 75 (29%) 26 (24%) 
0.15 Same as previous 112 (43%) 59 (54%) 
≥50 cells/μL higher than previous 73 (28%) 24 (22%) 
VL change       
>1 log lower than previous 15   (6%) 11 (10%)  
Same as previous 243 (93%) 98 (88%) 0.31 
>1 log higher than previous 3   (1%) 2   (2%)  
VL change       
>0.25 log lower than previous 31 (16%) 18 (16%) 
0.53 Same as previous 218 (79%) 88 (79%) 
>0.25 log higher than previous 12   (5%) 5   (5%) 




Table 3.13: Comparison of key characteristics of participants who were early for their 6 month 
appointment compared to those who were not early 
 










Age group      
≤15 years of age 1   (4%) 1   (1%) 
0.50 
16-18 years of age 8 (32%) 35 (41%) 
19-21 years of age 16 (64%) 49 (58%)  
Sex      
Male 12 (48%) 33 (39%) 
0.41 
Female 13 (52%) 52 (61%) 
Ethnicity      
Black 24 (96%) 73 (86%) 
0.27 
Asian/mixed/prefer 
not to say 
0    (0%) 8   (9%) 
White 1   (4%) 4   (5%) 
Clinic type      
Adolescent 17 (68%) 60 (71%) 
0.18 
Adult/GUM 6 (26%) 24 (28%) 
On all adult ART doses       
Yes 13 (52%) 39 (46%) 
0.59 
No 12 (48%) 46 (54%) 
Re-categorised flowchart definitions 
CD4 category1       
≥600 cells/μL 14 (56%) 60 (71%) 
0.14 
500-599 cells/μL 7 (28%) 9 (11%) 
400-499 cells/μL 3 (12%) 8   (9%) 
<400 cells/μL 1   (4%) 8   (9%) 
1 CD4 cell count is categorised into a greater number of categories than in the main analyses 
To understand whether participants who attended early fell into any particular terminals in the 
flowcharts, the 262 appointments attended two to five months early were then cross tabulated 
with all the possible terminal nodes separately in the three flowcharts, and results are presented 
for Flowcharts A, B and C in Table 3.14, Table 3.15, and Table 3.16 respectively.  
In total, 38% (n=195) of terminal nodes where participants attended early fell in Flowchart A 
(Table 3.14). The terminal node where appointments were most frequently attended early was 
for young people with a CD4 count >350 in adult care. This raised a question about whether it 
was common practice outside of the clinicians interviewed for this analysis to schedule clinic 
appointments for young people for 6 months. Unfortunately, there was not time to interview a 
wider range of clinicians; instead a sensitivity analysis was conducted in the modelling stages 
(Chapter 5) to examine the effect of 6 month scheduled appointments on the predictors of EIC. 
For this sensitivity analysis, the maximum time to next scheduled appointment was set at 4 
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months and the results of the model compared to results including time to next scheduled 
appointments at 6 months as detailed here.  
Forty-seven per cent of early visits were in flowchart B (Table 3.15). These early visits were 
spread across four terminal nodes. Early attenders fell most commonly in the terminal node 
where participants had a CD4 count ≤250 cells/μL, with an increase, no change or drop of <50 
in CD4 since last visit. Although the proportion is just over 50%, the numbers are quite small and 
it is perhaps not that surprising as this is one of the three terminal nodes with most visits in 
Flowchart B. 
Finally, 26% (n= 15) of the early visits fell in Flowchart C (Table 3.16). These early visits were 
spread across three terminal nodes and the numbers of visits were relatively small.
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1 None of the participants in this table had new ART at that clinic visit 
2 Terminal nodes in which no participants attended the clinic appointment early are not shown in the table 
3 As above due to a month’s leniency being added to early appointments, participants cannot be classified as early for visits with a 1 or 2 month follow-up time frame. Therefore, only visits with scheduled 
appointment time for 3, 4 or 6 months are included in this summary table. 
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3.4.7. Summary results across the three flowcharts 
In the previous sections, I described the number and proportion of visit months which fell 
into each terminal for each of the flowcharts. In this section, I will summarise the findings 
overall for the three flowcharts by presenting the:  
• Overall EIC across all participants 
• Timing of next visit scheduling for each flowchart 
• Number of visits per participant 
3.4.7.1. Overall engagement in care 
Of the 3,585 months of follow-up in this analysis, 3,126 (87%) months were classified as in 
care.  
3.4.7.2. Next scheduled appointment timing overall for the three flowcharts 
The majority of visit months (653/734) were in participants with a viral load ≤50c/mL 
(Flowchart A) who were categorised to have scheduled appointments in four to six months’ 
time. In participants on ART with a detectable viral load (Flowchart B), at half of visit months 
(158/320) participant had their next scheduled appointments categorised as in one month 
and over a third at three months. Where visit months were in participants off ART (Flowchart 
C), over two thirds were categorised to have their next scheduled visit at three or four 
months.  
Overall, nearly half of coded appointment months (522/1,166) were categorised as requiring 
the time to next scheduled appointment in four months, with around a fifth categorised with 
a time to next scheduled appointment at each of one (184/1,116), three (224/1166) or six 
months (173/1,166).   
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Number and % of visit months  
1 month 16 (2%) 158 (49%) 10 (9%) 184 (16%) 
2 months 6 (1%) 32 (10%) 25 (22%) 63 (5%) 
3 months 59 (8%) 130 (41%) 35 (31%) 224 (19%) 
4 months 480 (65%) -  42 (38%) 522 (45%) 
6 months 173 (24%) -  -  173 (15%) 
Total 734 (63%) 320 (27%) 112 (10%) 1,166 
 
3.4.7.3. Next scheduled appointment timing per participant 
Overall, 306 participants had 1,166 visits, equating to a median of 4 [IQR 3, 5] visits per 
patient. Table 3.18 presents for each time to next appointment scheduled (1, 2, 3, 4, 6 
months’ time) the number of participants that were predicted to be seen at this time at least 
once over follow-up. Over follow-up, 186 participants (61%) had at least one appointment 
scheduled for 4 months’ time. Over a third of participants (112, 37%) also had at least one 
appointment scheduled in one month’s time. Under a third of participants had at least one 
appointment scheduled for 3 months (94, 31%) or 6 months (n=73, 24%). Two months was 
the least common appointment timing (28, 9%). 




Number of  
appointments 





1 month 184 112 (37%) 
2 months 63 28 (9%) 
3 months 224 94 (31%) 
4 months 522 186 (61%) 
6 months 173 73 (24%) 
Not coded 38   
1 Total participants not shown as each participant could have multiple next schedule appointment timings 
When the timing of participants’ next scheduled appointment was examined for a single 
exemplar month (in participants classified in care), month 7 (Table 3.19), 4 months remained 
the most frequent time to next scheduled appointment (n=137, 46%). Around twenty per 
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cent of participants had appointments scheduled for 3 (n=60, 20%) and 4 months (n=54, 
18%), and as before the least common appointment timing was two months (n=8, 3%).  




n with ≥1  
appointment 
 n (%) 
1 month 28 (9%) 
2 months 8 (3%) 
3 months 60 (20%) 
4 months 137 (46%) 
6 months 54 (18%) 
Not coded1 9 (3%) 
No visit before month 7 4 (1%) 
Total 3002 ((0.0)%) 
1 ”Not coded” rows are where participants were given one month in care when missing data prevented classification  
2 Total is less than the total number of participants because some participants have rows/months dropped due to missing data 
or are ‘out of care’ 
 
Table 3.20 shows visit timings for two patients to explain why the findings in Table 3.18 and 
Table 3.19 differ. Patient A has nine 1 month scheduled appointments and Patient B only two 
1 month scheduled appointments over the 12 months follow-up. On this basis, both patients 
have a visit in 1 month over the year. In a cross sectional time point (month 7 in my example), 
Patient B is less likely to be captured as having a 1 month follow-up than Patient A, which is 
appropriate because Patient B only has two 1 month scheduled appointments over the 12 
month follow-up. This variation shows the changing clinic needs in these patients over the 
course of the year.  
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Table 3.20: Visit timings in two sample patients 
Month 1 2 3 4 5 6 7 8 9 10 11 12 
Month until next 
scheduled 
appointment  
1 1 1 1  1 1 1 3  1  
Patient A: Clinical 
characteristics 
(no CDC C event, in 
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3.5.1. Summary of main findings 
In this chapter, I detail the methods that I used to adapt the Howarth et al’s (151) EIC algorithm 
for young people living with PHIV in the AALPHI cohort. PENTA and BHIVA guidelines were used 
alongside clinician experience to modify and develop the flowcharts for this population. Due to 
the complexity in caring for young people living with HIV, the flowcharts developed in this thesis 
are more detailed and have more criteria to determine time to next appointment compared to 
the Howarth et al algorithm for adults.  
Patients were included in the analysis if they were in AALPHI and had clinical data in the follow-
up period. The AALPHI interview date was classified as the start of the follow-up period and 
clinical data were used as proxy visit markers in the absence of records of attended 
appointments. Clinical data were aligned to fit the defined EIC criteria so that at each visit, the 
time to the next scheduled appointment could be defined.  
Across 3,585 months of follow-up for the participants, 34% were months with a visit. At those 
visits, 61% of participants had an undetectable viral load (Flowchart A), 27% were on ART with 
a detectable viral load (Flowchart B) and reassuringly only 9% were off ART (Flowchart C). Three 
per cent were unclassified due to missing data.  Overall, nearly 90% of follow-up months were 
classified as ‘in care’. Participants had a median of 4 [IQR 3, 5] visits, and most frequently had 
time to next scheduled appointment at 4 months. However, 37% of participants had at least one 
of their appointments over the year scheduled in a month’s time, suggesting the changing 
clinical needs in these patients over the course of their year. Based on my model, participants 
attended 39% of visits early, most commonly when the time to their next scheduled 
appointment was at 6 months. 
3.5.2. Findings in comparison to the wider literature 
The methods that I used to measure EIC in this analysis are very different to the methods used 
in published EIC literature. The fundamental difference between the two is the purpose of the 
measurement. My measurement attempts to take into account clinical monitoring decisions, 
recognising that some patients will need to be seen more frequently than others, and is thus 
relatively complex to construct.  However most other analyses in the literature have more 
simplistic measures, for example, one or more visits in a given year, which give a population 
estimate useful for public health monitoring and the cascade of care.  
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In my analysis, I found that 87% of patient months of follow-up were in care. Noting the 
limitations above, as shown in Chapter 2, European studies of young people living with PHIV 
have reported engagement ranging from 80% to 98%, (155,156) and sub-Saharan African studies 
83% to 98%.(153,154,158–160)  Only one study estimated EIC in young people living with PHIV 
in the UK. Chappell et al (155) measured the proportion of children attending paediatric clinics 
in the CHIPS study. Patients were included if they had at least one visit in the year, and found 
98% engagement.  In that study the median age was 14.4 years [IQR 11.2, 16.4], so younger than 
in my study, and crucially all children had to be in care at baseline to be included in the analysis.  
Both of these factors may explain why engagement was so high. It should be noted that as my 
study sample is a subset of those ever in the national HIV paediatric study (CHIPS), some of the 
younger patients in my analysis may also be in the Chappell et al analyses. 
The proportion of participants in care in studies from the USA vary more than studies from 
Europe and sub-Saharan Africa, ranging from 56% to 99%.(138,161–168) This is despite relative 
consistency in their use of EIC definitions, favouring either ≥1 visit within 1 year (138,156,162), 
or the CDC recommended Health Resource & Services HIV/AIDS Bureau (HRSA HAB) measure of 
≥2 visits with ≥3 months apart within 1 year.(138,153,162–164,168) The study with the lowest 
EIC prevalence used a stricter multiple visit marker (≥2 visits with ≥3 months apart within 1 year), 
and measured EIC post-transition to adult care. In the second year post-transition, they reported 
56% were engaged in care in a cohort of 72 participants in which only 15% of the participants 
had PHIV.(163) In contrast, the study that found the highest prevalence of young people in care 
used a single visit measure (≥1 visit within 1 year) in exclusively young people living with PHIV 
(n=1,535). Data were stratified by age and 99% of 13-19 year olds were classified to be in 
care.(162)  
Besides the lack of consistency in EIC definitions used in the different regions, there are many 
other sociodemographic and health care factors that limit comparability between young people 
living with PHIV in the USA, UK and Africa. Sub-Saharan Africa has the highest burden of HIV with 
85% of all adolescents with PHIV living in this region (181) Healthcare provision in sub-Saharan 
Africa is largely decentralised with most care provided in large primary care clinics (153) and few 
specialist adolescent clinics exist.(154) In Europe and North America, numbers of patients are 
much smaller and care is provided in specialist HIV clinics often specifically adolescent 
clinics.(162,182) The sub-Saharan African birth cohort is younger than European and North 
American cohorts, patients have less ART exposure and HIV-related mortality is higher.(183) 
Differences also exist between European and North American cohorts of children and young 
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people born with PHIV. In the UK, most young people with HIV were born in sub-Saharan Africa 
and migrated to the UK, or were born in the UK but have parents from sub-Saharan Africa (32). 
In contrast, in the USA, many parents of children living with PHIV have a history of psychiatric 
illness and substance use (73,184). All of these differences could account for disparity in EIC 
across these populations. 
The use of such a complex measure in my analysis is inevitably much more time consuming to 
calculate than other simpler measures, demonstrating a trade-off between the detail and 
potential accuracy of the measure versus the simplicity and comparability of the definition used. 
However, the use of such a complex measure in this population of young people living with PHIV 
is perhaps justifiable. All groups of HIV patients have vulnerable sub-populations, but arguably, 
young people with PHIV are perhaps uniquely complex due to them having life-long HIV and 
long-term ART exposure.(185) There is of course variability within young people with PHIV. 
Young people born with PHIV more recently are more likely to have started effective cART 
regimens very young prior to experiencing AIDS defining illnesses, had higher CD4 counts at ART 
start and have been managed in a much more clinically optimistic era.(185)  For young people 
born prior to the era of effective cART, there was huge uncertainty about their life expectancy 
when they were diagnosed with HIV. They are more likely to have started ART later in life with 
lower CD4 nadirs which reduces the likelihood of immune reconstitution.(55,67,186) Early ART 
regimens were less efficacious and may have contributed to comorbidities and 
resistance.(67,162,186)  
3.5.3. Limitations 
The methods by which I adapted Howarth et al’s (151) algorithm to young people living with 
PHIV potentially introduced a number of biases, which need careful consideration when 
interpreting the flowcharts’ findings. The full list of biases considered, are shown in Table 3.21, 
I describe and the main ones below. 
Firstly, when developing the flowcharts for use in young people, I tried to categorise in detail 
something that might otherwise be considered by a clinician to be a “feeling” or “clinical 
suspicion” about how the patient will be over the next few months (Table 3.21, bias 1). In 
addition, the clinician is very likely to take the patient’s history into account, and not judge solely 
how they present at this one visit. The strict criteria and requirement for each patient to fit into 
a terminal box discounts all of this clinical “skill” and much of the patient history, which could 
result in a misclassification of the time to next scheduled appointment. This could result in an 
over- or underestimate of EIC.  
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When classifying patients in the flowcharts, it was only possible to use criteria that were 
measured in CHIPS (CD4, VL, weight etc.) (Table 3.21, bias 2). There are other criteria that I was 
not able to take into consideration, such as reported adherence to medication, which may 
influence the time to next scheduled appointment. This misclassification could result in either 
an over- or underestimation of EIC. 
It is also possible that the clinicians involved in the development and review of the flowcharts 
were not representative of clinicians across England, as they were all from large tertiary clinics 
(Table 3.21, bias 3). Therefore, the criteria of time to next scheduled appointment, as set out in 
the flowcharts, may not always reflect national practice. A possible example is the issue of a high 
proportion of patients apparently attending 6 month appointments early. A number of the 
clinicians reported they scheduled appointments with stable, older patients, and those away at 
university, every 6 months. However, participants classified for 6 months follow-up were more 
likely to come back earlier than those classified for 3 or 4 months. If clinicians were recalling 
patients more frequently than reported, I may have overestimated EIC. If time had allowed I 
would have further clarified scheduling with clinicians. Instead, to examine the possible effect 
of early attendance to 6 month appointments on the predictors of EIC, a sensitivity analysis was 
performed on the final logistic regression model, with results reported in Chapter 5. 
Howarth et al (151) classified newly diagnosed patients for an earlier follow-up visit because 
these patients need a number of baseline investigations, additional support and clinical input 
around their diagnosis and to start ART.(187) For my analysis, it was decided not to include new 
patients as a separate group because one of the inclusion criteria for the AALPHI study was that 
participants had to be aware of their diagnosis for at least 6 months (Table 3.21, bias 4). 
However, even after 6 months it is likely that young people with a new HIV diagnosis may need 
additional support and more careful management. Any new patients who attended more 
regularly would have been categorised in these flowcharts as an early attender, which would 
not bias the EIC estimate. However, any young people who did not attend these more frequent 
appointments would have been classified by these flowcharts as in care when in fact they were 
not. This differential bias could result in an overestimation of EIC. To investigate the extent of 
this possible bias, the number of patient diagnosed within the last year was examined. As there 
were only four participants who fell into this category, the effect of this is likely to be very small. 
When assembling the data sets, the methodological decision to use clinical markers to assemble 
proxy clinic appointments may also have led to possible bias. Firstly, in the assembling of the 
visit date, it was assumed that clinical markers occurring within a week of each other were a 
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cluster related to the same visit (Table 3.21, bias 5). Within this cohort there are a number of 
very complex patients with HIV sequelea, poor immune function, mental health problems and 
increased risk of mortality.(182) These patients may have periods attending clinic very 
frequently, and so it is plausible that in some instances the multiple clinical markers are actually 
related to separate visits. In these cases, grouping these visits would be a misclassification and 
EIC will have been underestimated.  
Howarth et al (151) highlight that one of the major weaknesses of their algorithm is that patients 
may visit HIV clinics for psychosocial issues which may not be captured in the clinical dataset 
(Table 3.21, bias 6). A fully comprehensive measure of EIC would capture this activity. However, 
visits for psychosocial reasons are not collected in the CHIPS dataset. Missing these additional 
appointments would be a measurement error and could result in an underestimation of EIC.  
Another potential problem with the use of clinical markers as proxy clinic visits is that there is 
an assumption that all of these measurements happen in conjunction with a clinic appointment 
(Table 3.21, bias 7). The EIC outcome measured in this analysis is of an interaction with a 
clinician. However, there is potential that some of the clinical markers could occur in the absence 
of an actual clinic visit, for example if a patient attends clinic for bloods with a phlebotomist and 
not a clinician. Therefore, this bias could have resulted in a misclassification and an 
overestimation of EIC.  
The final potential source of bias related to the use of proxy markers pertains to the frequency 
of HIV marker measurement (Table 3.21, bias 8). Xia et al (138) noted that due to guidelines 
recommending less frequent CD4 and viral load measurements, participants could be mistakenly 
classified as out of care because despite attending clinic where no blood test was taken. UK 
guidelines similarly recommend less frequent testing in adults.(187) Therefore, a young person 
who is stable on adult ART doses and has reached adult height may not have any anthropometric 
measurements taken (height or weight), a change in ART medication or any blood tests. 
Consequently, such visits may not be identified in this dataset. However, guidelines for patients 
in a paediatric clinic still recommend monitoring viral load every 3 to 4 months and CD4 every 
6-12 months.(173,188) Therefore, young people attending paediatric clinic, may be more likely 
to be classified as EIC than young people in adult clinic, resulting in differential misclassification 
and a possible underestimation of EIC in young people seen in adult clinic.  
As this was a retrospective analysis, all the blood results were assumed to be available at each 
‘visit’ during the categorisation of time to next scheduled appointment in the flowcharts (Table 
125 
 
3.21, bias 9). In the clinic setting, follow-up appointments are based on patient’s report of their 
health and adherence to ART and the findings during a clinical examination. Blood test results 
are not available to the clinician when scheduling the next appointment. If the blood test reveals 
an unexpected result, it is likely the patient may be contacted to have their appointment 
changed; this is especially likely if an earlier appointment is required.  However, in a busy clinic 
this may not happen in all cases. This possible bias would cause a misclassification of time to 
next scheduled appointment and could either over- or underestimate EIC. 
Another potential bias of the flowcharts was introduced when the data were changed moving 
from continuous time to month intervals and how this then affected classification of in or out of 
care (Table 3.21, bias 10). To make the model more like actual clinic visits, participants were 
given an extra 15 days beyond the time to their scheduled appointment date before they were 
expected to be back in care. It was also decided to classify participants as ‘in care’ if they 
attended a visit in a month irrespective of when in the month their visit was due that they 
attended. The risk of not doing this was that one month intervals would be classified as ‘out of 
care’ when actually the participant, or clinic, had just deferred the visit by mutual agreement. 
However, this introduces potential bias because participants were classified as in care despite 
being a possible maximum of 6 weeks late for their appointment. This may have caused 
misclassification and underestimated the periods and length of time participants had out of care. 
Reassuringly, when this was investigated, of 183 visits that were late but classified as ‘in care’, 
58% (n=103) were within the intended 15 days leeway and across the 183 visits median time 
from scheduled appointment to attended visit was 11 days [IQR 5, 25]. 
Missing data are inescapable in epidemiological studies but they do have the potential to 
undermine the validity of results so it important to consider them carefully.(189) At the 
beginning of this analysis, efforts were made to reduce the impact of missing data by collecting 
as much missing data as possible. Thereafter, imputation was performed where appropriate. 
Despite this, there remained a number of ways in which missing data may have impacted on the 
accuracy of the estimation of EIC for this analysis. The important issue when considering missing 
data is whether the data are missing at random or systematically (when there is a relationship 
between the risk of a value to be missing and its value).(189) 
There were a small number of patients who did not have any clinical data for the follow-up 
period and so they were excluded from the analysis (Table 3.21, bias 11). Other patients had 
partial missing clinical data resulting in months/rows being dropped (Table 3.21, bias 12). It is 
most likely that data were missing at random, as the missing data were due to clinic staff not 
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returning annual follow-up forms which affected the whole or part of the follow-up period. The 
instances where this occurred were small (<5% of months), but if this is selection bias, it could 
result in either an over- or underestimate of EIC.  
In addition to patients and rows being dropped, there were missing values that prevented time 
to next scheduled appointment being classified (Table 3.21, bias 14). These missing values could 
have been caused by values not being entered on the form, missing values at the clinic end (lost 
samples) or an incomplete range of blood tests being taken. These errors are most likely to be 
missing at random and could have caused either an over- or underestimate of EIC.  
Finally, participants could have proxy markers or serious event such as CDC C events not 
reported on their CHIPS forms (Table 3.21, bias 16). It is likely these were missing at random and 
could have over- or underestimated EIC.  
Overall, the bias caused by missing data is unlikely to have too great an impact on the outcome 
of EIC because the amount of missing data was relatively small. In total, 8% of all rows, 6% of 
rows with a visit and 3% of patients were dropped. Thirteen per cent of patients were in shared 
care but they had a similar number of median visits to patients not in shared are.  
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Table 3.21: Summary of potential biases in defining the EIC outcome, and their potential impact on the EIC estimate 
Method Issue, [bias number] Type of error  
Over-or under-
estimation of EIC  
Adjustments made 
Adapting the clinical criteria and developing the flowcharts for use in young people:   
Classification of 
clinical criteria 
for use in YP 
Strict categorisation of patient clinical data does not capture the 
clinical “skill” and historical context used when assessing patients 
and scheduling the timing of the next appointment. [1] 
Misclassification Either  
When classifying patients in the flowcharts, only criteria that were 
measured in CHIPS were taken into consideration. Additional 
factors, e.g. adherence, might have been useful. [2] 
Misclassification Either  




The time to next scheduled appointment classification used may not 
be reflective of wider clinical care practice in England, especially 
when criteria used deviated from Penta consensus guidelines. 
Therefore, actual times to next appointment might have been 
earlier or later than my classifications if my flowcharts did not 
represent actual practice. [3] 
Misclassification Either 
Patient characteristics and alternate 
clinical cut offs were assessed for 
participants who were but early vs. not 
early (all ‘in care’), and no substantial 
differences were found.  Sensitivity 
analyses are conducted and presented in 
Chapter 5 
New patients 
Flowcharts did not allow for more careful monitoring of newly 
diagnosed patients, who in reality may have been assigned more 
frequent appointments (e.g. recurring monthly appointments), and 
were incorrectly assigned longer gaps between appointments in my 
flowcharts.  New patients who attended these frequent 
appointments would have been categorised in my flowcharts as 
“early” attenders, and this does not affect their outcomes. However, 
new patients who did not attend these more frequent 
appointments would have been classified as EIC when in fact they 




The number of new patients was 
reviewed and was very small 
Assembling the dataset:    
Proxy markers 
When proxy visits were created using clinical data, the assumption 
was that clusters of ‘proxy markers’ in the same week were for the 
same visit, but this may not have been the case. [5] 
Misclassification Underestimation  
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Method Issue, [bias number] Type of error  
Over-or under-
estimation of EIC  
Adjustments made 
Patients could be attending additional appointments for 
psychosocial reasons not captured in clinical measurements used as 




My EIC outcome was a measure of interaction with a clinician. Some 
of the tests may have been taken outside of a clinic visit (for example 
bloods with a phlebotomist) and therefore my algorithm may be 
incorrectly assuming a clinic appointment when patients attended 
hospital just for a blood test and did not see a clinician. [7] 
Misclassification  Overestimation  
Adult HIV guidelines recommend less frequent monitoring of viral 
load and CD4 markers. Therefore, an older young person, who has 
reached their full height, is on stable ART and attends an adult clinic, 
may not have a CD4 count, viral load, or height or weight  
measurement recorded at every clinic visit, and visits may therefore 
be missed. However, paediatric HIV guidelines do recommend 
frequent monitoring of these markers, and so my methods are more 
likely to completely capture paediatric clinic visits than adult clinic 




Real time delay 
in blood results 
In real life clinical practice, the next appointment is often scheduled 
at the current visit, before all the blood results are available. 
Although appointments may be rescheduled if there are unexpected 
bloods results, in a busy clinic, this may not always happen. 
Therefore, the assumption that all of the results were available 
when then next appointment was scheduled may not be 
representative of real life scenarios.[9] 
Misclassification Either  
Classifying 
patients as in or 
out of care 
By adding 15 days and allowing participants to be considered in care 
whenever they attend a visit in the month following their schedule 
appointment may introduce too much leniency in the model 
underestimating the periods and length of time participants had out 
of care. [10] 
Misclassification Underestimation 
Late visits for participants in care were 
examined. 103/183 (58%) were with I 15 
days. Overall median time to visits from 
scheduled appointment date was 11 
days [IQR 5. 25] 
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Method Issue, [bias number] Type of error  
Over-or under-
estimation of EIC  
Adjustments made 
Missing data/data cleaning:    
Exclusion of 
patients 
A small number of patients had no clinical (CHIPS) data for the 
follow-up year and were excluded. [11] 
Selection bias Either  
Partial missing 
data 
Some patients had partial missing clinical (CHIPS) data, for which 
person months were dropped. [12] 
Selection bias Either  
Dropping rows 
If there were two visits within a single month, the first visit was 
dropped so that scheduling for next appointment was based on the 
most recent results. However, these two visits could have been true 
separate visits. [13] 
Misclassification Underestimation  
Data errors 
There may have been inaccurately recorded or missing clinical data 
on CHIPS forms, and data entry errors.  These may lead to patients’ 
time to next scheduled appointment being classified incorrectly. 
[14]  
Misclassification Either 
Data checks and imputation were 
performed 
HIV guidelines recommend that patients should be on cART, so 
those on 1 or 2 drugs could be indicative of errors in data entry. [15] 
Misclassification Underestimation 
Data checks were conducted on all 
patients on 1 or 2 drugs 
Unreported 
proxy markers – 
shared care 
Proxy markers or serious events such as a CDC C event may be 
erroneously omitted from CHIPS forms, due to them being 
completed elsewhere. [16]  
Missing data Underestimation  
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Many of the biases mentioned may account for the 39% of clinic visits that were attended 
early. For example, patients may be coming back for mental health visits or they could be 
coming back for a repeat viral load following a viral load blip. However, the classification of 
the 6 month appointments are likely to account for a substantial proportion of early visits  
which is why it is examined in the predictors chapter.  
In addition to the methodological limitations, there are a number of practical considerations 
and limitations of the flowcharts. Due to the number of criteria used in the classification of 
the follow-up of young people living with HIV, the flowcharts were complex and time 
consuming to set up and they require regular updates in accordance with changing 
guidelines, practice and treatment options. For example, these flowcharts focus on the 
treatment choice between the use of PIs and NNRTIs as third agents. Integrase inhibitors 
were new when the flowcharts were developed but now are recommended as possible first 
line third agents alongside PIs and NNRTIs.  
Finally, application of a “simpler” definition of EIC to my population of young people living 
with PHIV in addition to the flowcharts I have developed may have added value as it would 
have allowed a more direct comparison of different definitions of EIC. However, such 
“simpler” definitions still require relatively complex programming, and it was beyond the 
scope of my PhD to carry this out.  
3.5.4. Concluding remarks 
Despite the limitations and possible biases discussed, there are a number of benefits of the 
flowcharts that I developed that lend them to possible future use. The flowcharts are easy 
to understand and provide a flexible way to measure EIC taking into account changes in 
patients’ health status and ART treatment over time. Moreover, only routinely collected data 
were required to classify participants so the flowcharts can be adapted to other cohorts or 
datasets.   
Future possible application includes examining EIC over a much longer period of time and 
allowing comparison across different time periods. The flowcharts can also be used for 
commissioning purposes to examine the complexity of this cohort’s clinical care needs within 
clinics, regionally or nationally. Children and young people living with HIV have very different 
clinical needs compared to adults in the UK. Therefore, the existence of flowcharts that have 
been developed specifically to measure engagement in clinical care for young people living 
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with PHIV is a useful tool to highlight the clinical management needs of this group to HIV 
commissioners. 
3.5.5. Key messages from this chapter 
• Development of a flexible new approach to measuring EIC that takes into account 
changing health status 
• Classifications are based on both clinical guidelines and clinician’s experience 
• 87% of 3,585 person months of follow-up across 306 participants were engaged in 
care 
• Two thirds of clinic visits were in participants with on ART with a viral load ≤50c/mL 
• Participants off ART accounted for less than 10% of months with a visit 
• Nearly half of appointments were categorised as requiring the next schedule 
appointment after 4 months. 
• Participants were most likely to attend their appointment early if their time to next 





Chapter 4. Characteristics of participants enrolled in 
AALPHI contributing follow-up to the analysis 
 Introduction 
In this chapter, I describe the methods by which I complied the exposures considered as 
potential predictors for EIC in the models described in Chapter 6. I then present these 
exposure variables using descriptive statistics and compare to data from other relevant 
studies and populations to contextualise the AALPHI cohort for the reader. The exposures 
are grouped in “domains” of related factors. In this chapter, the characteristics are presented 
and then discussed within each domain, so this chapter does not follow the usual format of 
results then discussion.  
 Objectives 
• To describe the characteristics of AALPHI participants  
• To compare findings from analysis of AALPHI participants’ data to the national HIV 
cohort or the wider general population where comparisons are available 
 Methods 
4.3.1. Exposure variable inclusion 
Potential exposure variables considered for inclusion in the models in Chapter 5 were from 
the AALPHI and CHIPS studies. Due to the large number of data items collected in the AALPHI 
study, inclusion of exposure variables in this analysis were based on prior published reports 
of factors with a known to be associated with EIC in young people living with PHIV or expert 
opinion. In addition, exposure variables that may affect recognised factors were also 
included. For example, mental health has been found to be associated with poorer EIC,(190) 
therefore variables that are associated with mental health problems (such as exclusion from 
school and death of parents) have also been included in this analysis.  
Table 4.1 shows all the variables considered for inclusion in the predictive models analysis, 
grouped by domain, as well as the rationale for their inclusion.  A priori variables were those 
included in all multivariable models while variable selection methods (described in the next 
chapter) were applied to potential exposure variables in other domains. Variables in the a 
priori domain were selected based on the rationale that they were key potential confounders 
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for the analysis and as such, they needed to be included in all the multivariable models. A 
confounder is a variable that causes the distortion of the association between an exposure 
and health outcome.(191) In the a priori domain, sex, ethnicity and age are acknowledged as 
fundamental factors that may affect health and illness research. Time from AALPHI interview 
and born outside of the UK, are more specific to this analysis. Time from interview was 
included as an a priori variable as it was recognised that EIC might change over time since 
AALPHI interview (baseline) and to explore whether any potential associations between 
exposure variables (measured at baseline) and EIC changed over the one year follow up 
period. Whether patients were born abroad or in the UK was included specifically for this 
population because a high proportion of the cohort are born abroad, largely in Sub-Saharan 
Africa (192) and place of birth might be associated with EIC and a number of the other 
variables included in this analysis.   
Other exposure variables considered for inclusion in the predictive models were classified 
into six domains: sociodemographic; risk behaviour practices; mental health; cognition; clinic 
and HIV markers. Examples of variables that were considered based on evidence from the 
literature are alcohol use, which has been associated with lower EIC, and adolescent services 
(clinic type) which has been associated with better EIC. Examples of variables that were 
considered based on expert opinion were smoking (ever smoke cigarettes) and condom use, 
which were due to the association between other risk behaviour factors and lower EIC and 
mental health problems. Clinic location was included due to work by an MSc student being 
conducted at the time which suggested a possible cluster of complex patients in the North 




Table 4.1: Exposure variables considered for inclusion in the multivariable models, and the 
rationale for inclusion, by domain 
Domain, exposure variables 
Exposure – outcome rationale for inclusion in this analysis 
(references) 
A priori (included in all 
multivariable models)  
Time from AALPHI interview 
(months) 
To understand the effect of time since AALPHI variables 
were collected 
Sex  Males associated with lower EIC (161,162) 
Age at entry Older child age associated with lower EIC 
(161,162,193,194) 
Adolescents have lower EIC compared to adults 
(2,118,127,190,195) 
Ethnicity Ethnicity associated with EIC but varying trends across 
studies (127,161,162,190,195–198) 
Born outside of the  UK/Ireland Being born outside USA associated with higher EIC in USA 
(162) 
Sociodemographic   
Education/employment status Unemployment associated with lower EIC (199) 
Employment associated with lower EIC (200) 
HIV and socioeconomic disadvantage associated with 
underachievement and mental health problems (201–
203) 
Ever excluded from school Exclusion from school associated with mental health 
problems and social exclusion (204,205) 
Death of parents Death of parents associated with mental health problems 
and reduced social support (114,115,206) 
Fostered/adopted People who were orphaned and have frequent carers had 
lower EIC (160) Number of main carers 
Live with parents/carers Living in a household with another person living with HIV 
associated with increased EIC (199) 
Parent/carer in work Employment associated with lower EIC (200) 
Main language spoken at home Speaking a language other than English at home 
associated with mental health problems (114) 
Income deprivation affecting 
children index (IDACI) 
deprivation score 
Low socioeconomic areas associated with increased EIC 
(161) 
Risk behaviour practices   
Ever smoked cigarettes Based on expert opinion 
Had alcohol in the last year Alcohol misuse associated with lower EIC (190) 
Alcohol amount  Alcohol misuse associated with lower EIC (190) 
Ever used recreational drugs Use of recreational drugs (ever) associated with mental 
health problems  (207) and lower EIC  (1,11,24,25,26) 
Ever had sex (vaginal or anal) Sexual activity in young people associated with mental 
health problems (210) 
Age at first sex  Pre-adult sexual activity associated with mental health 
problems (207) 






Domain, exposure variables 
Exposure – outcome rationale for inclusion in this analysis 
(references) 
Mental health   
Feelings about HIV Acceptance of HIV associated with increased EIC (193) 
Ever self-harmed Self-harm associated with other mental health problems 
(211) 
Ever felt life was not worth 
living 
Ever felt life was not worth living is associated with other 
mental health problems (114)  
Major life events Negative life events cause other mental health problems 
(212,213) 
Pediatric Quality of Life 
Inventory (PedsQLTM) 
Lower social functioning associated with other mental 
health problems (204) 
Rosenberg  Self-Esteem Scale   Self-esteem associated with other mental health problems 
(204,211) 
Hospital anxiety and 
depression Scale (HADS) 
anxiety score   
Anxiety associated with other mental health and 
behavioural problems (77) 





composite z score-6 (NPZ-6) 
score1  
Cognitive impairment associated with worse EIC (190) 
Poorer cognition associated with depression (107) 
Clinic   
Clinic location Based on expert opinion 
Clinic type Adolescent friendly services associated with better EIC 
(164,214–217) 
Distance from home to clinic 
(km) 
Further distance from home to clinic associated with 
worse EIC (218) 
Travel time from home to clinic 
(min) 
Longer travel time from home to clinic associated with 
worse EIC (218) 
HIV experience and 
management  
 
Age told HIV diagnosis Had experience of disclosure associated with lower EIC 
(160) 
Number of people told about 
HIV 
Difficulty disclosing to others associated with increased 
internalised stigma and social isolation and decreased EIC 
(159) 
Doses of missed in last 3 days Missed doses associated with mental health problems 
(207) 
Self-assessment of adherence Associated with mental health problems (207) 
HIV markers   
HIV severity:  
Previous CDC C event Previous AIDS diagnosis associated with higher EIC (156) 
Lower EIC associated with CDC C events (119) 
Nadir CD4 cell count (cells/µL ) Higher CD4 nadir associated higher EIC (151) 
CD4 cell count (cells/µL ) Lower CD4 count associated with lower EIC (156,190,219) 
Viral load (c/mL) Treatment failure before disengagement associated with 
lower EIC (118,119,156,158,216,219,220) 
ART:  
Age at ART start Younger age at ART start associated with lower EIC (220) 
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Domain, exposure variables 
Exposure – outcome rationale for inclusion in this analysis 
(references) 
On efavirenz  Efavirenz associated with depression (221) 
Treatment interruption ≥30 
days 
Taking ART associated with better EIC (219,222) 
1 Summary score of six cognition domains  
4.3.1.1. Data collection tools  
A number of tools were used to collect the data included in this analysis. All the tools and 
scoring information related to each tool are described in Table 4.2. Nine tools were used 
predominantly in the mental health domain, but also in the sociodemographic, risk 
behaviour practices and cognition domains. All of the tools described are published tools 
apart from the ‘Feelings about HIV’ tool. Using published tools is beneficial because these 
tools have been validated and comparative data are available. An example is the Pediatric 
Quality of Life Inventory which has been utilised in many paediatric and adolescent cohorts. 
The ‘Feelings about HIV’ tool was developed by the AALPHI team in the absence of an 




Table 4.2: Data collection tools used in AALPHI 
Domain, variable Name of tool/source  Details of tool Scoring information 
Sociodemographic    
Deprivation IDACI (223) A residential deprivation score (based on 
postcode). Small areas of relatively equal size 
(Lower Super Output Areas) are scored based on 
multiple deprivation measures  
Timeframe: Current  (from the last updated 
postcode) 
Participant postcode can be used to measure 
deprivation. Scored from 0-1 on a continuous scale 
with 0 being the most deprived 
Risk behaviour practices    
Alcohol amount Alcohol Use Disorders 
Identification Test 
(AUDIT)(145) 
Self-report questionnaire to identify hazardous 
drinking and harmful patterns of alcohol 
consumption 
Timeframe: Current 
Each response was given a score ranging from 0-4 
and the scores summed over 10 questions. A total 
score of more than eight indicates hazardous and 
harmful alcohol use 
Mental health    
Feelings about HIV AALPHI feelings about 
HIV questions (not 
validated) 
Five response scales displayed as a visual 
analogue scale. 
Q: How do you feel about having HIV now?  
• Very upset-Not upset at all;  
• Think about it all the time–Don’t think 
about it at all;  
• Really sad–Not sad at all;  
• Feel really alone–Feel really supported  
• Really worry about my future health–Feel 
positive about my future health 
Timeframe: Current 
Scores ranged from 0-10 for each question. A 
summary score was created for analysis ranging 
from 0-50 where a higher score represents a 
better perception about living with HIV 
Quality of life Pediatric Quality of Life 
Inventory (140) 
Self-report questionnaire. Two versions: 
Teenage report (13-18) and the Young adult (18-
25) 
Responses to all 23 questions were on a five- point 
Likert scale scored from 0-4. Scores were then 
transformed as follows: 0=100, 1=75, 2=50, 3=25, 
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Domain, variable Name of tool/source  Details of tool Scoring information 
Timeframe: Past month 4=0. Then the mean score of all responses was 
calculated (Total scale score). Higher scores 
indicate better health related quality of life 
Major life events Avon Longitudinal Study 
of Parents and Children 
(ALSPAC) questionnaire 
Questionnaire from ALSPAC ‘Life of a 16+ 
Teenager’ questionnaire. Questionnaire includes 
a list of major life events. Participant answered 
yes or no to experiencing the event. If they had 
experienced the event they ranked the effect of 
the event 
Timeframe: Last year 
Responses to all 21 questions were on a five point 
Likert scale scored from -2 to 2. The summary of 
scores from the 21 questions were then 
categorised into quartiles from most unpleasant 
to most pleasant 




Responses to all questions were on a four point 
Likert scale scored from 0-3 (10 questions in total 
of which five are reverse scored). The total for the 
10 responses was calculated. Scores ranged from 







Self-report questionnaire. One questionnaire 
measures both anxiety and depression 
Timeframe: Past week 
Responses to all questions were four point Likert 
scale scored from 0-3 (14 questions in total of 
which six were reverse scored). Two scores were 
calculated, one for anxiety and one for depression 
(seven questions each). Scores ranged from 0-21. 
Higher score indicated higher anxiety or 
depression. Scores were categorised using 
standard definitions: normal <8, mild 8-10, 
moderate 11-15, severe >15 (224) 
Depression 
Cognition     
NPZ-6 Summary score across 
six cognitive 
domains(107)  
Details of the manufacturers’ reference data for 
the AALPHI cognitive NPZ-6 scores have 
previously been described.(107) 
Using the manufacturers’ reference data, z scores 
were calculated to measure how many standard 
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Domain, variable Name of tool/source  Details of tool Scoring information 
Manufacturers’ reference data were from 
Australian and UK adults. 
deviations AALPHI participants were below or 
above the normative population mean 
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4.3.2. Data cleaning and consistency checks 
4.3.2.1. Data cleaning/checking  
The study statisticians cleaned both the AALPHI and CHIPS datasets prior to this analysis to 
check for inconsistencies and errors. In addition, I carried out several checks for this analysis 
described below.  
4.3.2.2. Consistency 
Consistency was checked throughout the coding process, for example, using cross 
tabulations of derived variables with original variables. In addition, I made checks between 
the CHIPS and AALPHI data where variables were collected in both studies (sex, date of birth 
(DOB), ethnicity, born outside the UK Ireland). Inconsistencies were found for two 
participants who had their ethnicity documented in the CHIPS study but ticked the ‘Prefer 
not to answer’ option in AALPHI. I decided to classify these two as ‘Prefer not to answer’, as 
they had requested, in my analysis dataset. 
4.3.3. Description of variables, comparison to normative data and tests for 
difference 
The distributions of variables were described, presenting the number of participants in each 
category including those with missing data. Additionally, the proportion of participants by 
category is presented, excluding the missing data. To improve comparability between 
exposure variables, all scores were coded so that they went in the same directions, so higher 
scores were better and lower scores worse. 
For the majority of the domains (sociodemographic, risk behaviour practices, mental health, 
cognition, clinic and HIV experience and management domains) distributions were compared  
to normative data from the wider population of young people in the UK. However, for the a 
priori and HIV markers domains and the clinic type variable in the clinic domain, comparison 
to the CHIPS UK and Ireland dataset was possible.  
4.3.3.1. Comparison to UK normative data 
Where possible normative data from the time of the AALPHI interview (2013-2015) were 
selected. Normative data from the UK and Ireland were used;  one exception was the 
manufacturer reference data which for the Cognition Neuropsychological test composite z 
score-6 (NPZ-6) score was based on adult Australians.(107) Where population data were 
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available, the AALPHI sample proportion was compared to the population proportion (i.e. 
under a null hypothesis that the probability of “success” in the AALPHI data was the same as 
the population proportion, where a low p-value suggests the proportion in the AALPHI data 
was different to the population); the bitesti command in Stata was used. Similarly, the 
AALPHI sample mean was compared to the population mean using the ttest command.  The 
prtesti command for a test of two proportions was used to compare proportions in the 
AALPHI sample to another study sample (not population).  When analysing proportions 
“don’t know”, “prefer not to answer” and missing data categories were excluded from the 
denominator. 
As detailed in Table 4.2, a number of the mental health tools were used for which normative 
data were available (Pediatric Quality of Life Inventory, Rosenberg Self-Esteem, Hospital 
anxiety and depression Scale (HADS) anxiety score, HADS depression score). For each of 
these variables, z scores were calculated from the normative data using this equation: 
AALPHI mental health var-comparative study mean score 
comparative study standard deviation 
For the Pediatric Quality of Life Inventory there were two normative samples one to compare 
to healthy young people and the second to compare to young people with diabetes. 
Therefore, two z scores were calculated. For the Rosenberg Self-Esteem Scale, age/sex-
appropriate means and standard deviations were used, and for the HADS anxiety and 
depression scores, data were adjusted for sex. HADS anxiety and depression scores were the 
opposite direction to the rest of the scores (a score above zero means worse anxiety or 
depression). Therefore, scores were reversed for HADS anxiety and HADS depression so all 
the scores could be viewed in one direction (a minus value means worse anxiety or 
depression than population mean). Mean z scores were tested for difference from zero using 
the ttest command in stata.  
4.3.3.2. Comparison to the UK and Ireland CHIPS cohort 
For the a priori and HIV markers domains and the clinic type variable in the clinic domain, 
normative data were available from the UK and Ireland CHIPS dataset. CHIPS participants 
from across the UK and Ireland were included in the comparison group if:  
- they were not in AALPHI 
- they were aged 15-18 years (the IQR for participants in AALPHI) at the midpoint of 
the AALPHI interview period which was 01.01.14 
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The midpoint of the AALPHI interview period (2013-2015) was also chosen as a proxy date 
for selection of clinical data for CHIPS participants for comparison to AALPHI participants.  
Fifty-seven otherwise eligible CHIPS participants were excluded because they had died 
(n=26), moved aboard (n=26) or were lost to follow-up (n=5) prior to the proxy date.  For 
participants in CHIPS who had transferred to adult care before 01.01.14, their clinical data at 
transfer was used for this comparison as adult data were not routinely recorded in CHIPS.  
For most categorical variables, the number and proportion in each category were described 
and compared between the AALPHI and CHIPS groups using the chi-squared test. When the 
expected numbers in the categories were <5, a Fisher’s exact test was used. For continuous 
variables, which were not normally distributed, data were summarised as medians 
(interquartile range) and compared between AALPHI and CHIPS participants using the 
Wilcoxon rank sum test.   
In the HIV markers domain, the closest CD4 cell count (cells/µL) and viral load (c/mL) 
measurements prior to the first interview date were used if they were taken within a window 
of 6 months before and 7 days after the first interview for AALPHI participants or proxy 
interview date for CHIPS comparisons2. Treatment interruption was defined as a gap in ART 
treatment for ≥30 days within the last 2 years before the interview date.  
4.3.4. Missing data 
Individual variable missing data were described within each domain. Forty seven participants 
(15%) were found to have at least one missing AALPHI CRF out of a possible 12. 
 Characteristics 
4.4.1. A priori domain 
Table 4.3 compares a priori characteristics of young people in AALPHI to young people living 
with PHIV aged 15-18 years in the UK and Ireland national CHIPS cohort and not in AALPHI. 
Of the 316 AALPHI participants, 129 (41%) were male and the median age was 17 [IQR 15, 
18]. Most (258, 82%) were black African, and 184 (58%) were born outside of the UK or 
Ireland. 
 
2 The 7 days after the date of the AALPHI interview was given to match the leniency allowed to classify 
whether the AALPHI interview was at the same time as a clinic appointment.  
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Table 4.3: A priori characteristics of young people living with PHIV in AALPHI and a CHIPS 
comparison group 
Variable and categories 
AALPHI cohort 
(n=316) 
 CHIPS cohort 
(n=247) 
p value 
 n  (%)or median [interquartile range (IQR)]  
Male sex 129 (41%)  130 (53%)  0.005 
Age1 17 [15, 18]  17 [16, 17]  
Ethnicity: 
  Black African 
  Black other 
  Mixed 
  White 


























Born outside UK/Ireland 184  (58%)  151 (62%) 0.42 
1Age not compared due to it being a selection criterion. 
4.4.1.1. Comment 
A lower proportion of AALPHI participants were male compared to the remainder of the 
national cohort (41% vs. 53%, p=0.005).  The characteristics of young people who refused to 
participate in AALPHI were not collected, so it is not possible to say whether this finding is 
because fewer males were approached or more males declined. Apart from sex however, 
the other a priori characteristics were similar between AALPHI and the wider CHIPS cohort, 
suggesting that participants in AALPHI are broadly similar to the rest of the UK and Ireland 
population of young people living with PHIV, and therefore representative of the complete 
population. 
4.4.2. Sociodemographic domain  
Table 4.4 presents sociodemographic characteristics of AALPHI participants compared to 
normative data from a variety of studies in the UK. Two hundred and ninety-two (93%) 
AALPHI participants were in education, 8 (3%) were employed and 13 (4%) were not in 
education or employment at AALPHI interview. The majority (259, 82%) had never been 
excluded from school, while 47 (15%) had ever had a fixed period exclusion, and 8 (3%) had 
been permanently excluded. For 94 (30%) of the young people, one parent had died and for 
14 (4%) both parents had died. Fifteen (11%) of the participants were fostered or adopted. 
One in five (64, 20%) young people had ever had a change in main carer (e.g. mother and/or 
father and then grandparent/s) and 47 (15%) had more than two changes in main carer. The 
majority (286, 91%) lived with their parents or carers, and the majority (224, 73%) of parents 
and carers were in work.  Half (164, 52%) of participants only spoke English at home and 143 
(45%) spoke English and another language.  Two hundred and six (75%) lived in “more 
deprived” or the “most deprived” neighbourhoods in England. 
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Normative data p-value 
Education/employment status   
7% of 16-18 year olds in England 
were not in education or 
employment in Jan-March 2014 
(225) 
0.05 
  In full-time education 292 (93%) 
  Employed  






  Missing 3  
Ever excluded from school   Of pupils enrolled in England in the 
academic year 2013/2014, there 
were 0.1% permanent exclusions 
and 7% fixed exclusions (226) 
Permanent exclusion in black 




  No 259  (82%) 
  Fixed exclusion 





  Missing 
2  
Death of parents   
By the age of 16, the death of a 
mother or father occurred in 5% of 
11,000 participants in the 1970 
British Cohort Study  (228) 
<0.001 
  None 187  (60%) 
  One parent died  94  (30%) 
  Both parents died 14 (4%) 
  Don’t know 19 (6%) 
  Missing 2  
Fostered/adopted1   0.6% of children <18 years in the 
UK  
were fostered or adopted by the  
end of March 2014 (229) 
0.02 
  No 116 (89%) 
  Yes 15  (11%) 
  Missing 185  
Number of main carers   
No comparative data 
 
  1 carer 203 (65%)  
  2 carers 64 (20%) - 
  3 or more carers 47 (15%)  
  Missing 2   
Live with parents/carers   
93% of 10-19 year olds lived in 
households with a parent or carer 
in the UK in 2017 (230) 
0.18 
  Yes 286 (91%) 
  No 28 (9%) 
  Missing  2  
Parent/carer in work   73% of people in the UK aged 16-
64 were employed in Apr-June 
2014 (231) 
1.00   Yes 224 (73%) 
  No 83 (27%) 
  Don’t know 7  Of 781 adults living with HIV, 64% 
were  
employed (Data from Positive 
Voices  
Survey cited in HIV in the UK 
report, PHE (232) 
0.005 
  Missing 
2  
Main language spoken at home   
92% of residents in England aged 
>3 years spoke English as the main 




  English only 




(45%)           
  A language other than English 8  (3%) 
  Missing 1  
     






Normative data p-value 
     
IDACI deprivation score    IDACI measures childhood 
deprivation in small areas and 
categories represent  
population quartiles allowing 
comparison  
across England (223) 
<0.001 
  Least deprived  8  (3%) 
  Less deprived  63  (22%) 
  More deprived  140  (51%) 
  Most deprived 66  (24%) 
  Missing 39  
1Added halfway through interview process thus 50% missing data 
 
4.4.2.1. Comment 
A slightly lower proportion of AALPHI participants (4%) were not in education compared to 
national data (7%) for 16-18 year olds in a similar calendar period (p=0.05).(225) 
School exclusions reported by Department of Education figures for England (226) show that 
of pupils enrolled in secondary schools in the academic year 2013/2014, 0.1% were given 
permanent exclusions, and 7% fixed exclusions, with no difference for black African children 
(227). However, the national data are only for one academic year while AALPHI examined 
lifetime history of exclusion over a young person’s whole school career. After multiplying the 
national figure by 6 to approximate to the whole of secondary school, the proportion of 
young people ever reporting permanent exclusions in AALPHI was ~5 times higher than that 
for England (3% vs. 0.6%). It was not possible to compare the proportion of young people 
with fixed exclusions, but 15% is unlikely to be lower than the 7% for England. 
There was very strong evidence to suggest a higher proportion of participants in the AALPHI 
cohort experienced the death of a parent (one or both) compared to the UK population. 
Overall, for a third of AALPHI participants (108, 34%) one or both parents had died, in 
contrast to 5% of 11,000 participants by 16 years of age who were in the 1970 British Cohort 
Study (p<0.001).(228)  
A higher proportion of AALPHI participants (11%) had been fostered or adopted compared 
to children less than 18 years of age in the UK (0.6%, p=0.02).(229) No UK comparative data 
could be found for the change in number of main carers that young people in AALPHI 
experienced in their childhood. It seems likely, however, that young people in AALPHI would 
have had more changes than the general population due to the relatively high levels of 
parental death and adoption and fostering in the cohort. The majority of young people in 
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AALPHI (91%) still lived with their parents/carers, similar to data for 10-19 (93%, p=0.18) year 
olds in the UK (230) although the AALPHI group are older  
There was no difference in the proportion of working parents/carers (73%) as reported by 
the AALPHI participants when compared to adults in the general population in 2014 (73%, 
p=1.0) (234). This was significantly higher, however, than reported in a survey of 781 adults 
living with HIV from clinics across the UK (AALPHI: 73% vs. Positive Voices: 64%, 
p=0.005).(235) However, respondents to the survey were predominantly white men (68%) 
who had sex with men (78%) making comparison difficult.(236) It is also important to bear in 
mind that the percentage of parents/carers of participants in the AALPHI cohort who were 
living with HIV is not known. 
Census data from 2011 (233) reported that 92% of residents in England aged over three years 
spoke English at home. A greater proportion of people in the AALPHI cohort spoke some 
English in their home (97%=52% English only and 45% English and another language) but 
data were not collected in AALPHI about whether English was the main language spoken.  
Using the Income deprivation affecting children index (IDACI) measure of deprivation, three 
quarters (75%) of AALPHI participants were classified as living in areas in the lowest five out 
of 10 IDACI deprivation deciles (bottom 50%). There was strong evidence (75% vs. 50%, 
<0.001) therefore that AALPHI participants were living in disproportionately disadvantaged 
areas compared to other children and young people in England. 
4.4.3. Risk behaviours practices domain 
Risk behaviour practice characteristics in the AALPHI cohort are compared to normative data 
from various parts of the UK in  Table 4.5. The majority of AALPHI participants did not smoke 
cigarettes (242, 83%) and had not drunk alcohol in the last year (174, 59%).  Of the young 
people who did drink, 30 (25%) were classified in the Alcohol Use Disorders Identification 
Test (AUDIT) Tool as drinking to hazardous levels.(145) Forty-three (25%) young people had 
ever used recreational drugs.  
Ninety-three (32%) young people were sexually active, of whom 70 (77%) were aged 15-17 
years when they first had sex. Thirty young people (10%) reported ever having sex without a 







Normative data  
p value 
Ever smoked cigarettes   23% of 16-24 year olds 
were current smokers in 
2014 in Great Britain 
(237) 
0.05 
  No 242 (83%) 
  Yes 54 (18%) 
  Missing 20  
Had alcohol in the last year   48% of 16-24 year olds in 
2014 drank in the last 




  No 174 (59%) 
  Yes  123 (41%) 
  Missing 19  
Alcohol amount (n=123)   17% of 16-24 year olds 
who drank, consumed 
more than their weekly 
allowance in a single day 
in Great Britain (238) 
Data not 
comparable 
  Drink but not hazardous 92 (75%) 
  Hazardous drinking 30 (25%) 
  Missing hazardous drinking score  
1  
Ever used recreational drugs   19% of 16-19 year olds 
and 19% of 20-24 year 
olds had used 
recreational drugs in the 
last year in England and 
Wales from 2013/14 
(239) 
0.07 
  No 248 (75%) 
  Yes 43 (25%) 




Ever had sex (vaginal or anal)   
31% of all 16-34 year olds 
had sex before 16 years 
old in Britain (National 
Surveys of Sexual 
Attitudes and Lifestyles 




  No 195 (68%) 
  Yes 93 (32%) 
  Prefer not to answer 8    
  Missing 20  
Age at first sex (n=93)   
  ≤14 18 (20%) 
  15-19 70 (77%) 
  20+ 3   (3%) 
  Missing 2  
Condom Use     
Not sexually active 195 (68%) 14% of 16-24 year olds 
had at least 2 sexual 
partners with whom no 
condom was used in the 
last year (NATSAL) in 
2010-2012 (240) 
0.09 
Always use a condom 63 (22%) 






The fifth (18%) of young people in AALPHI who ever smoked cigarettes was marginally lower 
than the proportion of 16-24 years olds in Britain who reported currently smoking in 2014 
(23%, p=0.05).(237) It seems likely that this difference would have been even bigger if 
current smoking had been measured in the AALPHI cohort. There are no UK normative data 
for the AUDIT tool for young people, although Office for National Statistics data suggest that 
48% of 16-24 year olds in Great Britain drank in the last week. Notwithstanding the different 
reporting window used by the Office for National Statistics, these results suggest that AALPHI 
participants’ alcohol consumption was either less than or similar to other young people in 
Great Britain.(238) Of the 48% of 16-24 year olds who drank in the last week in the Office for 
National Statistics study, 17% drank more than the recommended weekly alcohol limit on 
their heaviest day, which compares to 25% of AALPHI participants who were classified as 
hazardous drinkers based on alcohol consumption in the last year. Although the two studies 
were using different reporting windows to measure hazardous drinking, the findings are not 
inconsistent with each other. Similar proportions of participants in AALPHI (25%) and 16-24 
year olds (19%) in England and Wales had used recreational drugs (p=0.07), although the 
reporting windows were lifetime in AALPHI and in the last year in the national dataset.(239)  
In the National Survey of Sexual Attitudes and Lifestyle (NATSAL) in 2010-2012, a third of 16-
34 year olds reported having sex before the age of 16.(240) In the AALPHI cohort, a third of 
the cohort also reported being sexually active, but the cohort was older (aged 13-21 years of 
age) suggesting that young people in AALPHI may be delaying their first sexual encounters. 
Comparable proportions of young people in NATSAL reported inconsistent condom use as in 
AALPHI (14% vs. 10%), but the definitions were dissimilar (“do not always use a condom” vs. 
“had at least 2 sexual partners with whom no condom was used in the last year”) to consider 
testing formally.  
4.4.4. Mental health domain 
The mental health characteristics of the AALPHI cohort, and comparative data from studies 
in the UK and Ireland, are presented in Table 4.6. The median score for feelings about HIV 
was 35 out of 50 (maximum score) [IQR 22,43] where a higher score represents a better 
perception about living with HIV, and as this measure was not a standard tool, no 
comparative data were available. Thirty-seven (12%) young people had ever self-harmed and 
117 (39%) had ever felt that life was not worth living. Three-fifths reported experiencing life 
events in the last year which were pleasant (106, 35%) or very pleasant (82, 27%).  
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Table 4.6: Mental health characteristics of participants in AALPHI (n=316) and normative 
data 
Variable 
AALPHI n(%) or mean {standard 
deviation (SD)} median 
[interquartile range (IQR)] 
Normative data p value 
Feelings about HIV (summary 
score) 
  
No normative data - 
Median score 35 [22, 43] 
Ever self-harmed   19% of 4,810 16-17 year 
olds ever self-harming in 
England (ALSPAC)  
2007-2008 (142) 
 
No 265 (88%) 
0.002 Yes 37 (12%) 
Missing 14  
Ever felt life was not worth living   16% of 4,810 16-17 year 
olds ever felt life was not 




No 182 (61%) 
<0.001 
Yes 117 (39%) 
Missing 17  
Major life events in the last year 
(quartiles) 
    
Most unpleasant events 49 (16%) 
No normative data - 
Some unpleasant events 63 (21%) 
Some pleasant events 106 (35%) 
Most pleasant events 82 (27%) 
Missing 16  
 
The mean Pediatric Quality of Life Inventory summary score was 75 out of 100 (maximum 
score) (SD=14) and the mean Rosenberg Self-Esteem Scale was 21 out of 30 (maximum score) 
(SD=5).  There were 172 (61%) participants who scored within the normal range on the HADS 
anxiety tool, and 112 (40%) who scored above the normal range. Only 8 (3%) of AALPHI 
participants scored within the severe range for anxiety. The majority of young people had a 
normal score for the HADS depression measure (240, 85%), while 32 (11%) participants 
scored within the mild range, 12 (4%) within the moderate range, and none within the severe 
range for depression (Table 4.7).  
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Table 4.7: Mental health variables compared to normative compared to mean and z scores 
Variable 









Pediatric Quality of Life 
Inventory 
    
 
  Mean total score 75 {14} Mean total score 
from 8-18 year olds 
in UK: Healthy 84 





  Mean z score healthy -0.77 {1.2}                 -0.90, -0.63 
  Mean z score diabetes -0.59 {1.1} -0.73, -0.48 
  Missing 14   
Rosenberg Self-Esteem      
  Mean score 21 {5} Mean score for 13-
17 year olds -27 {4.0} 
in Ireland (242) 
  
  Mean z score -1.91 {1.6} -2.11, -1.72 <0.001 
  Missing 14    
HADS anxiety score2      
  Mean score 6  {4} Mean scores for 25-
29 year olds in 
England: females 
7{4} and males 6 {4} 
(243) 
  
  Mean z score 0.2 {0.8} -0.08, 0.12 0.66 
  Normal  172 (61%)   
  Mild 64 (23%)   
  Moderate 40  (14%)   
  Severe 8 (3%)   
  Missing 32    
HADS depression score2      
  Mean score 4 {3} Mean score for 25-
29 year olds in 
England: females 




  Mean z score  -0.10 {0.8} -0.20, -0.01 0.04 
  Normal 240 (85%)   
  Mild 32 (11%)   
  Moderate 12 (4%)   
  Severe 0 (0%)   
  Missing 32    
1Mean quality of life score from children with diabetes 





No normative data exist for the feelings about HIV score because this was a set of questions 
developed by the AALPHI team in the absence of any available measure specific to young people 
living with PHIV. Reassuringly there was strong evidence to suggest that the proportion of young 
people who self-harmed was lower in the AALPHI cohort (37, 12%) than in 16-17 year olds in the 
Avon Longitudinal Study of Parents and Children study (ALSPAC) (19%, p=0.002).(142) However, 
there was very strong evidence that a higher proportion of young people in AALPHI had felt life 
was not worth living compared to 16-17 year olds in the ALSPAC study (39%  vs. 16%, p=<0.001)  
Z scores were calculated for Pediatric Quality of Life Inventory, Rosenberg Self-Esteem and the 
Hospital Anxiety and Depression Score (HADS). For the Pediatric Quality of Life Inventory 
normative data were from a sample of 8-18 year olds in the UK (mean scores available from 
healthy young people and young people with diabetes). For Rosenberg Self-Esteem, normative 
data were from 13-17 year olds in Ireland. For the HADS anxiety and depression score, data were 
from 25-29 year olds in England.  
Z scores from Table 4.6 are displayed in a forest plot in . The z-scores were significantly below 0 
in four out of the five mental health variables suggesting that AALPHI participants had on 
average worse mental health scores than the reference population used to derive the scores. 
The AALPHI participants Pediatric Quality of Life Inventory mean z scores were significantly 
below 0 when compared to healthy young people, (p<0.001) and young people with diabetes 
(p<0.001). Most noticeably, the AALPHI participant’s Rosenberg Self-Esteem mean scores (-1.91, 
95% CI -2.11, -1.72, p<0.001), were close to two standard deviations below 0 when compared 
to the reference population. There was no difference between AALPHI participants’ mean HADS 
anxiety z scores and reference population (0.2, 95% CI -0.08, 0.12, p=0.66) and weak evidence 
of worse mean HADS depression scores compared to the reference population, with the upper 
limit of the confidence interval for the mean very close to 0 (z score -0.10, 95%CI -0.20, -0.01, 
p=0.04). However, it was not possible to find age-appropriate normative date for the HADS 






Figure 4.1:Forest plot of mean (95%CI) mental health scores for young people in AALPHI 
 
4.4.5. Cognition domain 
Table 4.8 presents the NPZ-6 z score mean and the NPZ-6 category for AALPHI participants. The 
mean z score was -0.54 and 215 participants (75%) scored below the reference mean, with 74 
(26%) of young people scoring more than one standard deviation below the reference mean.  
Table 4.8: Cognition characteristics of participants in AALPHI (n=316) and 
normative data 
Variable 




Normative data 95% CI 
p value1 
(z score) 
NPZ-6 z score -0.54 {0.86} Manufacturer 
normative data 
used for 11 
tests 
in 6 cognitive 
domains (107) 
-0.57, -0.52 <0.001 
NPZ-6 category     
  <-1 74 (26%)   
  ≥ -1 to <0 141 (49%)   
  ≥0 75 (26%)   
  Missing 27 (24%)   








  0.66 
 






When summary NPZ-6 scores were compared to reference population, there was strong 
evidence that young people in the AALPHI study had poorer cognitive performance 
(p<0.001).  
4.4.6. Clinic domain 
Table 4.9 presents the clinic characteristics for the clinics from which the AALPHI cohort were 
recruited or where participants received their HIV care (if recruited in the voluntary sector), 
as well as the available UK and Ireland normative data for comparison. Two hundred and 
thirty (73%) AALPHI participants were recruited from London clinics and 234 (77%) from 
paediatric care. The median distance from home to clinic was 10km ([IQR 5, 21], min 1, max 
405) and the median travel time to clinic was 31 minutes ([IQR 19, 46], min 5, max 327). In 
paediatric HIV, a number of patients do travel long distances (and therefore have a long 
travel time) usually to tertiary clinics because paediatric HIV is a rare disease and is managed 
in a small number of clinics across the UK.  
Table 4.9: Clinic characteristics of participants in AALPHI (n=316) and normative data 
Variable 




     Normative data 
P 
value 
Clinic location   
No UK data 
 
  Enrolled in London 230 (73%) 
-   Enrolled outside London 86 (27%) 
  Missing 0  
Clinic type1   Of 247 15-18 year old participants in CHIPS 
but not in AALPHI, 201 (81%) were still in 
paediatric care, 14 (6%) had transitioned to 
adolescent clinic, 32 (13%) to an adult/GUM 
clinic  
 
  Paediatric care 234 (77%) 
- 
  Adolescent clinic 51 (17%) 
  Adult/GUM clinic 17 (6%) 
  Missing 4  
Distance from home to 
clinic (km) 
  
No UK data - 
  Median distance  10 [5, 21] 
  0-59 245 (90%) 
  ≥60 28 (10%) 
  Missing 43  




  Median travel time  31 [19, 46] No UK data - 
  0-59  231 (85%)   
  ≥60  42 (15%)   





Clinics were purposively selected for the AALPHI study based on having large numbers of 
eligible participants for the study, which meant that research nurses recruited in all of the 
largest adolescent clinics in the country. Therefore, although a higher proportion of young 
people in AALPHI had transferred to adolescent clinics than in the comparative CHIPS group 
(17% vs. 6%) the clinics attended by the AALPHI cohort are not representative of clinics 
attended by adolescents living with HIV in the UK. In addition, clinic type was classified by 
AALPHI research nurses for the AALPHI clinics and by clinic staff in the CHIPS study, which 
may cause further disparity. There were no comparative data in the UK for clinic location, 
travel time to clinic or distance to clinic. 
4.4.7. HIV experience and management domain 
Table 4.10 presents the HIV experience and management characteristics of AALPHI 
participants. The median age when AALPHI participants were told their HIV diagnosis was 12 
years [IQR 11, 13]. Fifty young people (17%) were told about their HIV diagnosis when they 
were 13 years or older.  More than half of the AALPHI participants (161, 55%) had never 
independently told anyone about their HIV status and only a small proportion had told 5 or 
more people (4% had told 5-9 people and 4% had told ≥10 people). One hundred and ninety 
(73%) AALPHI participants reported that they had not missed doses of ART in the three days 




Table 4.10: HIV experience and management characteristics of participants in AALPHI 
(n=316) and normative data 
Variable 
n (%) or median 
[interquartile range 
(IQR)] 
Normative data p value 
Age told HIV diagnosis:    
Median age at naming of HIV 12 [11, 13] 
UK audit of clinics providing 
HIV services for PHIV in UK 
& Ireland. Median age of 
naming 12 year olds (age 
range 10-15) Cited in (79) 
- 
Age at naming of HIV     
  <11 years 88 (30%) 
- 
  11 years 43 (15%) 
  12 years 38 (13%) 
  ≥13 years 50 (17%) 
  Don’t know 75 (26%) 
  Missing 22   





  0 161 (55%) 
No UK normative data - 
  1-2 75 (26%) 
  3-4 32 (11%) 
  5-9 12   (4%) 
  10+ 12   (4%) 
  Missing 24  
Adherence:     
Doses missed in last 3 days   In 502 adults living with HIV 
(on treatment) in London 
based adults (aged >18 year 
olds) 79% did not miss a dose 
in last week (244) 
 
  No 190 (73%) 
0.061 
  Yes 70 (27%) 
  Not on ART 35  
  Missing 21  
Self-assessment of adherence     
  Excellent 104 (35%) 
No UK normative data - 
  Good 121 (41%) 
  Not so good 24   (8%) 
  Bad 10   (4%) 
  Not on ART 35 (12%) 
  Missing 22   
1 Proportion of AALPHI participants on ART (260) who had not missed a dose (190, 73%) were compared to 79% of adults in 
London 
4.4.7.1. Comment 
The age at which participants in AALPHI were told their HIV diagnosis (median age 12, [IQR 
11,13]) was the same as data from an audit of clinics seeing children and young people living 
with PHIV in the UK in 2007.(79) Of note, a quarter of participants in AALPHI (75, 26%) could 
not remember how old they were when they were told their HIV diagnosis. No comparative 
data were available for the number of people, young people had themselves, told about their 
HIV status. Of those on ART (260), a similar proportion of AALPHI participants (190, 73%) did 




p=0.06), although the time frame for missing a dose in AALPHI was only 3 days compared to 
7 in the adult study.  
4.4.8. HIV markers domain 
Variables from the HIV markers domains, comparing all young people in AALPHI to young 
people living with PHIV not in AALPHI in the UK and Ireland national CHIPS cohort are shown 
in Table 4.11. A total of 84 (27%) AALPHI participants had had a previous CDC C event, the 
median CD4 nadir was 221 [IQR 121, 352], the median CD4 cell count was 597 cells/µL [IQR 
427, 791] and 202 (69%) had a viral load ≤50c/mL. The majority of participants (88%) were 
on ART and the median age at ART start was 7 years [IQR 3, 12]. Nearly a third of AALPHI 
participants on ART (85, 30%) were taking efavirenz as part of a cART regimen. Of the 37 













n  (%) or median [interquartile range (IQR)]  
HIV severity:      
  Previous CDC C event  84 (27%) 48 (19%) 0.05 
  Nadir CD4 cell count (cells/µL) 221 [121, 352] 276 [180, 362] 0.005 
  CD4 cell count (cells/µL)1 597 [427, 791] 592 [446, 752] 0.97 
  Viral load ≤50c/mL2  202 (69%) 152 (70) 0.82 
ART:      
  On ART 279 (88%) 207 (84%) 0.12 
   On efavirenz3 85 (30%) 9 (4%) 0.64 
  Off ART 37 (12%)    
    On an ART  interruption (≥30 days) 4 14 (38%)    
  Age of ART start 7 [3, 12] 8 [3, 12] 0.84 
1 Data only available on 492 patients (279 in AALPHI and 213 in CHIPS) at the time of the AALPHI interview 
2 Data only available on 507 patients (291 in AALPHI and 216 in CHIPS) at the time of the AALPHI interview 
3 Proportion of participants on ART (279/316) 
4 Proportion of participants off ART (14/37) 
 
4.4.8.1. Comment 
A slightly lower proportion of young people in CHIPS (19%) had had a previous CDC C event 
than in AALPHI (27%, p=0.05) and, consistent with this, there was strong evidence to suggest 
young people in CHIPS had a higher median CD4 nadir (276 [IQR 180, 362] vs. 221 [IQR 121, 
352], p=0.005). Otherwise, there was little difference between the HIV markers of the two 






4.5.1. Summary of main findings 
In this chapter, I defined the variables included in my quantitative analysis and outlined the 
rationale for their use. In addition, all the tools used to collect data that were then used in 
the analysis were described. I also outlined the methods for cleaning the data and comparing 
the variables between young people living with PHIV in AALPHI and HIV- youth in the general 
UK population. Summary statistics for the domains (a priori, sociodemographics, risk 
behaviour practices, mental health, cognition, clinic, HIV experience and management and 
HIV markers) were presented with comparative data, where it existed, to contextualise 
AALPHI participants. In summary for each domain: 
• A priori domain: participants in AALPHI were broadly similar to participants in CHIPS 
except AALPHI participants were more likely to be female than CHIPS participants.  
• Sociodemographic domain: similar proportions of young people were in education 
and employment as well as living at home when compared to other young people in 
the UK population. However, young people in AALPHI were much more likely to have 
had a parent die and or to be fostered or adopted.  
• Risk behaviour practices domain: AALPHI participants were not taking more risks 
than other young people and were perhaps drinking less and having sex later, 
although it is difficult to compare the data due to different definitions employed.  
• Mental health domain: AALPHI participants differed noticeably from other young 
people in the UK general population in regard to their mental health. AALPHI 
participants had on average worse scores or higher prevalence for self-harm, feeling 
life was not worth living, quality of life, self-esteem and depression. 
• Cognition domain: AALPHI participants had lower cognition scores than normative 
data.  
• Clinic domain: There were no comparative data in the UK for clinic variables.  
• HIV markers domain: When AALPHI participants were compared to CHIPS 
participants, HIV markers were similar across the two groups except for CD4 nadir 
count, which was on average lower in AALPHI participants and there was marginal 





My results need to be considered alongside some limitations of AALPHI, many of which are 
common to cohort studies. Firstly, there was a risk of selection bias because young people 
who regularly attended their HIV appointments were more likely to have been recruited into 
the study, as much recruitment took place in the clinic setting. To try and limit this bias, 
recruitment also took place in the voluntary sector, where young people who drop out of 
care may also attend. Reassuringly, AALPHI participants’ characteristics were broadly 
representative of young people with HIV in the UK and Ireland. However, the cohorts were 
only compared in terms of demographics and clinical markers. It is much harder to compare 
issues such as cognitive function and so possible differences may have been be missed. 
Another possible selection bias was that young people with severe cognitive delay may not 
have been referred by clinical staff to the study, despite clinic staff being encouraged to make 
such referrals. The final possible source of selection bais, is that to be included in the AALPHI 
study, young people had to have been aware of their diagnosis for at least six months, 
therefore no newly diagnosed young people are included in this analysis. The reason newly 
diagnosed young people were not recurited, was because there was concern this goup may 
be especially vulnerable. However, the number of children and young people newly 
diagnosed in paediatric care in the UK has been stable at 30-50 per year since 2012 and the 
average age at diagnosis is below four years old.(245) Therefore the effect of this is likely to 
be very small. 
The use of questionnaires can also introduced a number of possible measurment errors into 
the analysis. Self-completed questionnaires may introduce social desirability bias by 
respondants completing the questionniare in a way that they think will please the 
administrator.(246) For example, respondants may rate their adherence higher than it 
actually is or report more or less sexual partners than they have actually had. In an attempt 
to reduce this, AALPHI interviews were carefully constructed so that all of the more sensative 
questionnaires asking about topcis such as drugs, sex and mental health measures were 
completed using Computer Assissted Interview (CASI) techniques.(114) Young people 
completed these parts of the interview without help from the research nurse, with the 
screen turned away so the research nurses could not see their responses. Young people were 
also reassured that the research nurse would not see their answers and these were analyses 




Another possible source of measurement error was that respondents were sometimes asked 
to recall events from the past. In these instances, recall bias may have occurred when young 
people remember events incorectly.(246,247)  Examples of interview questions where young 
people sometimes seemed more hesitant were in response to questions about their past 
medical history or the reasons and dates of their parents deaths. Measurement error can 
also occur when questionnaires are poorly phrased and misleading.(247) To try and reduce 
this risk, where possible, standardised tools were utilised in AALPHI. In addition, a working 
manual was produced and updated on a regular basis. Training sessions  were also carried 
out with all the research nurses throughout the study to try and standardise responses to 
commonly asked questions or to update the patient guidance text where possible. 
Measurment error can also occur when participants do not read the instructions properly. 
The main way this error was reduced was by tyring to make sure the instructions were clear 
and by spending time explaining all the sections to the participants. 
Other sources of possible measurement error are related to poor execution of the study 
protocol.(247) Multiple nurses were involved in the study and there may have been a failure 
to carry out the protocol properly by all of the nurses througout the whole of the study. 
Regular training was carried out to try and reduce this. Errors can also occur at any point of 
the data collection and data entry process or when the variables were being programmed 
for the analysis.(246,247) Attempts were made to mitigate this risk by carrying out data entry 
checks (10% overall) throughout the study by a data manager and the proportion of errors 
by each resrearch nurse reported to the study coordinator so that specific training could be 
implemented if needed. Research nurses may have also influenced participants responses 
due to their own sociodemographic characteristics or nursing background. Finally, the 
statistician carried out best practice and included appropriate checks when creating variables 
and programming the data. 
Variables were chosen for inclsuion in this analysis based on the literature and expert 
opinion, however, important exposures for EIC may have been missed using this methods. In 
addition, factors identified in the literature that were not included in the AALPHI iterview will 
be missed. For example, issues to do with youth friendliness of the clinic and relationships 





4.5.3. Concluding remarks 
There are a number of strengths of the AALPHI study. Few such cohorts exist worldwide 
making AALPHI an important addition to the evidence base. Young people recruited into 
AALPHI are some of the first generation of young people surviving perinatal HIV and reaching 
adulthood globally. Understanding these young people’s needs can help health workers in 
the UK and further afield provide appropriate services. AALPHI asked questions on a broad 
range of themes providing information on many aspects of the participants’ lives which could 
then be used to interigate topcs such as EIC in a way that many other stuides cannot. 
A combination of data collection methods were used in AALPHI (face to face, self-
administered, use of medical records) to maximise the benefits of the different data 
collection methods. Employment of research nurses allowed the collection of more complex, 
detailed questions. To try to improve the acceptability of the study questions, the AALPHI 
interview was piloted extensively with young people who were HIV negative and not 
exposed, HIV negative but exposed and young people who were living with HIV.  
In this chapter, I summarised the variables used in this analysis and compared them to 
literature from the UK. Young people in AALPHI are broadly similar to the UK population in 
many ways. However, they are much more likely to have experienced the death of a parent 
and subsequent multiple alternative carers creating a much more unstable environment 
growing up. In addition, young people in AALPHI scored worse in almost all of the mental 
health assessments when compared to young people in the general UK population.   
 Key points from this chapter 
• Due to the breadth of the data collected in the AALPHI study, a large number of 
variables were available for consideration for inclusion in this analysis 
• Variables were justified for inclusion based on evidence from the literature or expert 
opinion 
• Participants in AALPHI were broadly similar to participants in CHIPS except AALPHI 
participants were more likely to be female than CHIPS participants, and have lower 
CD4 nadir on average 
• AALPHI participants were also broadly similar to the UK population in many ways. 
Where they differed was that more young people in AALPHI had lost a parent and 










Chapter 5. Predictors of engagement in care 
 Introduction 
In this chapter, I take the exposure variables assembled and described in Chapter 5 and the 
EIC outcome variable detailed in Chapter 4 and put them together to investigate whether 
the exposure variables predict EIC in multivariable methods. I first describe the statistical 
methods outlining the multiple stages of variable investigation, the four stages of 
multivariable logistic regression modelling, and the methods and rationale for the sensitivity 
analyses. Then I present descriptive results for each exposure variable within each domain 
(a priori, sociodemographic, risk behaviour practices, mental health, cognition, clinic, HIV 
experience and management, HIV markers), including the person months and proportion in 
care. Finally, I present results from the four stages of multivariable logistic regression 
analyses examining the effect of the variables on the EIC outcome, as well as the results from 
the sensitivity analyses.  
 Objective 
• To investigate the relationship between a broad range of potential exposures and 
EIC in AALPHI participants, through quantitative analysis 
 Statistical methods 
5.3.1. Missing data 
A variable comparing participants with at least one missing AALPHI CRF vs. participants with 
no missing CRFs was created to help describe missing data. To assess if there was evidence 
for CRFs being missing at random or not, the missing CRF variable was fitted in a model as a 
predictor of EIC adjusted for time from AALPHI interview (month of follow-up). Missing data 
from the CHIPS study are described in detail in Chapter 4. Methods for examining missing 
data for individual variables are described in section 5.3.2.1. 
5.3.2. Exposure variable investigation 
As described in Chapter 5, a wide variety of exposures potentially related to engagement in 
HIV care were considered for this analysis. Therefore, all exposure variables were examined 




linearity and to improve model stability. The investigation process is shown in Figure 5.1. Six 
stages of investigation (a-f) were performed and thresholds were set at each stage for when 
variables would be dropped. Investigations were conducted separately for each domain (a 
priori, sociodemographic, risk behaviour practices, mental health, cognition, clinic, HIV 
experience and management, HIV markers) as individual domains were most likely to include 
interrelated variables. Variables that remained at the end of the investigations were 
considered for inclusion in the modelling stages. Of note, there were situations where the 
decision process occasionally differed and this is described in the results section. 
During the variable investigation described in the following sections, logistic regression 
models were used to examine associations between exposure variables and the binary 
outcome of ‘in care’. Patient months were treated as separate observations in this analysis; 
therefore, models were fitted with a generalized estimating equation (GEE) using ‘xtgee’ in 
STATA, to take into account the clustered nature of the data, whereby each patient 
contributes multiple months:  
noi xtgee incare var, link(logit) corr(indep) family(binomial) 
i(subjectid) eform robust 
 
where ‘in care’ is a binary variable (0=out of care, 1=in care). 
Prior to exposure variables being fitted into any models in the exploratory stage, categorical 
variables with small numbers of observations in a single category were recoded (e.g. in 
“language spoke at home” exposure variable, a “language other than English” (n=3) was 




Figure 5.1: Flowchart describing exposure variable investigation 
 
 
d) Examine pairs of 
variables  for association -
use categorical variables 
and Cramer's V test
Exposure variables
within a domain
Variables are grouped in the 
same domain because they are 
l inked and so therefore may be 
associated with each other
a) Examine individual 
variables for missing data
For each variable, if 
>15% missing data 
consider dropping 
variable at this stage
e) For two associated 
variables (A, B) fit
predictive model 'in 
care' including: 
i) A, ii) B, iii) A,B and
iv) A,B interaction (AB)
If OR or SE do not change
substantially (from single 
predictor model) when both 
variables fitted, consider both 
associated variables for 
inclusion in model. If 
interaction found investigate, 
if found to be significant 
consider for model selection
f) Where OR/SE change 
substantially, compare AIC 
for single predictor models 
Consider variable with 
lowest AIC value for 
inclusion in model 
(dropping other variable)
b) Investigate individual 
variables for a linear 
association with 'in care'
If non-linear association found 
(p<0.05) fit as a cubic spline and 
consider for inclusion in model
c) Investigate interaction 
between individual 
variables for an 
association with time from 
interview
Consider variable 










5.3.2.1. Examine individual exposure variables for missing data – stage (a) 
Firstly, the missing data for all the variables in the domain were examined. If any variable 
had a substantial amount of missing data (>15%) it dropped from the analysis due to the 
effect on the sample size during modelling and the risk of introducing bias. 
5.3.2.2. Investigate individual exposure variables for a non-linear association with 
engagement in care – stage (b) 
All continuous variables were investigated for evidence of a non-linear association with EIC 
using scatter graphs and by fitting spline functions. Restricted cubic splines were fitted using 
the stata ‘mkspline’ function with three knots. Stata chooses knots based on Harrell’s 
recommended percentiles locations.(249) 
mkspline newvar=oldvar, cubic nknots (3) 
Logistic regression models were fitted to explore the association between the spline and the 
outcome in care, adjusted for time since AALPHI interview. Where evidence for non-linearity 
was found (p<0.05), variables were fitted using a spline function in subsequent models. 
5.3.2.3. Investigate interactions between individual exposure variables and time since 
AALPHI interview – stage (c) 
Interactions were investigated between each individual exposure variable and time since 
AALPHI interview (months 1 to 12 following AALPHI interview) in a model including the 
respective variable, time and interaction terms for each level of the covariate with time and 
the outcome EIC. Where an interaction was found (p<0.05), the corresponding variable was 
considered for inclusion with the interaction term, if it would otherwise be dropped.  
5.3.2.4. Examine pairs of exposure variables for association – stage (d) 
Including collinear exposure variables in the same statistical model can cause instability by 
increasing the variance, which can result in difficulty identifying correct predictors as it can 
appear that neither variable is associated with the outcome (250). When two variables are 
strongly collinear, large increases are present in standard errors,  therefore, careful 
examination of exposure variables that may be associated is important (251).  
Where exposure variables contained the same or largely overlapping groups, the variable 




year” has two levels, “no drinking” and “drinking”, while the variable “Current alcohol 
amount” has three levels, “no drinking”,  “drinking but not hazardously”, and “hazardous 
drinking”. Both variables have a group of non-drinkers which completely overlaps.  
Therefore, “Alcohol amount” was kept as it splits the group of participants who do drink, and 
thus provides more information.   
Continuous exposure variables were categorised using quartiles for this stage. The 
relationships between all pairs of exposure variables within domains were then examined 
using cross-tabulations (shown in the results where evidence for a strong association was 
found) and a Cramer’s V test. The advantage of the Cramer’s V over a standard Chi-squared 
test is that it provides a measure of the association between two categorical variables (where 
0 is no association and 1 is perfect association) rather than just a significance test. A Cramer’s 
V of ≥0.5 was considered to indicate strong association between two two-level categorical 
variables, and ≥0.35 for cross tabulations with more dimensions, and suggested further 
investigation of the effect of including both exposure variables in the same model was 
required.(252)   
Exposure variables with no pairwise associations were considered directly for inclusion in the 
modelling process. Pairs of variables that were strongly associated (as above) were examined 
in more detail (stages (e) and (f)).  
5.3.2.5. For two associated exposure variables (A, B) fit predictive model for 
engagement in care – stage (e) 
Where two exposure variables were strongly associated with each other, a series of logistic 
regression models were built (all adjusted for the a priori variables). Firstly, each exposure 
variable was fitted as a predictor of EIC, then both exposure variables were fitted 
simultaneously as predictors, and finally where indicated, both exposure variables were 
fitted simultaneously with an interaction term included between the two. Models were 
compared between those with the two variables fitted individually (A or B) and the joint 
model (including A and B). If the inclusion of both variables did not change the odds ratios or 
standard errors substantially when compared to the individual models (A or B), or cause a 
qualitative change in the odds ratio which would change the interpretation, then both 




Where the inclusion of both exposure variables in the same model changed the 
interpretation of the effects of either/both individual variables, these variables were 
examined for evidence of an interaction. Where an interaction was found between two 
categorical variables (p<0.05) a new variable was created combining information from the  
two variables (e.g. for two two-level factors (A(0), A(1) and B(0), B(1)), a four-level variable 
was created as A(0) B(0), A(0) B(1), A(1) B(0) and A(1) B(1). The new combined exposure 
variable was then fitted in a logistic regression model with the EIC outcome (adjusted for the 
a priori variables) to help interpretation. Variables where an interaction was found were still 
considered for inclusion in the modelling stages separately and interactions were further 
examined when both variables were retained. Where inclusion of both variables caused a 
substantial changes in odds ratio or standard error but no interaction was found (suggesting 
collinearity and that only one variable should be included), further investigation was required 
(see (f)). 
5.3.2.6. Comparing models using an Akaike Information Criteria (AIC) value– stage (f) 
When the inclusion of both exposure variables changed the odds ratios and standard errors 
in the models but no interaction was found (e.g. the two associated variables were providing 
very similar information) further investigation was carried out. Models including the 
associated individual exposure variables (A in first model and B in the second), and adjusted 
for a priori variables and the other variables in the domain, were compared using the Akaike 
Information Criteria (AIC) value. AIC is a formula to determine the best fitting model using 
the likelihood function but including a penalty for increasing numbers of parameters. When 
comparing models, a lower AIC value is the best fit as it signifies the model that minimises 
the amount of information lost. Therefore, the variable with the lowest AIC value was 
included in the modelling stage.  
For this stage, models were fitted ignoring the clustered nature of the data, as the GEE does 
not use the likelihood function.(253) While this is not ideal, more complex methods for 
comparisons of GEEs were outside the scope of this thesis. 
5.3.3. Logistic regression modelling 
The multivariable logistic regression model was constructed in four stages. The outcome for 
all models was in care. For all four stages, the models were fitted with GEE using ‘xtgee’ in 




data. For categorical exposure variables with more than two categories, a Wald test was 
carried out using the ‘testparm’ function in Stata to obtain an overall p value for the variable. 
Continuous exposure variables that were converted into categorical variables during the 
investigation of pairwise associations between variables were included in the modelling 
stages as continuous variables.  
5.3.3.1. Stage 1 - Adjusting for time since AALPHI interview 
In this first stage, exposure variables were fitted individually as predictors of EIC adjusting 
for time from interview (month of follow-up). Variables with a p value <0.15 were considered 
associated with EIC. 
5.3.3.2. Stage 2 - Adjusting for a priori exposure variables 
In this second stage, exposure variables were fitted individually in multivariable models for 
EIC, adjusting for the a priori factors (time from interview, sex, age at entry and ethnicity and 
born abroad) and effect estimates and p values compared to the stage 1 outputs. Where the 
OR for an exposure variable changed considerably between stage 1 and stage 2 or where the 
effect changed direction (from being more likely to be in care (OR >1.0) to less likely (OR 
<1.0) or vice versa, ), a priori exposure variables were taken out of the model one by one to 
understand what was causing the change. Exposure variables with a p value <0.15 were 
considered associated with EIC. 
5.3.3.3. Stage 3 – Domain-specific multivariable model including a priori and domain 
exposure variables  
In this third stage, all exposure variables in a domain were included in a multivariable model 
for EIC, adjusting for a priori variables. Manual backwards selection was used to build a 
domain specific model. Exposure variables with a p value ≥0.15 were removed one by one 
(starting with the variable with the highest p value and fitting an updated model each time a 
variable was removed) until only the exposure variables with a p value <0.15 and the a priori 
variables remained in the model. At this stage, all removed variables were added back into 
the model individually to see if the p value for each remained ≥0.15. If any p value was lower 
than this cut off, this variable was added back in and the same process was performed again. 
If a variable was removed where an interaction with time since AALPHI interview had 




As described in stage 2, where effect estimates changed considerably, these changes were 
examined.  
At the end of this stage, any pairs of exposure variables with a plausible rationale for an 
interaction were investigated.  
5.3.3.4. Stage 4 - Full multivariable model  
In this fourth stage, all exposure variables from the domain specific models with a p value 
<0.15 were fitted in a combined multivariable model for EIC adjusting for the a priori factors. 
Manual backwards selection was used to identify independent predictors of EIC. Variables 
with a p value ≥0.05 were removed one by one (the highest first, fitting a new model each 
time a variable was dropped) until only exposure variables with p<0.05 remained in the 
model with the a priori variables. All variables previously dropped in this stage were then 
added back into the model one at a time to see if they became significant. If any of the 
variables became significant, the variable was included in the primary stage 4 model and the 
same procedure was conducted again.  
5.3.4. Checks to the final model (stage 4 model) and sensitivity analyses 
A number of steps were conducted to improve the model stability including stages (a) to (f) 
in the variable investigation and the four stages of the model building process (Stage 1 to 
Stage 4). Once the final stage 4 model was completed, a number of additional checks and 
sensitivity analysis were conducted to further check the stability and thus confidence in the 
model and to test some key methodological decisions. 
5.3.4.1. Alternate final model exposure variables  
Due to the large number of variables included in this analysis, checks to the final model were 
made by replacing exposure variables found to be associated with EIC with similar exposure 
variables within the same domain (other than those in the a priori domain). For example, 
self-harm was replaced with all of the other mental health variables one by one (feelings 
about HIV, ever felt life was not worth living, major life events, Pediatric Quality of Life 
Inventory, Rosenberg Self-Esteem Scale, HADS anxiety score, HADS depression score). In 
addition, for any exposure variable that was investigated with AIC values in stage (f) and 
remained in the final model, the other exposure variable was replaced in the model (for 




5.3.4.2. Alternate p value cut off (<0.1 compared to <0.05) 
The first sensitivity analysis tested the impact of changing the p value cut off at which 
variables were retained in the final stage 4 model. Statistical significance in medical research 
is commonly considered as a p value <0.05 (251) and was therefore used for this analysis. 
However, other p value cut offs are used for identifying predictors, particularly where sample 
sizes are not large, so a sensitivity analysis was performed using p<0.1 in the final stage4 
model. 
5.3.4.3. Alternate start date 
In the second sensitivity analysis, an alternate start date was used to address possible bias 
introduced by using the AALPHI interview date as the start date. The AALPHI interview date 
was selected as the beginning of the one year follow up for two reasons.  Firstly, the variables 
used in the analysis were collected at this time point.  Secondly, many participants were 
recruited in their clinic at the time of a clinic appointment which meant there were also 
clinical data available from this date. However, 57% (n=175) of the AALPHI cohort were 
interviewed in the community (home, study offices or voluntary sector) or in clinic but not 
on the day of a clinic visit and therefore did not have clinical data available on this day.  As a 
result, participants who were not interviewed on the same day as a clinic visit could 
potentially start the one year of follow up classified as ‘out of care’ (or be lost from care 
quickly) whereas this could not happen for the group with a clinic visit on the same day (who 
remained in care until their next predicted visit date). Therefore, a start date three months 
after the AALPHI start date for all participants was used for the stage 4 model to assess this 
potential bias.  
5.3.4.4. Early attenders  
To assess the issue of participants attending early for their appointments (described in the 
EIC Flowcharts, Chapter 3) a sensitivity analysis was performed to see if changing the 
maximum predicted appointment time from 6 months to 4 months altered the final 
multivariable results. This sensitivity analysis was conducted for all four stages of the 





5.4.1. Missing data 
No association was found between having a missing AALPHI CRF and the EIC outcome 
(p=0.78). 
5.4.2. Exposure variable investigation 
Descriptive results for the exposure variables within each domain are presented below. A 
summary of results of all of the within domain variable investigations is shown in Appendix 
D. 
5.4.2.1. Investigation of a priori exposure variables 
Table 5.1 shows the exposure variables in the a priori domain, along with each category’s 
total person months and proportion of months in care. The number of person months for 
some of the ethnicity categories was relatively small and thus combined. The proportion in 
care was similar across categories for time since AALPHI interview, sex and born outside of 
the UK/Ireland. However, EIC appeared to decline with increasing age group, and was 
perhaps lower in the Asian ethnicity category (though numbers were small).  
Table 5.1: A priori exposure variables included in the analysis 





















Time from AALPHI interview 
(months 1-12). 



















Inclusion criteria 13-21 years 
of age. 




















Categories used in 
modelling: (1) Black (black 
African/black other) (2) 
Asian/mixed (Asian/mixed/ 
prefer not to say) (3) White  













Examination of missing data – stage (a) 
There were no missing data in a priori variables. 
Investigation of a non-linear association with engagement in care- stage (b) 
There was no evidence for a non-linear association between either time since AALPHI 
interview (p=0.42) or age at entry (p=0.45) and the EIC outcome.  
Investigation of an association with time since AALPHI interview – stage (c) 
No interactions were found between time since AALPHI interview and any of the a priori 
variables as predictors of EIC (p≥0.05 for all interaction tests). 
Examination of paired exposure variables for association – stage (d) 
Cramer’s V between pairs of exposure variables are shown in Table 5.2.There was evidence 
for an association between ethnicity and born abroad (p=0.002) however, the strength of 
this association was weak (Cramer’s V = 0.20). No other significant pairwise associations 
between exposure variables were found in the a priori domain.  
Table 5.2: Stage (d) test for association of paired exposure variables in the a priori domain 
A priori variable Sex 
Age group at 
entry 
Ethnicity Born abroad 
Sex 
 a) 0.11  a) 0.09 a) 0.10 
b) 0.13 b) 0.30 b) 0.09 
Age group 
  a) 0.09 a) 0.10 
b) 0.33 b) 0.21 
Ethnicity 
   a) 0.20 
b) 0.002 
Born abroad 
    
a = Cramer's V  
b = P value for Cramer’s V 
Strong association on V test (Cramer’s V ≥0.5 between two two-level categorical variables and ≥0.35 for tables with more 
dimensions)  
 
5.4.2.2. Investigation of sociodemographic exposure variable 
Table 5.3 shows the exposure variables in the sociodemographic domain, along with each 
category’s total person months and proportion of person months in care. A number of the 
subgroups in the sociodemographic categories were small and therefore combined with 
other subgroups (education/employment status, death of parents and main language 
spoken at home).  The proportion in care was similar across categories for death of parents, 
fostered/adopted, number of main carers and IDACI deprivation score. However, EIC 




fixed or permanent exclusions from school, who lived with others, did not know if their 
parent/carer was employed, and spoke another language at home, although numbers were 




Table 5.3: Sociodemographic exposure variables included in the analysis 











Categories used in modelling: (1) in full time 
education (2) employed OR not in education, 
employment or training 
Ever excluded from school 
No 
Yes - fixed term exclusion 







Categories used in modelling:  (1) no 
exclusion (2) fixed term OR permanent 
exclusion (i.e. any exclusion)   
Death of parents 
None  
Death of one parent 










Categories used in modelling: (1) none OR 









Number of main carers 
1 carer 
2 carers 







Categories used in modelling: (1) 1 carer (2) 2 
carers (3) ≥ 3 carers.  
(Participants had up to 10 carers but small 
numbers so grouped ≥3)  
Live with parents/carers 
Live with parents 

















Main language spoken at home 
English only 








Categories used in modelling:  (1) English 
only OR English and another language (2) A 
language other than English 













Based on postcode. Higher number=worse 
deprivation. 




Examination of missing data – stage (a) 
The proportion of each exposure variable in the sociodemographic domain which was 
missing in shown in Table 5.4. The fostered/adopted variable had 58% missing data and was 
dropped from the analysis. Missing data were below the threshold (15%) in all the other 
variables which were therefore retained to the next stage. 
Table 5.4: Stage (a) missing data in the sociodemographic exposure variables 
Sociodemographic variable Participants with  
missing data 
 n % 
Education/employment status 3 1% 
Ever excluded from school 2 1% 
Death of parents 2 1% 
Fostered or adopted 179 58% 
Number of main carers 2 1% 
Live with parent/carer 2 1% 
Parent/carer in work 2 1% 
Main language spoken at home 1 <1% 
IDACI deprivation score 36 12% 
Investigation of a non-linear association with engagement in care- stage (b) 
There was no evidence for a non-linear association between the IDACI deprivation score 
exposure variable and the EIC outcome (p≥0.05).  
Investigation of association with time since AALPHI interview – stage (c) 
No interactions were found between time since AALPHI interview and any of the 
sociodemographic exposure variables as predictors of EIC (p≥0.05). 
Examination of paired exposure variables for association – stage (d) 
For this stage of the analysis, IDACI was treated as a categorical variable with four levels. 
Table 5.5 shows the results of the tests for pairwise associations in the sociodemographic 
domain. For seven pairs of variables there was evidence of an association, however for each 
pair the strength of association (measured by Cramer’s V) was less than the pre-specified 




Table 5.5: Stage (d) test for association of paired exposure variables in the sociodemographic domain 
a = Cramer's V  
b = P value for Cramer’s V 
Strong association on V test (Cramer’s V ≥0.5 between two two-level categorical variables and ≥0.35 for tables with more dimensions)  
 

























 a) 0.01 a) 0.08 a) 0.15 a) 0.11 a) 0.13 a) 0.04 a) 0.10 
b) 0.85 b) 0.17 b) 0.04 b) 0.05 b) 0.07 b) 0.43 b) 0.45 
Ever excluded from school 
  a) 0.06 a) 0.07 a) 0.15 a) 0.08 a) 0.09 a) 0.14 
 b) 0.32 b) 0.47 b) 0.007 b) 0.42 b) 0.13 b) 0.15 
Death of parents 
   a) 0.23 a) 0.17 a) 0.07 a) 0.10 a) 0.07 
  b) <0.001 b) 0.002 b) 0.45 b) 0.09 b) 0.77 
Number of main carers 
    a) 0.16 a) 0.10 a) 0.06 a) 0.09 
   b) 0.02 b) 0.24 b) 0.62 b) 0.68 
Live with parent/carer 
     a) 0.29 a) 0.03 a) 0.09 
     b)<0.001 b) 0.62 b) 0.51 
Parent/carer in work 
      a) 0.10 a) 0.16 
      b) 0.21 b) 0.03 
Main language spoken at 
home 
       a) 0.13 
       b) 0.22 
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5.4.2.3. Investigation of risk behaviour practices exposure variables 
Table 5.6 shows the exposure variables in the risk behaviour practices domain, along with each 
category’s total person months and proportion of person months in care. The number of person 
months for some of the age at first sex categories were relatively small and so were combined. 
The proportion EIC was similar across the recreational drug categories. However, EIC appeared 
to decrease with increasing amount of current alcohol use, and was lower if participants 
smoked, if age of first sex was ≥20 years (though numbers were small) and if participants did 
not always use a condom. 































Drink but not hazardous 
score = <8, Drink hazardously 
score= ≥8 












Categorised as per literature 
to show hierarchical effect of 
cannabis vs. harder drugs 
Age of first sex 












Categories used in modelling:  
(1) Not sexually active (2) ≤14 
years (3) ≥15 years (15-19 and 
≥20 years due to small 
numbers in ≥20 group) 
Condom use 
Not sexually active 
Always use a condom 









Examination of missing data – stage (a) 
Missing data were below the threshold (15%) and so no variables were dropped at this stage 
(Table 5.7). 
Table 5.7: Stage (a) missing data in the risk behaviour practices exposure variables 
Risk behaviour practices variable Participants with  
missing data 
 n % 
Ever smoked 19 6% 
Current alcohol amount 19 6% 
Ever taken recreational drugs 24 8% 
Age of first sex 30 10% 




Investigation of a non-linear association with engagement in care- stage (b) 
None of the variables were continuous therefore investigation for non-linearity was not 
required. 
Investigation of an association with time since AALPHI interview – stage (c) 
No interaction was found between time since AALPHI interview and ever smoked, current 
alcohol amount, ever taken recreational drugs or condom use (all p≥0.05) models with EIC as 
the outcome. However, an interaction between time since interview and age of first sex was 
found (p=0.04). There was no effect of time since AALPHI interview on EIC for young people who 
had sex for the first time aged 15 years or older (OR 0.98 per month, 95%CI 0.90, 1.07, p=0.64). 
However, participants who had sex for the first time aged less than 15 years of age were less 
likely to be in care over time (OR 0.80 per month, 95% CI 0.67, 0.95, p=0.01). 
Examination of paired exposure variables for association – stage (d) 
All pairwise combinations of variables were significantly associated with each other (Table 5.8). 
The association was strong for four pairs: ever smoked and current alcohol amount (Cramer’s 
V=0.42); ever smoked and ever taken recreational drugs (Cramer’s V=0.49); current alcohol 
amount and ever taken recreational drugs (Cramer’s V=0.47) and age at first sex and condom 
use (Cramer’s V=0.71). These variables were therefore investigated further. 


















 a) 0.42 a) 0.49 a) 0.25 a) 0.24 
 b) <0.001 b) <0.001 b) <0.001 b) <0.001 
Current alcohol 
amount 
  a) 0.47 a) 0.34 a) 0.32    
  b) <0.001 b) <0.001 b) <0.001 
Ever taken  
recreational drugs 
   a) 0.26 a) 0.28 
   b) <0.001 b) <0.001 
Age at first sex     a) 0.71 
     b) <0.001 
a = Cramer's V  
b = P value for Cramer’s V 
Values meeting the threshold for strong association on V test (Cramer’s V ≥0.5 between two two-level categorical variables and 
≥0.35 for tables with more dimensions) are underlined 
 
Findings from predictive models for associated exposure variables (A, B) and engagement in care 
– stage (e) 
For the four associated exposure pairs found in stage (d), variables were investigated in a series 
of logistic regression models (all adjusted for the a priori variables) for EIC (tables of model 
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results are shown in Appendix E). For ever smoked and current alcohol amount there was little 
change in the odds ratios when both variables were included in the same model, compared to 
models with the two variables included individually, and no evidence for an interaction between 




Table 5.9: Stage (e) predictive model for effect of ever smoked and current alcohol amount on EIC in the risk behaviour practices domain 
Risk behaviour practices 
variable 
Ever smoked adjusted 
for a priori 
Current alcohol amount 
adjusted 
for a priori 
Ever smoked and current 
alcohol amount adjusted for 
a priori 
Ever smoked and current 






















Ever smoked             
  No 1 - -    1 - - 1 - - 
  Yes 
0.68 
(0.40, 1.13) 







Current alcohol amount             
  No drinking    1 - - 1 - - 1 - - 
  Drink but not      
  hazardous 
























Ever smoked# current 
alcohol amount 
            
  Yes smoke# not     
  hazardous drinking 





  Yes smoke#  
  hazardous drinking 







For ever smoked cigarettes and ever taken recreational drugs, the effect of ever smoked 
remained stable and showed a similar association with EIC when fitted separately or in 
combination with ever taken recreational drugs (Table 5.10).  The ORs and SEs for the effects 
of drug use did change when fitted in the model with ever smoked but the confidence 
intervals were very wide and the direction of the effects were the same. No interaction was 
found between the variables (p=0.67), and therefore, both variables were considered for 
inclusion in the model, although it was expected that use of recreational drugs would be 




Table 5.10: Stage (e) predictive model for effect of ever smoked cigarettes and ever taken recreational drugs on EIC in the risk behaviour practices domain 
Risk behaviour 
practices variable 
Ever smoked adjusted 
for a priori 
Ever taken recreational 
drugs adjusted for a priori 
Ever smoked and ever taken 
recreational drugs adjusted 
for a priori 
Ever smoked and ever taken 






















Ever smoked             
  No 1 - -    1 - - 1 - - 
  Yes 
0.68 
(0.40, 1.13) 









            
  No     1 - - 1 - - 1 - - 























Ever smoked# ever 
recreational drugs 
            
  No smoke# Other      
  drug ever     
         1 empty 
0.67 
  Yes smoke# 
  Cannabis ever 




  Yes smoke# Other  
  drug ever 
         1 empty 
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The effects of current alcohol amount were similar when fitted separately or in combination 
with recreational drug use and was associated with EIC (Table 5.11). The ORs and SEs for the 
effects of drug use did change when fitted in the model with current alcohol amount, but the 
confidence intervals were wide and the direction of the effect was in the same direction. No 
interaction was found between the two variables (p=0.11) however, there was a change in 
the direction of the relationship between recreational drug use and EIC. It was therefore 
decided to drop recreational drug use as there was a consistent association between current 




Table 5.11: Stage (e) predictive model for effect of current alcohol amount and ever taken recreational drugs in EIC in the risk behaviour practices domain 
Risk behaviour practices 
variable 
Current alcohol amount 
adjusted for a priori 
Ever recreational drugs 
adjusted for a priori 
Current alcohol amount and 
ever recreational drugs 
adjusted for a priori 
Current alcohol amount and ever 






















Current alcohol amount             
  No drinking 1 - -    1 - - 1 - - 
  Drink but not      














  Hazardous drinking 
0.64 
(0.32, 1.27) 







Ever recreational drugs             
  No    1 - - 1 - - 1 - - 
  Cannabis ever 
 













  Other drug other 
 










Current alcohol amount#  
ever recreational drugs  
            
  No drinking# Other  
  drug ever  
         1 empty 
0.11 
  Drink not hazardous#    
  Cannabis ever 




  Drink not hazardous#  
  Other drug ever  




  Hazardous drinking#  
  Cannabis ever 




  Hazardous drinking#   
Other drug ever 




Age at first sex and condom use were not fitted in a joint model because the category “not 
sexually active” was the baseline level for both variables (Table 5.12).  
Table 5.12: Stage (e) predictive model for effect of age of first sex and condom use and EIC 
in the risk behaviour practices domain 
Risk behaviour practices 
variable 
Age at first sex 
adjusted for a priori 
Condom use 











Age of first sex       
  Not sexually active 1 - -    





   
  ≥15 years 
1.12 
(0.65, 1.93) 
0.31    
Condom use       
  Not sexually active    1 - - 





  Do not always use a 
condom 





Therefore, a combined variable was created with five subgroups (Table 5.13). When the new 
combined variable was fitted in a logistic regression model (adjusted for the a priori 
variables) there was no evidence of an association with EIC (p=0.17).   











Combined age of first sex 
and condom use variable 






Combined age at first 
sex/condom use 
variable 
      
  Not sexually active 190 69% 88% 1 - 
- 
 
  ≤14 years, always use 
condom 





  ≤14 years, do not 
always use a condom 




  ≥15 years, always use 
condom 




  ≥15 years, do not 
always use a condom 







Comparing models using Akaike Information Criteria (AIC) value – stage (f)  
Two logistic regression models (with no adjustment for clustering) were fitted to estimate 
the AIC, the first including condom use and the second age at first sex, both adjusted for a 
priori variables and the other variables in the domain. The AIC was lower for the model 
including condom use compared to age at first sex (2294.771 vs 2305.752).  The condom use 
variable was therefore taken forward to the modelling stages instead of the age at first sex 
variable or the combined variable. As age at first sex was dropped prior to the modelling 
stage, there was no need to investigate the interaction with time since AALPHI interview any 
further. 
5.4.2.4. Investigation of mental health exposure variables 
Table 5.14 shows the exposure variables in the mental health domain, along with each 
category’s total person months and proportion of person months in care. No categories were 
very small and so none were combined.  The proportion of person months in care was similar 
across all of the categories in the domain, except for ever self-harmed, where EIC was 















Worst feelings about HIV 
Bad feelings about HIV 
Good feelings about HIV 
























Ever felt  









Major life  
events 
Most unpleasant events 
Some unpleasant events 
Some pleasant events 














Quality of  
Life Inventory 
Worst quality of life 
Low quality of life 
Good quality of life 















































Higher score is better 
(0-21, scores reversed 
for consistency with 















Higher score is better 
(0-21, scores reversed 
for consistency with 
other variables)  
Modelled as 
continuous 
Examination of missing data – stage (a) 
Missing data were below the threshold (15%) therefore no variables were dropped at this 




Table 5.15: Stage (a) missing data in the mental health exposure variables 
Mental health variable 
Participants with  
missing data 
n % 
Feelings about HIV 22 7% 
Ever self-harmed 14 5% 
Ever felt life was not worth living 17 6% 
Major life events 16 5% 
Pediatric Quality of life 
Inventory 
14 5% 
Rosenberg Self-Esteem Scale 14 5% 
HADS anxiety score 32 10% 
HADS depression Score 32 10% 
Investigation for a non-linear association with engagement in care- stage (b) 
There was no evidence for a non-linear association between feelings about HIV (p=0.13), 
major life events (p=0.84), Pediatric Quality of Life Inventory (p=0.90), Rosenberg Self-
Esteem Scale (p=0.31), HADS anxiety score (p=0.72) or HADS depression score (p=0.32) and 
EIC.  
Investigation for association with time since AALPHI interview – stage (c) 
No interactions were found between time since AALPHI interview and any of the mental 
health exposure variables as predictors of EIC (all p≥0.05). 
Examination of paired exposure variables for association – stage (d) 
A number of exposure pairs showed a significant association with each other, based on the 
p value for Cramer’s V (Table 5.16). However, there were only three pairs where the 
association was strong, namely ever thought life was not living with each of: Pediatric Quality 
of Life Inventory (Cramer’s V=0.44); Rosenberg Self-Esteem Scale (Cramer’s V=0.46); and 
HADS anxiety score (Cramer’s V=0.41). The associations between these variables were 
therefore investigated further. 
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Ever felt life 
was not 

















 a) 0.09 a) 0.29 a) 0.15 a) 0.25 a) 0.22 a) 0.17 a) 0.10 
 b) 0.51 b) <0.001 b) 0.02 b) <0.001 b) <0.001 b) 0.005 b) 0.45 
Ever self-harmed   a) 0.36 a) 1.7 a) 0.20 a) 0.26 a) 0.12 a) 0.13 
  b) <0.001 b) 0.05 b) 0.008 b) <0.001 b) 0.25 b) 0.10 
Ever felt life was 
not worth living  
   a) 0.30 a) 0.44 a) 0.46 a) 0.41 a) 0.14 
   b) <0.001 b) <0.001 b) <0.001 b) 0.001 b) 0.09 
Major life events     a) 0.18 a) 0.20 a) 0.19 a) 0.14 
    b) 0.001 b)<0.001 b) 0.001 b) 0.13 
Pediatric Quality 
of Life 
     a) 0.29 a) 0.29 a) 0.15 
     b) <0.001 b) <0.001 b) 0.05 
Rosenberg Self-
Esteem Scale 
      a) 0.34 a) 0.23 
      b) <0.001 b) <0.001 
HADS  
anxiety score 
       a) 0.23 
       b) <0.001 
a = Cramer's V  
b = P value for Cramer’s V 
Values meeting the threshold for strong association on V test (Cramer’s V ≥0.5 between two two-level categorical variables and ≥0.35 for tables with more dimensions) are underlined 
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Findings from predictive models for associated exposure variables (A, B) and engagement in 
care  – stage (e) 
The three paired exposure variables found in stage (d) were investigated in a series of logistic 
regression models (all adjusted for the a priori variables) with EIC as the outcome (Table 5.17, 
Table 5.18 and Table 5.19). In all three models, there was little change in the odds ratios 
when both variables were included in the same model, compared to the models with the 
two variables included individually, and no interactions were found (all p≥0.05). Therefore, 




Table 5.17: Stage (e) predictive model for effect of ever felt life was not worth living and quality of life on EIC in the mental health domain 
Mental health variable 
Ever felt life was 
not worth living adjusted 
for a priori 
Quality of life (total score)  
adjusted 
for a priori 
Ever felt life was not 
worth living and quality of 
life adjusted for a priori 
Ever felt life was not 
worth living and quality of life 





















Ever felt life was not 
worth living 
            
  No 1 - -    1 - - 1 - - 
  Yes 
0.98 
(0.64, 1.52) 







Quality of life (total score)       
  (Higher score is better) 
           
0.48 










Ever felt life was not 
worth living # quality of life 
           
0.95 







Table 5.18: Stage (e) predictive model for effect of ever felt life was not worth living and Rosenberg Self-Esteem Scale on EIC in the mental health domain 
Mental health variable 
Ever felt life was 
not worth living adjusted 
for a priori 
Rosenberg Self-Esteem Scale 
adjusted for a priori 
Ever felt life was not 
worth living and Rosenberg 
Self-Esteem Scale adjusted 
for a priori 
Ever felt life was not 
worth living and Rosenberg 






















Ever felt life was not 
worth living 
            
  No 1 - -    1 - - 1 - - 
  Yes 
0.98 
(0.64, 1.52) 







Rosenberg Self-Esteem Scale 
(higher score is better) 
            










Ever felt life was not 
worth living # Rosenberg 
Self-Esteem Scale 
            








Table 5.19: Stage (e) predictive model for effect of ever felt life was not worth living and HADS anxiety score on EIC in the mental health domain 
Mental health variable 
Ever felt life was 
not worth living adjusted 
for a priori 
HADS anxiety score  adjusted 
for a priori 
Ever felt life was not 
worth living and HADS 
anxiety score adjusted 
for a priori 
Ever felt life was not 
worth living and HADS 






















Ever felt life was not 
worth living 
            
  No 1 - -    1 - - 1 - - 
  Yes 
0.98 
(0.64, 1.52) 







HADS anxiety score               










Ever felt life was not 
worth living # HADS anxiety 
score   
            






5.4.2.5. Investigation of cognition exposure variables 
NPZ-6 was the only variable in the cognition domain, therefore it was only necessary to 
investigate it for missing data (stage (a)), a linear association with EIC (stage (b)) and an 
association with time since AALPHI interview (stage (c)). Table 5.20 shows the total person 
months and proportion in care for NPZ-6. The proportion of person months in care appeared 
to decline with increasing NPZ-6 score.  






% in care Further details 
NPZ-6 
<-1 











Examination of missing data – stage (a) 
Twenty-seven (9%) participants had missing NPZ-6 scores, which was below the threshold 
(15%), so NPZ-6 was not dropped at this stage.  
Investigation of a non-linear association with engagement in care- stage (b) 
There was no evidence for a non-linear association between NPZ-6 scores and EIC (p=0.56). 
Investigation for association with time since AALPHI interview – stage (c) 
No interaction was found between time since AALPHI interview and the NPZ-6 score as 
exposure predictors of EIC (p≥0.05).  
5.4.2.6. Investigation of Clinic exposure variables 
Table 5.21 shows the exposure variables in the Clinic domain, along with each category’s 
total person months and proportion of months in care. No categories were very small and so 
none were combined. For all four variables, there was an indication of better or worse EIC in 
specific categories.  The proportion in care appeared lower if young people attended a clinic 
in London compared to outside London, if they attended an adolescent clinic and if they 
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Examination of missing data – stage (a) 
Missing data were below the threshold (15%), therefore no variables were dropped at this 
stage (Table 5.22).  




 n % 
Clinic location 0 0% 
Clinic type 4 1% 
Distance to clinic (km)  40 13% 
Travel time to clinic (min) 40 13% 
Investigation of a non-linear association with engagement in care - stage (b) 
There was no evidence for a non-linear association between distance to clinic (p=0.43) or 
travel time to clinic (p=0.53) and EIC. 
Investigation of association with time since AALPHI interview – stage (c) 
No interactions were found between time since AALPHI interview and any of the Clinic 
variables as predictors of EIC (p≥0.05). 
Examination of paired exposure variables for association – stage (d) 
Continuous variables (distance to clinic and travel time to clinic) were categorised for this 
stage. A number of exposure pairs showed a significant association with each other based 
on the P value for Cramer’s V (Table 5.23). However, there was only evidence for a strong 
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association between distance to clinic and travel time to clinic (Cramer’s V=0.74). Therefore, 
these variables were investigated further. 
Table 5.23: Stage (d) tests for association of paired exposure variables in the Clinic domain 
Clinic variable 
Clinic location Clinic type 
Distance to 
clinic (km) 
Travel time to 
clinic (min) 
Clinic location 
 a) 0.22 a) 016 a) 0.19 
 b) 0.001 b) 0.008 b) 0.001 
Clinic type 
  a) 0.15 a) 0.12 
  b) 0.06 b) 0.13 
Distance to  
clinic (km)  
   a) 0.741 
   b)<0.001 
a = Cramer's V  
b = P value for Cramer’s V 
Values meeting the threshold for strong association on V test (Cramer’s V ≥0.5 between two two-level categorical variables and 
≥0.35 for tables with more dimensions) are underlined 
Findings from predictive models for associated exposure variables (A, B) and 
engagement in care – stage (e) 
Distance to clinic and travel time to clinic were investigated for association in a series of 
logistic regression models (all adjusted for the a priori variables) with EIC as the outcome 
(Table 5.24). The ORs and SEs for the effect of both distance to clinic and travel time to clinic 
did change when the two variables were fitted together compared to when the variables 
were fitted individually. There was also a change in the OR for distance when fitted in a model 
with travel time. The close association of the two variables is shown in the scatter plot in 
Figure 5.2. No interaction was found between the two variables (p=0.16). Therefore, these 
two variables were compared further in stage f using AIC. 
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Table 5.24: Stage (e) predictive model for effect of distance to clinic and travel time to clinic on EIC in the Clinic domain 
Clinic variable 
Distance  adjusted 
for a priori 
Travel time adjusted 
for a priori 
Distance and travel time 
adjusted for a priori 
Distance and travel time fitted 





















Distance/10 km  
0.90 
(0.80, 1.02) 

















Distance/10 km # 
travel time/10 min 






Comparing models using Akaike Information Criteria (AIC) value – stage (f)  
Logistic regression models were fitted to estimate the AIC for EIC including travel time (per 10 
min increase) or distance to clinic (per 10 km increase) adjusted for a priori variables and the 
other variables in the domain. The two models had very similar AIC scores, suggesting that they 
were measuring the same thing. However, the model including travel time with a priori variables 
and the other variables in the domain had a lower AIC when compared to a model including 
distance to clinic (2289.509 vs. 2291.224), and so distance to clinic was dropped. 
5.4.2.7. Investigation of HIV experience and management exposure variables  
The exposure variables in the HIV experience and management domain, along with each 
category’s total person months and proportion of months in care are shown in Table 5.25. The 
numbers of person months for some categories in the age told HIV diagnosis, number of people 
told about HIV, and self-assessment of HIV exposure variables were relatively small and so these 
were combined. The proportion of person months in care was similar across categories of the 
age told HIV diagnosis variable. However, EIC appeared lower for participants who had told ≥10 
people their HIV diagnosis, were not on ART (in both the doses missed in the last three days and 
self-assessment of adherence variables), and who reported in the self-assessment of adherence 
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remember  
Number of people 
















Categories used in 
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0-2 (2) 3-4  
(3) 5-9 (4) ≥10  
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last 3 days 
No  
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Not so good 
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Categories used in 
modelling:  (1)  
excellent/ good (2) 
not so good/ bad  
 
Examination of missing data – stage (a) 
Missing data were below the threshold (<15%) therefore all of the variables were carried 
forward (Table 5.26). 
Table 5.26: Stage (a) missing data in the HIV experience exposure variables 




 n % 
Age told HIV diagnosis 22 7% 
Number of people told about HIV 24 8% 
Doses missed in last 3 days 20 7% 
Self-assessment of adherence 21 7% 
Investigation of a non-linear association with engagement in care- stage (b) 
There were no continuous variables in the HIV experience and management domain and so this 
stage was not relevant.  
Investigation of an association with time since AALPHI interview – stage (c) 
No interactions were found between time since AALPHI interview and any of the HIV experience 
and management variables as predictors of EIC (all p≥0.05). 
Examination of paired exposure variables for association – stage (d) 
Cramer’s V between pairs of exposure variables are shown in Table 5.27. There was evidence 
for an association between doses missed in last three days and self-assessment of adherence, 
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and the strength of association was strong (Cramer’s V=0.78). Therefore, doses missed in the 
last three days and self-assessment of adherence were investigated further. 
Table 5.27: Stage (d) tests for association of paired exposure variables in the HIV experience 










in last 3 days 
Self-assessment 
of adherence 






Number of people 
told about HIV 




Doses missed in 
last 3 days 
   a) 0.78 
   b) <0.001 
Self-assessment of 
adherence 
    
a = Cramer's V  
b = P value for Cramer’s V 
Values meeting the threshold for strong association on V test (Cramer’s V ≥0.5 between two two-level categorical variables and 
≥0.35 for tables with more dimensions) are underlined 
Findings from predictive models for associated exposure variables (A, B) and engagement in care 
– stage (e) 
When fitted individually in logistic regression models (adjusted for a priori variables) strong 
evidence for an association with EIC was found for doses missed in the last three days (p=0.002) 
and self-assessment of adherence (p<0.001) (Table 5.28). However, it was clear from a cross 
tabulation of these two variables that they were measuring the same thing i.e. adherence. In 
addition, both variables included a group who were not on ART (Table 5.28). Therefore, the 
variables were not fitted in the same model. Instead, the variables were compared in stage (f) 
to see which of the two variables should be taken forward to the modelling stages. 
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Table 5.28: Stage (e) predictive model for effect of doses missed in the last 3 days and self-




Doses missed in the 
last 3 days adjusted 
for a priori 
Self-assessment of adherence 
adjusted 











Doses missed in 
the last 3 days 
      
  No 1 - -    





   
  Not on ART 
0.39 
(0.23, 0.65) 
0.10    
Self-assessment 
of adherence 
      
  Excellent    1 - - 





















last 3 days 








 n (% row)  
No 94 (51) 79 (43) 9 (5) 1 (1) 0 (0) 183 (100) 
Yes 6 (9) 40 (60) 14 (21) 7  (10) 0 (0) 67 (100) 
Not on 
ART 
0 (0) 0 (0) 0 (0) 0 (0) 35 (100) 35 (100) 
Total 100 (35) 119 (42) 23 (8) 8 (3) 35 (12) 285 (100) 
Comparing models using Akaike Information Criteria (AIC) value – stage (f) 
Logistic regression models (with no adjustment for clustering) were fitted to estimate AIC 
including doses missed in the last three days or self-assessment of adherence and adjusted for 
a priori variables and the other variables in the domain. The model including self-assessment of 
adherence had a lower AIC when compared to a model with doses in the last three days 
(2367.317 vs. 2396.45), and so doses missed in the last three days was dropped. 
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5.4.2.8. Investigation of HIV marker exposure variables 
Table 5.30 shows the exposure variables in the HIV marker domain, along with each category’s 
total person months and proportion of person months in care.   No categories were very small 
and so none were combined.  The proportion in care was similar across categories for previous 
CDC C event, nadir CD4 cell count, time on ART, and on efavirenz exposure variables. However, 
EIC appeared lower in participants with a lower CD4 count, a detectable viral load and in 
participants who had a treatment interruption in the last 2 years. Of note, all of the HIV marker 
exposures represent status at AALPHI interview date (baseline). 








HIV severity:     
  Previous CDC C  
  event  
No CDC C event  





Measured at baseline 
  Nadir CD4 cell  
  count  













Baseline nadir CD4 count. 
Modelled as continuous 
 CD4 cell count  













Baseline CD4. Value 
included if collected within 
6 months prior to baseline. 
Modelled as continuous 










Baseline viral load. Value 
included if collected within 
6 months prior to baseline 
ART:     
  Time on  ART  
  (cumulative) 
0 to ≤1 year 
>1 to ≤5 years 













Cumulative time on  
ART at baseline 








Measured at baseline 
  Treatment  
  interruption   







Gap in ART treatment for 
≥30 days in last 2 years as 
measured at baseline 
  
Examination of missing data – stage (a) 
Only viral load and CD4 count had any missing data and the proportion missing was below the 
cut off for this analysis (15%) for both variables, therefore all of the variables were carried 
forward (Table 5.31).  
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Table 5.31: Stage (a) missing data in the HIV markers domain 
HIV markers variable Participants with 
missing data 
 n % 
Previous CDC C event 0 0% 
Nadir CD4 cell count (cells/µL) 0 0% 
CD4 cell count (cells/µL) 21 7% 
Viral load (c/mL) 17 6% 
Time on ART (cumulative) 0 0% 
On efavirenz during follow-up 0 0% 
Treatment interruption in last 2 years 0 0% 
Investigation of a non-linear association with engagement in care - stage (b) 
There was no evidence for a non-linear association between nadir CD4 cell count (p=0.87) or 
CD4 cell count (p=0.35) and EIC. 
Investigation of an association with time since AALPHI interview – stage (c) 
No interactions were found between time since AALPHI interview and any of the HIV marker 
domain variables as predictors of EIC (all p≥0.05). 
Examination of paired exposure variables for association – stage (d) 
Tests for association were carried out on all paired variables in the HIV markers domain. A 
number of exposure pairs showed a significant association with each other based on p value for 
Cramer’s V (Table 5.32).  However, the association was only strong for two pairs, previous CDC 
C event and time on ART (Cramer’s V=0.37), and CD4 cell count and viral load (Cramer’s V=0.45). 















count    
 






n in last 2 
yrs 
Previous  
CDC C event 
 a) 0.16 a) 0.04 a) 0.05 a) 0.371 a) 0.11 a) 0.04 
 b) 0.06 b) 0.90 b) 0.40 b) <0.001 b) 0.05 b) 0.48 
Nadir CD4 cell 
count  
  a) 0.28 a) 0.12 a) 0.18 a) 0.15 a) 0.13 
  b) <0.001 b) 0.22 b) 0.005 b) 0.07 b) 0.17 
CD4 cell count  
   a) 0.45 a) 0.12 a) 0.21 a) 0.28 
   b) <0.001 b) 0.44 b) 0.005 b) <0.001 
Viral load 
    a) 0.33 a) 0.34 a) 0.34 
    b) <0.001 b) <0.001 b) <0.001 
Time on   
ART  
     a) 0.29 a) 0.17 
     b) <0.001 b) 0.06 
On efavirenz 
      a) 0.24 
      b)<0.001 
a = Cramer's V  
b = P value for Cramer’s V 
Values meeting the threshold for strong association on V test (Cramer’s V ≥0.5 between two two-level categorical variables and 
≥0.35 for tables with more dimensions) are underlined
Findings from predictive models for associated exposure variables (A, B) and engagement in care 
– stage (e) 
The two associated pairs found in stage (d) were investigated in a series of logistic regression 
models, adjusted for a priori variables, for EIC. There was little change in the odds ratio when 
both previous CDC C event and time on ART were included in the same model, compared to 
models with variables included individually, and no interaction between the variables were 





Table 5.33: Stage (e) predictive model for effect of previous CDC C event and time on ART on EIC in the HIV markers domain 
HIV markers variable 
Previous CDC C event 
adjusted for a priori 
Time on ART adjusted for a 
priori 
Previous CDC C event and 
Time on ART adjusted for a 
priori 
Previous CDC C event and 






















Previous CDC C event             
  No 1 - -    1 - - 1 - - 
  Yes 
0.86 
(0.57, 1.31) 







Time on ART              
  >10 years    1 - - 1 - - 1 - - 












































Previous CDC C event # Time 
on ART  
            
  CDC C event#On ART for >5 
to ≤10 yrs 





  CDC C event#On ART for >1 
to ≤5 yrs 




  CDC C event#On ART for 0 
to ≤1 yr 
         1 empty 
  CDC C event#ART naïve          1 empty 
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When CD4 cell count was fitted with viral load in a logistic model for EIC, odds ratios for both 
variables remained stable and similar to the individual models, but baseline CD4 cell count 
changed from having evidence for an association with EIC (p=0.001) when fitted without viral 
load, to no association (p=0.23) when fitted without. There was very strong evidence for an 
association with viral load and EIC when viral load was in the model individually (p=<0.001) 
and when it was fitted with CD4 cell count (p=<0.001) (  Table 5.34). This suggested that viral 
load explained the effect of CD4 on EIC, so CD4 cell count was dropped and viral load 
considered for the modelling stages. 
  Table 5.34: Stage (e) predictive model for effect of CD4 cell count (cells/µL) and viral load     




CD4 cell count 
 (cells/µL) adjusted 
for a priori 
Viral load 
(c/mL) adjusted 
for a priori 
CD4 cell count (cells/µL)  
and viral load (c/mL)  
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5.4.3. Logistic regression modelling 
In this section, I present the results of the four stages of modelling. Stage 1-3 models are 
presented by domain.  
5.4.3.1. A priori domain logistic regression modelling 
All a priori variables were investigated in the modelling process (models 1 and 2), and were: 
• Sex 
• Age at entry 
• Ethnicity 
• Born outside the UK 
Stage 1 models - Adjusting for time since AALPHI interview   
As might be expected based on the results from Table 5.1, when a priori variables were fitted 
individually, along with time since AALPHI interview, in multivariable models to explore the 
association with EIC, age at entry was the only variable that was associated with the 
outcome. There was strong evidence of an association between age at entry and EIC, with 
older participants having worse EIC (OR 0.90 per 1 year increase, 95% CI 0.83, 0.97, p=0.009). 
There was also weak evidence of an association between ethnicity and EIC (p=0.06) with 
young people from Asian/ mixed ethnicity being less likely to be in care than black young 
people, while white young people were similar to black young people ((Asian/mixed OR 0.53, 
95% CI 0.31, 0.89, white OR 0.98, 95%CI 0.34, 2.81, reference black ethnicity). Results are 
shown in Table 5.37. 
Stage 2 models - Adjusting for a priori exposure variables 
In models including time since AALPHI interview and all the a priori variables, findings were 
very similar to stage 1 models. Age at entry and ethnicity remained associated with EIC, with 
older participants, and those from Asian/ mixed ethnicity, being less likely to be in care (Table 
5.37). 
Stage 3 of the modelling process was not carried out for the a priori domain. 
5.4.3.2. Sociodemographic domain logistic regression modelling 




• Education/employment status 
• Ever excluded from school 
• Death of parents 
• Number of main carers 
• Live with parent/carer 
• Parent/carer in work 
• Main language spoken at home 
• IDACI Deprivation Score 
Stage 1 models - Adjusting for time since AALPHI interview 
In multivariable models in which sociodemographic variables were fitted individually, along 
with time since AALPHI interview, four variables were associated with EIC. As might be 
expected based on results from Table 5.3, these variables were education/employment 
status, ever excluded from school, living with parent/carer, and main language spoken at 
home.  Young people were less likely to be in care if they were: employed or not in education, 
employment or training (OR 0.46, 95% CI 0.21, 0.97, p=0.04) compared to young people in 
full-time education; had ever been excluded from school (OR 0.61, 95% CI 0.39, 0.95, p=0.03) 
versus had not; if they did not live with their parents (OR 0.50, 95% CI 0.25, 0.97, p=0.04) 
compared to young people living with their parents; or if they spoke a language other than 
English at home (OR 0.50, 95% CI 0.22, 1.14, p=0.10) compared with English only/ English and 
another language (Table 5.37). 
Stage 2 models - Adjusting for a priori exposure variables 
When the domain-specific variables were fitted individually in models including the a priori 
variables, only ever excluded from school and main language spoken at home continued to 
show evidence of an association with the outcome (Table 5.37) and ORs for these two 
variables in the stage 2 models were similar to the stage 1 models.  
Stage 3 model – Domain-specific multivariable model including a priori and 
sociodemographic domain exposure variables  
After backwards selection was conducted, both ever excluded from school (OR 0.61, 95% CI 
0.38, 0.99, p=0.04) versus not, and speaking a language other than English at home (OR 0.52, 
95% CI 0.24, 1.16, p=0.11) compared with English only/ English and another language 
remained associated with EIC. Therefore, both of these variables were considered in the 
primary stage 4 model (Table 5.37), full stage 3 model results are shown in see Appendix E, 
Table s4).   
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5.4.3.3. Risk behaviour practices domain logistic regression modelling 
The following variables from the risk behaviour practices domain were investigated in the 
modelling process: 
• Ever smoked cigarettes 
• Amount of alcohol  
• Condom use 
Stage 1 models - Adjusting for time since AALPHI interview   
In multivariable models in which risk behaviour practice variables were fitted individually, 
along with time since AALPHI interview, as might be expected based on results from Table 
5.6, all three variables showed an association with EIC. Young people were less likely to be in 
care if they had ever smoked (OR 0.55, 95% CI 0.35, 0.89, p=0.01) compared with never 
smokers, or if they reported drinking but not hazardously or hazardous drinking compared 
to young people who did not drink (OR for drink but not hazardously, 0.58, 95% CI 0.39, 0.87; 
OR for hazardous drinking OR 0.46, 95% CI 0.24, 0.87, reference do not drink, p=0.006). 
Young people who did not always use a condom during sex were less likely to be in care, and 
young people who always used a condom were more likely to be in care, than young people 
who were not sexually active (did not use a condom OR 0.57, 95% CI 0.31, 1.04, always use 
a condom OR 1.17, 95% CI 0.73, 1.87, reference not sexually active, p=0.11) (Table 5.37). 
Stage 2 models - Adjusting for a priori exposure variables 
When the domain-specific variables were fitted individually in models including the a priori 
variables, only ever smoked and condom use continued to show evidence of an association 
with the outcome (Table 5.37) and the ORs for these two variables in the stage 2 models 
were similar to the stage 1 models.   
Stage 3 model – Domain-specific multivariable model including a priori and risk behaviour 
practice domain exposure variables  
After backwards selection was carried out, both current alcohol amount (drinking but not 
hazardously OR 0.64, 95% CI 0.40, 1.01; hazardous drinking OR 0.57, 95% CI 0.28, 1.19, 
reference do not drink, p=0.12) and condom use (always use a condom OR 0.1.76 95% CI 
0.95, 3.26; do not always use a condom OR 0.80, 95% CI 0.42, 1.54, reference not sexually 
active, p=0.07) remained associated with EIC (Table 5.38). Therefore, both of these variables 
were considered in the primary stage 4 model (Table 5.37.), full stage 3 model results are 
shown in Appendix E, Table s5).   
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5.4.3.4. Mental health domain logistic regression modelling 
The following variables from the mental health domain were investigated in the modelling 
process: 
• Feelings about HIV 
• Ever self-harmed 
• Ever felt life was not worth living 
• Major life events 
• Paediatric Quality of Life (PedsQL) 
• Rosenberg Self-Esteem Scale 
• HADS anxiety score 
• HADS depression score 
Stage 1 models - Adjusting for time since AALPHI interview 
In multivariable models in which mental health variables were fitted individually, along with 
time since AALPHI interview, as might be expected based on results in Table 5.14, only self-
harm showed an association with EIC. Young people who had ever self-harmed (OR 0.67, 
95% CI= 0.40, 1.11, p=0.12) were less likely to be in care than those who had never self-
harmed (Table 5.37).   
Stage 2 models - Adjusting for a priori variables 
When the mental health variables were fitted individually in models including the a priori 
variables, self-harm continued to be the only variable to show evidence of an association 
with the outcome (Table 5.37). ORs in the stage 2 models were similar to the stage 1 models. 
Stage 3 model – Domain-specific multivariable model including a priori and mental health 
domain exposure variables  
After backwards selection was conducted, ever self-harmed (OR 0.66, 95% CI 0.38, 1.14, 
reference no self-harm, p=0.14) remained the only variable associated with EIC. Therefore 
this variable was considered in the primary stage 4 model (Table 5.37), full stage 3 model 
results shown in Appendix E, Table s6). 
5.4.3.5. Cognition domain logistic regression modelling 
The NPZ-6 variable was the only variable in this domain. 
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Stage 1 model - Adjusting for time since AALPHI interview   
In a multivariable model in which NPZ-6 was fitted with time since AALPHI interview, there 
was no evidence of an association of NPZ-6 with EIC (OR 0.88 per one unit increase in Z score, 
95% CI 0.68, 1.15, p=0.37) (Table 5.37). 
Stage 2 model - Adjusting for a priori variables 
When NPZ6 was fitted in a model including the a priori variables, there remained no evidence 
of an association with EIC (Table 5.37). ORs in the stage 2 model were similar to those in the 
stage 1 model. 
Stage 3 model – Domain-specific multivariable model including a priori and cognition domain 
variables  
The stage 3 model was not carried out because NPZ-6 was the only variable in this domain 
and it was not considered in the final model because there was no evidence of an association 
between it and the outcome. 
5.4.3.6. Clinic domain logistic regression modelling 
The following variables from the clinic domain were investigated in the modelling process: 
• Clinic location 
• Clinic type 
• Travel time to clinic 
Stage 1 models - Adjusting for time since AALPHI interview   
In multivariable models in which clinic variables were fitted individually, along with time 
since AALPHI interview, as might be expected based on results in Table 5.21, clinic location 
and travel time to clinic were associated with EIC.  Young people were more likely to be in 
care if they attended clinic outside London (OR 1.43, 95% CI 0.93, 2.19, p=0.10) compared to 
if they attended clinic inside London, or if their travel time to clinic was longer (OR 0.97 per 
10 minute increase, 95% CI 0.94, 1.01, p=0.14) (Table 5.37).   
Stage 2 models - Adjusting for a priori variables 
When the domain-specific variables were fitted individually in models including a priori 
variables, clinic location and travel time to clinic continued to show evidence of an 
association with EIC. ORs for these two variables in the stage 2 models were similar to the 
stage 1 models. In addition, clinic type showed evidence of an association with EIC, with 
young people attending either an adolescent or adult/GUM clinic being more likely to be in 
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care compared to young people still in paediatric care (adolescent clinic OR 1.28, 95% CI 0.64, 
2.58, adult/GUM clinic OR 4.13, 95% CI 1.23, 13.89, reference paediatric clinic,  p=0.07) 
although confidence intervals were quite wide for young people attending adult/GUM clinic 
(Table 5.37).   
When the clinic type variable was adjusted for a priori variables, there was a change in 
direction of the OR for the adolescent clinic (stage 2 and 3 models) compared to when 
adjusted for time since AALPHI interview only (stage 1 model) (stage 1 model: adolescent 
clinic OR 0.75, 95% CI 0.45, 1.25; stage 2 model adolescent clinic OR 1.28. 95% CI 0.64, 2.58; 
stage 3 model adolescent clinic OR 1.42, 95% CI 0.67, 3.00). Therefore, clinic type was 
investigated further. A series of multivariable models were fitted with clinic type and a priori 
variables to explore this association with EIC, dropping one a priori variable in each model. 
The change in direction of the OR remained when sex and ethnic group were dropped, 
however when age at entry was dropped, young people in adolescent clinics were less likely 
to be in care when compared to young people in paediatric clinic as in stage 1 model. This 
suggests that young people’s EIC may not change in the same way by age for each clinic type 
category. A new variable was created, combining age group and clinic type (Table 5.35). The 
combined variable suggested that young people aged 16 and older had worse EIC in 
paediatric care than those of the same age range in adolescent or adult care.  
Table 5.35: Proportion of person-months engaged in care for new combined clinic type and 
age variable 
Combined clinic type and age variable Person-months % in care 
In paediatric care aged 13-15 years 1,414 90 
In paediatric care aged 16-18 year 1,202 85 
In paediatric care aged 19-21 years 120 76 
In adolescent care aged 16-18 years 174 84 
In adolescent care aged 19-21 years 426 84 
In adult care aged 18-19 years 84 99 
In adult care aged 19-21 years 117 90 
 
In addition, as shown in Table 5.36, all young people aged 13-15 years were in paediatric care 
and the majority of young people aged 16-18 years were also in paediatric clinics, rather than 
adolescent or adult clinics.  
215 
 
Table 5.36: Number of person-months by clinic type and age group 
Age group  






13-15 years 1,414 0 0 1,414 
16-18 years 1,202 174 84 1,460 
19-21 years 120 426 117 663 
Total 2,736 600 201 3,537 
 
An interaction was fitted between clinic type and age at entry and no interaction was found 
(p=0.67), therefore, clinic type remained in the model at this stage 
Stage 3 model – Domain-specific multivariable model including a priori and clinic domain 
variables  
After backwards selection was conducted, both clinic type (adolescent clinic OR 1.42, 95% CI 
0.67, 3.00; adult/GUM clinic OR 3.88, 95% CI 1.00, 15.10, reference paediatric clinic, p=0.14) 
and travel time to clinic (OR 0.97 per 10 minute increase, 95% CI 0.94, 1.00, p=0.08) remained 
associated with EIC (Table 5.37), full stage 3 model results are shown in Appendix E, Table 
s7).   
5.4.3.7. HIV experience and management domain logistic regression modelling 
The following variables from the HIV markers domain were investigated in the modelling 
process: 
• Age at naming of HIV 
• Number of people told about HIV  
• Adherence self-assessment 
Stage 1 models - Adjusting for time since AALPHI interview 
In multivariable models in which HIV experience and management variables were fitted 
individually, along with time since AALPHI interview, two variables showed an association 
with EIC. As might be expected based on results from Table 5.25, these variables were 
number of people told about HIV, and adherence self-assessment.  The direction of the 
association varied between the categories in the number of people told about HIV variable. 
Compared to young people who had told 0-2 people about their HIV status, young people 
were less likely to be in care if they had told 3-4 other people (OR 0.70, 95% CI 0.38, 1.29) or 
≥10 people (OR 0.40, 96% CI 0.17, 0.93), and they were more likely to be in care if they had 
told 5-9 people (OR 1.43, 95% CI 0.41, 5.00)(p=0.11). Young people were also less likely to be 
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in care if their adherence self-assessment was not so good or bad (OR 0.38, 95% CI 0.22, 0.66) 
or if they were not on ART (OR 0.37, 95% CI 0.22, 0.63) compared to those on ART who rated 
their adherence as excellent or good (p=<0.001) (Table 5.37).   
Stage 2 models - Adjusting for a priori variables 
When the HIV experience and management variables were fitted individually in models 
including a priori variables, number of people told about HIV and adherence self-assessment 
continued to show evidence of an association with EIC (Table 5.37). ORs for these two 
variables in the stage 2 models were similar to variables in the stage 1 models.   
Stage 3 model – Domain-specific multivariable model including a priori and HIV experience 
and management domain variables  
After backwards selection was carried out only adherence self-assessment (not so good or 
bad OR 0.39, 95% CI 0.23, 0.64, p=<0.001; not on ART OR 0.35, 95%CI 0.21, 0.59, reference 
excellent or good adherence, p=<0.001) remained associated with EIC. Therefore, adherence 
self-assessment was considered in the primary stage 4 model (Table 5.37, full stage 3 model 
results shown in Appendix E, Table s8).   
5.4.3.8. HIV markers domain logistic regression modelling 
The following baseline variables from the HIV markers domain were investigated in the 
modelling process: 
• Previous CDC C event  
• Nadir CD4 cell count (cells/µL) 
• Viral load (c/mL) 
• Time on  ART (cumulative) 
• On efavirenz  
• Treatment interruption in last 2 years 
Stage 1 models - Adjusting for time since AALPHI interview 
In multivariable models in which HIV marker variables were fitted individually, along with 
time since AALPHI interview, three variables showed an association with EIC. As might be 
expected based on results from Table 5.30, these variables were viral load, on efavirenz, and 
having had a treatment interruption in the 2 years. Young people were less likely to be in 
care if they had a viral load >50c/mL (OR 0.34, 95% CI 0.23, 0.49, p=<0.001) compared with 
those who were suppressed, or if they had had a treatment interruption in the last two years 
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(OR 0.56, 96% CI 0.35, 0.91, p=0.02) compared with those who had not. Young people were 
also more likely to be in care if they were on efavirenz at baseline (OR 2.01, 95% CI 1.24, 3.28, 
p=0.005) compared to those who were not (Table 5.37).   
Stage 2 models - Adjusting for a priori variables 
When the domain-specific variables were fitted individually  models including a priori 
variables, viral load, on efavirenz, and treatment interruption in the 2 years continued to be 
associated with EIC (Table 5.37). ORs for these three variables in the stage 2 models were 
similar to the stage 1 models.  
Stage 3 model – Domain-specific multivariable model including a priori and HIV markers 
domain variables  
After backwards selection was conducted, only viral load (>50c/mL OR 0.33, 95% CI 0.23, 0. 
48, reference ≤50c/mL, p=<0.001) continued to have evidence of an association with EIC 
(Table 5.37). Therefore, viral load was considered in the primary stage 4 model (full stage 3 
model results are shown in Appendix E, Table s9). 
Table 5.37:Logistic regression results for stage 1-3 models across all domains 
Domain, variable and 
category 
Stage 1 models: 
Adjusted for time since 
AALPHI interview 
Stage 2 models: 
Adjusted for a priori 
variables 
Stage 3 models: 
Domain-specific multi-
variable model 











A priori domain      
Month of follow-up (1-12), 




0.49   
Sex        
  Male 1 - 1 -   






0.79   







0.004   
Ethnicity       
  Black 1 - 1 -   






(0.31, 0.89) (0.28, 0.85)   
  White 
0.98 0.98   
(0.34, 2.81) (0.35, 2.77)   
Born outside of UK 
  No 



















Sociodemographic domain      
Education/employment 
status 
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Domain, variable and 
category 
Stage 1 models: 
Adjusted for time since 
AALPHI interview 
Stage 2 models: 
Adjusted for a priori 
variables 
Stage 3 models: 
Domain-specific multi-
variable model 











  In full time education 1 - 1 -   
  Employed or not in 
education,  






0.21   
Ever excluded from school      
  No 1 - 1 - 1 - 










Death of parents       
  None or unknown 1 - 1 -   






0.41   
Number of main carers       
  1 carer 1 - 1 -   















Live with parents/carers       
  Yes 1 - 1 -   






0.37   
Parent/carer in work       
  Yes 1 - 1 -   














Main language spoken at 
home 
      
  English/English and another    
  language 
1 - 1 - 1 - 











IDACI deprivation score2, per 








0.28   
Risk behaviour practice 
domain 
     
Ever smoked        
  No 1 - 1 -   






0.14   
Current alcohol amount       
  No drinking 1 - 1 - 1 - 








(0.40, 1.01) 0.12 
 









Domain, variable and 
category 
Stage 1 models: 
Adjusted for time since 
AALPHI interview 
Stage 2 models: 
Adjusted for a priori 
variables 
Stage 3 models: 
Domain-specific multi-
variable model 











Condom use        
  Not sexually active 1 - 1 - 1 - 





















Mental health domain      
Feelings about HIV, per 1 







0.49   
Ever self-harmed       
  No 1 - 1 - 1 - 










Ever felt life not worth living       
  No 1 - 1 -   






0.94   
Major Life events, per 1 point 







0.42   
Pediatric Quality of Life, per 
1 point increase (higher 






0.46   
Rosenberg Self-Esteem 
Scale, per 1 point increase 






0.22   
HADS anxiety score, per 
point 1 increase (higher 






0.92   
HADS depression score, per 







0.83   
Cognition domain       
NPZ-6 score, per unit 







0.87   
Clinic domain       
Clinic location       
  In London 1 - 1 -   






0.10   
Clinic type       
  Paediatric 1 - 1 - 1  




















Domain, variable and 
category 
Stage 1 models: 
Adjusted for time since 
AALPHI interview 
Stage 2 models: 
Adjusted for a priori 
variables 
Stage 3 models: 
Domain-specific multi-
variable model 






















HIV experience and management domain     
Age at naming of HIV       
  Aged ≤11 years 1 - 1 -   
















How many people told about 
HIV 
      
  0-2 1 - 1 -   























Adherence self-assessment       
  Excellent or good 1 - 1 - 1 - 



















HIV markers domain       
HIV severity       
Previous CDC C event       
  No CDC C  1 - 1 -   






0.49   
Viral load        
  ≤50c/mL 1 - 1 - 1 - 










ART       
Time on ART       
 >10 years 1 - 1 -   


























On efavirenz at baseline       
  No  1 - 1 -   






0.01   
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Domain, variable and 
category 
Stage 1 models: 
Adjusted for time since 
AALPHI interview 
Stage 2 models: 
Adjusted for a priori 
variables 
Stage 3 models: 
Domain-specific multi-
variable model 











Treatment interruption in 
last 2 yrs 
      
  No 1 - 1 -   





0.04   
1 Modelling carried out using backwards selection 
5.4.4. Stage 4 model 
When all the exposure variables showing an association with in care from the stage 3 
domain-specific models were combined in a multivariable model across domains, following 
backwards selection, four variables continued to show evidence of an association with EIC in 
this primary stage 4 model.  These were ethnicity, ever self-harmed, adherence self-
assessment, and baseline viral load.  Young people were less likely to be in care if they were 
Asian/ mixed ethnicity compared to black ethnicity, with the white ethnic group similarly 
likely to be in care to the black ethnic group (Asian/mixed ethnicity OR 0.44, 95% CI 0.25, 
0.78, white OR 1.05, 95%CI 0.29, 3.81, reference black ethnicity, p=0.02).  Young people were 
also less likely to be in care if they had ever self-harmed (OR 0.55, 95% CI 0.32, 0.95, p=0.03) 
compared to those who had not, and if they had assessed their adherence to ART as not so 
good or bad (OR 0.46, 95% CI 0.25, 0.84) or were not on ART (OR 0.64, 95% CI 0.34, 1.21) 
compared to those on ART who assessed their adherence as excellent or good (p=0.04). 
Finally participants were less likely to be in care if they had a baseline viral load >50c/mL (OR 





Table 5.38: Primary stage 4 model  




A-priori domain   





Sex    











Ethnicity   
Black 1 - 
Asian/mixed  0.44 
0.02 





Born outside the UK   










Yes  0.55 
(0.32, 0.95) 
0.03 
Adherence self-assessment   
Good / excellent 1  
 
0.04 
Not so good/ bad 0.46 
(0.25, 0.84) 
Not on ART 0.64 
(0.34, 1.21) 
 
Viral load    





5.4.5. Results of checks to the final model and sensitivity analyses 
The results of a number of checks and sensitivity analyses that were performed on the 
primary stage 4 model are described below.  
5.4.5.1. Alternate stage 4 model exposure variables 
The primary stage 4 model was rerun, replacing self-harm with all of the other mental health 
variables one by one (feelings about HIV, ever felt life was not worth living, major life events, 
Pediatric Quality of Life Inventory, Rosenberg Self-Esteem Scale, HADS anxiety score, HADS 
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depression score) and none were found to be associated with EIC (p≥0.05) (results not 
shown). Self-assessment of adherence was replaced in the model with missed doses in last 
three days but was not found to be associated with EIC (p≥0.05) (results not shown). Finally, 
viral load was replaced in the model by CD4 cell count but this was not found to be associated 
with EIC (p≥0.05) (results not shown).  
5.4.5.2. Sensitivity analysis – using an alternate p value cut off (<0.1 compared to 
<0.05) 
The primary stage 4 model was rerun, including all the exposure variables with a p value 
<0.15 from the stage 3 model but using an alternative <0.1 p value for inclusion in the final 
model (instead of <0.05).  The stage 4 model for this sensitivity analysis was very similar to 
the primary stage 4 model with all the exposure variables from the primary stage 4 model 
remaining. However, two additional exposure variables were found to be associated with 
EIC: language spoken at home; and type of clinic attended. Participants who spoke a 
language other than English at home were less likely to be in care (OR 0.39, 95% CI 0.14, 1.08 
p=0.07) than participants who spoke English or English and another language. In addition, 
participants who attended adolescent or adult clinics (adolescent clinic OR 1.66, 95% CI 0.83, 
3.32; adult clinic OR 4.08, 95% CI 1.28, 12.99, p=0.04) were more likely to be in care 






Table 5.39: Stage 4 model sensitivity analysis with p value <0.1 cut off   




A-priori domain   





Sex    











Ethnicity   
Black 1 - 
Asian/mixed 0.42 
0.005 





Born outside the UK   






Other domains   
Main language spoken at home   
English/English and another language 1 - 




Type of clinic attended   








Self-harm ever   
No 1 - 
Yes  0.53 
(0.31, 0.92) 
0.02 
Adherence self-assessment 1 - 
Good / Excellent 0.47 
(0.26, 0.84) 
0.03 
Not so good/bad 0.62 
(0.33, 1.17) 
Viral load    





When these two additional exposure variables were included in the model, the a priori age 
at entry variable became associated with EIC, when it was not previously. The relationship 
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between age at entry and language spoken at home and type of clinic was therefore 
investigated. Stage 4 models (using a cut off of <0.1) were run removing clinic type and 
language individually. Age at entry was only associated with EIC when clinic type was in the 
model. As shown previously (Table 5.35) young people aged 16 years and older had worse 
EIC in paediatric care than those of the same age range in adolescent or adult care. As shown 
in Table 5.40, all young people aged 13-15 years were in paediatric care and the majority of 
young people aged 16-18 years were also in paediatric clinics, rather than adolescent or adult 
clinics. There was no evidence for an interaction between clinic type and age at entry was 
fitted (p=0.67). 
Table 5.40: Number of person-months by clinic type and age group 
Age group  
Person-months by clinic type 





13-15 years 1,414 0 0 1,414 
16-18 years 1,202 174 84 1,460 
19-21 years 120 426 117 663 
Total 2,736 600 201 3,537 
 
5.4.5.3. Sensitivity analysis using an alternate start date 
In a sensitivity analysis, the primary stage 4 model was fitted using an alternate start date 
for the follow-up year, which was three months later than the AALPHI interview date 
(baseline) used for the main analysis.  The model using the alternate start date was very 
similar to the primary stage 4 final model (Table 5.41). The retained variables were the same 
apart from the addition of travel time to clinic, and the odds ratios, confidence intervals and 
p values were all similar. Travel time was kept in the final model for this sensitivity analyse 
despite having a p value of ≥0.05. After the initial backwards elimination process, only 
adherence remained in the model. However, when travel time was added to this model, it 
was found to be significant. Self-harm and viral load were also found to be significant when 
adherence and travel time were included in the model; however, travel time became just 




Table 5.41: Stage 4 model sensitivity analysis using an alternate start date 




A-priori domain  





Sex    











Ethnicity   
Black 1 - 
Asian/ mixed  0.46 
0.04 





Born outside the UK   










Yes  0.52 
(0.28, 0.96) 
0.04 
Adherence self-assessment   
Good / excellent 1 - 
 
0.03 
Not so good/bad 0.43 
(0.24, 0.80) 
Not on ART 0.64 
(0.33, 1.24) 
 
Viral load   




Travel time to clinic (per 10 min increase) 0.96 
(0.92, 1.00) 
0.06 
5.4.5.4. Sensitivity analysis using a four month maximum time to next appointment 
In a sensitivity analysis including all of the stages of modelling, the maximum time to next 
scheduled appointment was reduced to 4 months instead of 6 months. Results from all four 
stages of modelling are presented in Appendix F and stage 4 model results are shown in Table 
5.42. 
The stage 4 model for this sensitivity analysis was similar to the primary stage 4 model.  Thus 
young people were less likely to be in care if they: self-harmed (OR 0.56, 95% CI 0.34, 0.93, 
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p=0.03); had not so good/bad adherence (OR 0.44, 95% CI 0.25, 0.75) or were not on ART 
(OR 0.64, 95%CI 0.35, 1.18)(p=0.01); or had a viral load >50c/mL (OR 0.62, 95% CI 0.41, 0.96, 
p=0.03). Similarly to the primary stage 4 model, young people who were of Asian / mixed 
ethnicity were also less likely to be in care compared to black young people, with white young 
people similar to black young people (Asian/mixed OR 0.52, 95% CI 0.30, 0.91, white OR 1.05, 
95% CI 0.36, 3.07) although only a weak association with ethnicity was found (p=0.07). In 
contrast to the main model, young people were less likely to be in care with increasing month 
through the 12 month follow up period (time per month from baseline OR 0.95, 95% CI 0.91, 





Table 5.42: Stage 4 model sensitivity analysis using 4 month maximum time to next 
appointment 




A-priori category  




(0.91, 0.99) 0.02 
Sex    











Ethnicity   
Black 1 - 
Asian/mixed  0.52 
0.07 





Born outside the UK   










Yes  0.56 
(0.34, 0.93) 
0.03 
Adherence self-assessment   
Good / excellent 1 - 
 
0.01 
Not so good/ bad 0.44 
(0.25, 0.75) 
Not on ART 0.64 
(0.35, 1.18) 
 
Viral load   







 Discussion  
5.5.1. Summary of the main findings 
In this chapter, I detailed the methods used to identify predictors of EIC in young people 
living with PHIV in the AALPHI cohort. Due to the large number of exposure variables which 
may be related with EIC, extensive investigations as part of stages (a) to (f) were carried out 
to detect any between-covariate associations, to avoid introducing co-linearity and to 
improve model stability. Once the variables for inclusion were established, four stages of 
multivariable logistic regression modelling for EIC were employed. Stage 1 to 3 models were 
fitted within domains, and the stage 4 model brought together variables from across the 
domains.  
In the primary stage 4 model, four factors were found to be associated with EIC, each from 
a different domain. From the a priori domain, young people were less likely to be in care if 
they were of Asian/mixed ethnicity compared to being of black or white ethnicity.  From the 
mental health domain, participants had worse EIC if they reported having ever self-harmed 
compared to not.  From the HIV experience and management domain participants were less 
likely to be in care if they reported having not so good/bad adherence to ART or if they were 
not on ART compared to excellent/good adherence to ART.  Finally from the clinical markers 
domain, participants had poorer EIC if they had a viral load >50c/mL compared to ≤50c/mL. 
The sensitivity analysis models were reassuringly similar to the primary stage 4 model, 
suggesting that the role of identified potential biases in affecting the findings might be small. 
Self-harm, adherence and viral load remained associated to in care in all three sensitivity 
analyses. Ethnicity remained associated with in care in the models using a higher p-value cut 
off (<0.1)  and an alternate start time (3 months after AALPHI interview date) although it was 
only weakly associated to in care when the maximum time to next appointment was changed 
to 4 months (p=0.07). Of note, entry age was found to be associated to in care in both the 
sensitivity analyses using a higher cut off (p=0.004) and when the maximum time to next 
appointment was 4 months (p=0.001). In addition, it was only very marginally above the 
significance cut off in the alternate start time model (p=0.05). Investigations showed that 
young people age 16 and older had worse EIC in paediatric care than young people of the 
same age in adult or adolescent care. However, the majority of young people aged age 16-
18 (1,202/1,460) and about a fifth of 19-21 years olds were still seen in paediatric care.  
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5.5.2. Findings in comparison to the wider literature 
My analysis of exposure variables and their association with EIC was largely exploratory, and 
I included a large number of potential exposures. In order to facilitate a structured and 
thorough approach to model building, I grouped these variables into eight different domains.  
This allowed me to better identify the complex interplay between variables which may be 
associated with each other, and to prevent issues of collinearity and model instability.  Two 
examples are described below. On initial investigation of the risk practices domain variables, 
the proportion of young people in care who smoked was lower than young people who did 
not smoke (81% vs. 89%) suggesting a possible association with EIC. A strong association was 
then found between ever smoked and alcohol amount (Cramer’s V=0.42), with no evidence 
of an interaction between the two variables and when both variables were fitted in the same 
logistic regression model for EIC, there were very few changes to the ORs or confidence 
intervals for either variable. Although when fitted in a model with a priori variables as well 
as with a priori variables and alcohol amount, ever smoked was no longer associated with 
EIC. Nevertheless, ever smoked was taken ahead to the modelling stages. When adjusted for 
only time in a logistic regression model for EIC, ever smoked was associated with EIC 
(p=0.01), as expected based on previous results, this association however disappeared when 
the a priori and other risk behaviour variables were included in the model (p=0.14) and 
therefore ever smoked was dropped.  
Based on the proportion of months in care, there was also the suggestion of a trend for CD4 
count and EIC in the HIV markers domain (<200=78%, 200-350=80%, 351-499=88%, 
≥500=91%). When tests for association were carried out, a strong association was found 
between CD4 count and viral load (Cramer’s V=0.45). When CD4 count was fitted in a logistic 
regression model adjusted for a priori variables, an association with EIC was found (p=0.001), 
however, when viral load was also included in the model, the association between CD4 and 
EIC disappeared (p=0.23) suggesting that viral load explained the effect of CD4 on EIC. CD4 
count was therefore not carried forward to the modelling stages.  
My approach was similar to a “conceptual framework” approach used in other analyses of 
young people with HIV,(93,254) and proposed by Haberer and Mellins.(72)  Their conceptual 
framework comprised of four categories: the child, caregiver(s) and family, the ART regimen, 
and society and culture. Harberer and Mellins (72) recommend that due to the complex 
challenges of long-term adherence to ART, factors within these four categories  need to be 
taken into consideration when measuring adherence or planning adherence interventions. I 
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benefited from a wide range of potential exposures measured in AALPHI, far beyond the 
more common and rather limited range of clinical HIV factors included in many analyses.  
This approach is supported by my findings, in which predictors found to be associated with 
EIC, were from four different domains (a priori, mental health, HIV experience and 
management, and HIV markers). This suggests that similarly to adherence, a complex array 
of factors influence young people’s EIC and therefore need to be taken into consideration 
both when measuring EIC and when suggesting possible ways of improving EIC. 
As detailed in Chapter 3, flowcharts used in this analysis were derived from an algorithm 
developed by Howarth et al (151), in their analyses of adults with HIV in the UK. 
Consequently, the results from their analyses are perhaps the most directly comparable to 
findings from this analysis. I will therefore first compare the findings to the Howarth et al 
findings and then to the wider literature. 
Howarth et al (151) applied their EIC algorithm to 44,432 patients aged 16 years or older 
from the UK CHIC study in the UK. In their multivariable analysis, they reported that age was 
associated with EIC, with lower EIC in adults aged 25-45 years (OR 0.74, 95% CI 0.59, 0.93, 
p=0.008) compared to adults aged >45 years. In addition, the proportion of patients EIC was 
lowest in the <25 age group (<25 years in care 77%, 25-45 years in care 83%, >45 years in 
care 87%) however, when compared to >45 year olds in multivariable analysis, only a weak 
association with EIC was found (<25 years OR 0.67, 95% CI 0.42, 1.06, p=0.09). Although age 
was not found to be associated with EIC in my primary model 4 results, an association with 
increasing age and worsening EIC was found in the two sensitivity analyses in which the p 
value for inclusion in the model was increased to <0.1 (instead of <0.05) and when the 
maximum time to next appointment was capped at 4 months. In addition, there was a weak 
association between age and EIC in the third sensitivity analysis, when an alternate start date 
was used (p=0.05). This is consistent with the rest of the literature. 
Howarth et al (151), also described that while people of black African or ‘unknown’ ethnicity 
were found to have similar EIC to people of white ethnicity (black African OR 0.96, 95% CI 
0.83, 1.11, p=0.55, unknown OR 0.87, 95% CI 0.73, 1.03, p=0.11, reference white ethnicity) 
people of ‘Other ethnicity’ were less likely to be in care (OR 0.79, 95% CI 0.68, 0.92, p=0.002) 
compared to people of white ethnicity. Patients in Howarth et al’s ‘other ethnicity’ group 
and in my Asian/mixed ethnicity group are minorities in HIV clinics in the UK, which may 
create a barrier to engaging in care. People of white ethnicity are also a minority in paediatric 
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HIV clinics, however, white patients are not a minority in many adolescent and adult clinics, 
which may be why there is no association with worse EIC in this group. 
Similarly to my analysis, Howarth et al (151) reported that ART status was associated with 
EIC. People who were on ART were more likely to be in care than people who were off ART 
(OR 1.44, 95% CI 1.15, 1.81, p=0.022). Howarth et al also found that patients with lower nadir 
CD4 counts were less likely to be in care (nadir CD4 count <200c/µL: OR 0.55, 95% CI 0.41, 
0.74 , 200-349 c/µL: OR 0.37, 95% CI 0.28, 0.50, reference ≥350 c/µL, p=0.0001).(151) In my 
analysis, nadir CD4 was not associated with EIC, and CD4 count was dropped in the early 
modelling stages as there was evidence that viral load explained the effect of CD4 on EIC.  
However, Howarth et al did not include viral load in their model. Howarth et al also described 
an association between three additional variables and EIC that were not included in my 
analysis because they are either not relevant to young people with PHIV, (route of HIV 
acquisition and time since entry in the UK CHIC study) or to this analysis (calendar time which 
was not relevant as this analysis included  one year follow-up which only spanned two 
calendar years).   
In addition to my and the Howarth et al analysis, other studies have also found an association 
between ethnicity and EIC, although there were varying trends across the studies. In Gray et 
al’s (162) population-based analysis of young people with PHIV across the USA (n=11,747), 
Hispanics/Latinos were more likely to be in care than people of white ethnicity (unadjusted, 
prevalence ratio (PR) 1.1, 95% CI 1.1, 1.2). In contrast, in a population-based cohort analysis 
of young people aged 13-24 years with HIV in Florida (n=2,872), Gebrezgi et al (161) reported 
that after adjusting for sociodemographic and neighbourhood factors, Hispanics were less 
likely to be in care than people of non-Hispanic white ethnicity (PR 0.88, 95% CI 0.81, 0.95). 
However, only 28% of the young people in Gebrezgi et al’s analysis had perinatal HIV as their 
mode of HIV acquisition. Additionally the differences between the social and cultural 
contexts of young people of Latino/Hispanic ethnicity in the USA and Asian/mixed ethnicity 
in the UK may limit comparability.  
Another of the variables which was associated with EIC in my analysis was self-harm. Young 
people who reported ever having self-harmed were less likely to be in care than young 
people who did not report a history of self-harm. None of the other EIC papers included self-
harm in their analyses so it is not possible to compare my finding to other studies. In my 
analysis, 12% of participants reported a history of self-harm, using computer assisted self 
interviewing to encourage honest reporting. This prevalence is similar to a large (n=6,477) 
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analysis of responses to the Adult Psychiatric Morbidity Survey of adults ages 16-74 in the 
UK general population from 2014.(255) In that Survey, the prevalence of self-harm was 
highest at 13.7% in persons aged 16-24 compared to all the other age groups. However, using 
self-harm in a clinical setting to identify young people at risk of disengagement may be 
problematic because of the secrecy around self-harm. In Copelyn et al’s (211) analysis of self-
harm from the AALPHI cohort, only 14% of young people reported seeking help following an 
incident of self-harm. Although young people in AALPHI were not asked whether they 
discussed their self-harm with clinical staff, hiding self-harm from health care professionals 
is consistent with the literature.(142,211,255) 
Based on the relatively high prevalence of self-harm found in AALPHI population, all clinics 
seeing young people could consider routinely discussing self-harm with their patients. 
However, due to the hidden nature of self-harm, clinics routinely assessing young people for 
self-esteem or depression could perhaps use these as a proxy for risk of disengagement in 
care or introduce simple assessment tools in clinics to measure them. Although none of the 
other mental health variables were found to be associated with EIC in my analysis even when 
self-harm was not in the model, studies have described associations between other mental 
health exposures and self-harm as an outcome variable. In Copelyn et al (211) , in analysis 
from the AALPHI cohort, self-esteem was strongly associated with self-harm, with each one 
point increase in the Rosenberg Self-Esteem Scale (higher score=better self-esteem) being 
associated with a 10% reduction in the odds of self-harm (95% CI 0.8, 0.9, p<0.001). In the 
Avon Longitudinal Study of Parents and Children (ALSPAC) ongoing population based study, 
investigators reported that concurrent depression was associated with a much increased risk 
of self-harm (OR 5.43, 95% CI 4.60, 6.40, p=<0.001).(142)  
Also found to be associated with EIC in my analysis was self-assessed adherence. Young 
people with not so good/bad adherence or who were off ART were less likely to be engaged 
in care than people with excellent/good adherence. Most other studies of EIC only included 
routinely collected sociodemographic and clinical factors in their analysis and therefore no 
analysis of the effect of adherence on EIC was conducted. Adherence self-assessment may 
be useful in the clinical setting as it is ostensibly very easy to assess and so offers a simple 
way of identifying those at risk of disengaging from care.  However, it is important that 
discussions about adherence are not limited to just simply authoritatively reinforcing 
message about the importance of taking ART.(104,256,257) Conversations around ART 
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adherence need to be pre-emptive rather than reactive and it’s essential that  both the social 
and structural complexities of taking long-term ART are acknowledged.(104,258)  
Young people in my analysis with an unsuppressed viral load were less likely to be in care 
than young people with suppressed viral load. Other studies have similarly described an 
association between EIC and viral load. Pantelic et al (158) in their study of 979 young people 
(79% PHIV) in the Eastern Cape, South Africa reported that EIC was associated with lower 
odds of viral failure (VL>1000c/mL) (OR 0.37, 95%CI 0.22, 0.61). What it is not possible to tell 
from either the Pantelic et al study, or my analysis, is whether EIC improves viral load or 
whether having a viral load ≤50c/mL leads to improved EIC. It does mean however, that 
people who have a viral load >50c/mL may be more likely to disengage in the future; so these 
young people would be a good group for which additional support could be offered. 
In addition to Howarth et al,(151) two other studies identified age as a predictor of EIC. Gray 
et al (162) in the USA, reported that young people living with PHIV aged 13-17 years had a 
higher EIC that 18-25 year olds (PR 1.2, 95% CI 1.1, 1.2) although this finding was from a 
univariable model. Similarly, Gebrezgi et al (161) reported that 13-17 year olds had better 
EIC than 18-20 year olds (PR 0.85, 95% CI 0.78, 0.92) and 21-24 year olds (PR 0.74, 95% CI 
0.68, 0.80) in a multivariable model. This is similar to the trend shown in this analysis with 
EIC declining as young people got older.  
In this analysis, young people who attended adolescent and GUM or adult clinics were more 
likely to be in care than young people who attended paediatric clinics. Clinic structures such 
as having appointments outside school hours (159,164) and adolescent friendly clinic 
environments (164) have been reported to be associated with improved EIC in other studies. 
Lee et al (164) assessed the impact of youth friendliness on 680 young people (35% PHIV, 
65% BHIV) aged 15-24 years attending 15 clinics across the USA. After adjusting for 
demographic and clinical factors, they reported that three youth friendly structures were 
found to be associated with EIC: youth friendly space (OR 2.47, 95% CI 1.11, 5.52); evening 
clinic hours (OR 1.94, 95% CI 1.13, 3.33); and providers with adolescent training (OR 1.98, 
95%CI 1.01, 3.86).  
Travel time to clinic was also found to be associated to EIC with young people who had to 
travel further having worse EIC. Similarly, a study 771 adults aged ≥18 years receiving HIV 
care in Chicago, USA, reported that median travel time to care was 15.9 [IQR 10, 23] versus. 
17 [IQR 12, 25] minutes for those not retained in care compared to those who were 
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(p=0.04).(218) The final variable found to be associated to EIC in the analysis was language 
spoken at home. Young people who lived in homes where only another language apart from 
English was spoken were less likely to be in care than young people who lived in a household 
that spoke English, or English and another language. No other studies reported this finding.  
It is important to note that relatively few studies have looked at EIC in young people living 
with PHIV. Additionally the method of measuring EIC varies widely in the literature, limiting 
direct comparisons. In general, the other analyses included most variables from the a priori 
and HIV markers domains while variables from the sociodemographic, mental health, 
cognition, clinic, and HIV experience and management domains were largely absent. 
5.5.3. Limitations 
My analysis has several limitations and possible sources of biases that could affect the overall 
findings. The limitations discussed here include those that are specific to the methods used 
in this chapter, as well those discussed in previous chapters focusing on how they could affect 
my modelling. 
In this analysis, the EIC outcome was measured across one year for each participant, whilst 
the exposure variables were measured at baseline (AALPHI interview). This approach was 
taken to avoid time dependent confounding, however variables including baseline viral load 
and adherence may have been influenced by previous EIC, thus meaning it is still not 
straightforward to disentangle predictors and mediators 
For this analysis, variables were considered within domains and much of the selection took 
place prior to considering the full multivariable model including variables across these 
domains. Arguably some exposure variables could have been included in other domains, for 
example ever excluded could have been included in the risk behaviours domain rather than 
the sociodemographic domain. Thus between-covariate associations may have been missed, 
and variables might have been erroneously dropped in the modelling stages. Additionally, 
due to the large number of related variables, sometimes decisions were made about which 
variable to take forward and which to drop. It is possible that errors were made in these 
decisions.  
As detailed in Chapter 3, a number of participants apparently attended early for their 
appointments, particularly where the next appointment was predicted 6 months later. This 
was a possible example of misclassification of time to next appointment due to the 
classifications in the flowcharts not being representative of countrywide practice. This 
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misclassification would then result in young people being classified as in care, when they in 
fact were out of care. This could result in a dilution of the effect of predictors or result in 
predictors being missed entirely. Reassuringly, when the time to next appointment was 
capped at 4 months (instead of 6 months) in a sensitivity analysis, the stage 4 model results 
were very similar to the primary stage 4 model.   
A number of the additional biases resulting in a misclassification of the outcome discussed 
in Chapter 3 could also lead to a dilution in the strength of effect or a missed predictor. 
Examples include limitations resulting from the use of proxy markers; people may be 
attending clinic but not having a blood test or measurement, or dates might be inaccurately 
recorded or missed on the CHIPS forms. Additionally, serious events such as a CDC events, 
which would require much shorter time to next appointment schedules, may not have been 
reported. Again, reassuringly, results from the sensitivity analysis provides some confidence 
in my findings. When a more lenient p <0.1 cut off was assessed (as opposed to p value <0.05) 
the stage 4 model was very similar to the primary stage 4 model, with only two new exposure 
variables becoming associated with EIC. 
Another possible cause of dilution was the choice of the AALPHI interview date as the start 
date (baseline). It was chosen because this is the time point when the exposure 
measurements were taken, however 43% of participants had a clinic visit on the day of their 
AALPHI appointment, which could also dilute the strength of associations. For example, if 
baseline self-esteem was associated with poorer EIC, then no effect of low self-esteem would 
be apparent in participants who had a clinic visit at interview until their next visit was due 
(meaning they would be in care on average for 4 months despite low self-esteem). In the 
remaining 57% who did not have a clinic visit at baseline, a more immediate drop out in 
participants who had low self-esteem might be seen. If the effect of self-esteem was 
marginal, it might be missed. Thus a sensitivity analysis was designed to assess this, utilising 
a start date 3 months after the original start date (AALPHI interview). The findings in the 
sensitivity analysis were very similar to the primary stage 4 model, suggesting that the start 
date is unlikely to have caused too much dilution to the strength of association of exposure 
variables with EIC.  
As discussed in Chapter 4, a number of biases related to the AALPHI interview may affect the 
EIC model. Selection of appropriate measurement tools is complicated, due to the lack of 
tools specifically designed and validated in young people and due to the compromises 
required to ensure the AALPHI interview was not too lengthy for the participants. In addition, 
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issues such as social desirability or misinterpretation/ misunderstanding of question can 
impact the answers given. For example, if the depression tool did not effectively identify 
depression in young people, or many young people reported that they took their medication 
when in fact they did not, both of these circumstances would affect the exposure variable. 
If, as a result of either of these problems, the measures only pick up the most extreme values, 
this might overestimate the strength of the association between the exposure and EIC. 
Conversely, if the measurements more randomly identify young people with true problems 
with adherence or depression, the strength of the exposure would be diluted.  
Finally, if patients who were excluded from this analysis due to missing CHIPS data were not 
missing at random, then this would introduce selection bias.  This bias could potentially limit 
the generalisability of the model, with the findings only being applicable to young people 
with CHIPS data, and not more broadly generalisable.  
5.5.4. Concluding remarks 
In this analysis, I was able to investigate the association between a broad range of exposure 
variables and EIC in young people living with PHIV. Rigorous variable investigation and four 
stages of modelling were performed to reduce collinearity and strengthen the stability of the 
final model. This is the first analysis that I am aware of that examines predictors of EIC in 
young people living with PHIV in the UK, and the first multi-clinic analysis in Europe.  Four 
main predictors of EIC were identified, all of which can be considered by clinics to identify 
young people most at need of support in attending clinic appointments. 
5.5.5. Key points from this chapter 
• Rigorous variable investigation was performed across eight domains 
• Four stages of modelling were carried out to identify predictors of EIC 
• In the primary stage 4 final model, worse EIC was associated with Asian/mixed 
ethnicity, self-harm, not good/bad adherence and viral load >50c/mL 
• Sensitivity analyses findings were similar to the primary stage 4 final model but also 
suggest there may be effects of age, travel time to clinic, language spoken at home 
and type of clinic attended.  
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Chapter 6. Exploring young people’s perspectives on the 
predictors of engagement in care 
 Introduction  
It is crucial to include young people in health care research about issues that affect their care 
for a number of reasons. Firstly, to make sure any recommendations about health care 
provision are patient centred, participatory work is essential to understand how young 
people feel about their health care.(259) Any recommendations made about health care 
delivery runs the risk of being disconnected from young people’s realities if they are not 
involved in the research process.(89,259,260) Additionally, it is imperative for young people 
to be included in health care research to raise their profile within the health care setting and 
with decision makers.(260) Where meaningful youth participation occurs, it can be hugely 
beneficial for research, health care practice and policy and for young people 
themselves.(261) 
In order to understand young people’s experiences of, and engagement in, health care, I 
wanted to gain their perspectives on this research to help interpret and contextualise the 
quantitative findings. This would then help to better understand how to support optimum 
EIC for this group.(262) Importantly for this project, I hypothesised that EIC was related more 
to the psychosocial rather than clinical aspects of living with HIV. Therefore, experiential 
accounts of young people living with PHIV gathered via qualitative data collection methods 
were a pertinent component of understanding the psychosocial dimensions of EIC.  
In this chapter, I present findings from focus groups discussions with young people with PHIV. 
There were two main topics. The first topic was the use of clinical markers as a proxy for 
clinic visit attendance in the flowcharts. I explored with young people their reasons for clinic 
visits and regularity of tests and measurements to analyse the strengths and limitations of 
using proxy markers in the flowcharts. The second topic was the exposure variables found to 
be associated with EIC. I presented and discussed these with young people to elucidate if the 
predictors of EIC found in the quantitative analysis resonated with their experiences as 
patients. This helped me contextualise the overall findings and gain a deeper understanding 




• To take the results from the quantitative analyses, and explore them through focus 
group discussions with young people with PHIV 
• To assess whether the quantitative results of this study resonated with young 
peoples’ own experiences and to enhance our understanding of them. 
 Methods 
I chose focus groups discussions to explore the quantitative findings. The advantage of focus 
group discussions over other qualitative methods such as interviews is the social interaction 
and communication between the participants (263) which helps interrogate the quantitative 
data. I specifically chose focus groups as they retained the potential to help increase the 
group interaction around the otherwise possibly abstract topics of EIC. For example, where 
people in the group have different experiences or views, the subsequent debate can lead to 
a much more detailed and reflective discussion in a way that may not occur in individual 
interviews. This is especially useful when exploring sensitive issues, such as barriers to care 
or non-attendance. Although social interaction may inhibit some discussions, hearing other 
people voice their concerns and experiences can also help participants to discuss their stories 
more freely, moving beyond socially acceptable answers.(264)  
The benefits of the focus group may be all the more pertinent when working with young 
people.  In a study into communication among children with HIV in Uganda, Kajubi et al (265) 
found that the hierarchical nature of adult-child and doctor-adult-child relationships resulted 
in children being much less vocal in interviews where adults were present. In contrast, 
children communicated freely and were very interactive when they attended group activities 
with other children and young people living with HIV.  
6.3.1. Participants  
All young people living with PHIV were eligible to be involved in the focus groups as long as 
they were aged 16-26 years and were aware of their HIV status. Being an AALPHI participant 
was not an eligibility criterion.  However, the age range of 16-26 was chosen to be able to 
include young people who may have taken part in AALPHI (the age range for AALPHI was 13-
21 years but the focus groups were carried out five years after the baseline AALPHI 
interviews). Recruitment of focus group participants was facilitated by voluntary sector staff 
at two different voluntary organisations working with young people living with PHIV.  
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Voluntary sector staff were requested to purposively select participants to include different 
sexes and ages and to try and include people who had a variety of experiences in attending 
clinic (e.g. consistent attenders, irregular attenders, lost to follow-up) based on their 
knowledge (if any) of young people’s attendance in clinic. 
Of the participants who were approached by voluntary sector staff, two young people who 
initially agreed to take part did not participate. One young person who was supposed to 
attend focus group discussion 1 (FGD1) was ill on the day and a second young person who 
was supposed to attend the voluntary sector support group was unable to attend on the 
night. These people are therefore not included in Table 6.1. All young people were given £20 
vouchers for taking part.  
Table 6.1 shows the demographic characteristics of the participants. In total, three focus 
groups were carried out with 16 participants taking part overall. I had intended to carry out 
a fourth focus group but this was prevented by the national COVID-19 related lockdown in 
March 2020. Focus Group Discussion 1 (FGD1) had six participants, of whom half were 
female. The median age of the group was 20 years (min 18, max 21 years); there were four 
participants of black ethnic background and two of white ethnic background. The 
participants lived across the UK and Ireland. In FGD2, there were five male participants. This 
was the oldest group with a median age of 23 years (min 18, max 21 years). All the 
participants were of black ethnicity and lived in a city in the UK. In FGD3, there were also five 
participants, three of whom were female. This was the youngest group with a median age of 
16 years (min 16, max 19 years). Four participants were of black ethnicity and one was of 
mixed back and white ethnicity and, as with FGD1, the participants were from across the UK 
and Ireland. Overall, the median age of the participants was 20 years (min 16, max 25 years). 




FGD1 (n=6) FGD2 (n=5) FGD3 (n=5) 
Male sex  3 5 3 11 





















Geographic region of 
participants 
Across UK Same UK city 






FGD1 included a group of participants who had previously supported other young people 
living with PHIV, and were peer support workers or team leaders at events run by voluntary 
sectors organisations. Through their volunteering activities, they had spent a considerable 
amount of time as a group and were quite familiar with each other. FGD2 comprised of young 
men who usually attended the same support group. The voluntary sector staff informed me 
that the participants in this second group all knew each other but the voluntary sector worker 
did not specifically identify them as friends. FGD3 included new members of a group being 
brought together to work on an HIV project. When the focus group was carried out, it was 
only the second time they had met as a group.  
6.3.2. Confidentiality and anonymity  
At the start of each session, I informed all participants taking part in the focus group 
discussions that it is not possible to control what information other participants in the focus 
groups might share outside of a focus group because of the group nature of the discussion. I 
did ask the young people to treat each other respectfully and to respect each others privacy, 
but advised participants both verbally and in the consent forms not to disclose anything they 
would not want to be shared outside the group. The Patient Information Sheet (Appendix G) 
included a section that explained the processes used to protect anonymity and 
confidentiality. 
I reassured participants that information discussed in the groups would not be fed back to 
the their HIV clinics. I informed participants that the only reason information would be 
passed on to clinic or voluntary sector staff would be at the request of the participant, or if 
a participant under 18 years reported something that made me worried about the 
participant safety or the safety of someone else under 18 years of age.  
An unexected problem arose in the third FGD. I had been pre-warned that two interpreters 
would be present during the focus group to interpret for a participant with profound hearing 
loss. However, during my introduction to the discussion, an additional voluntary sector 
worker who organised the groups, came in the room and sat down. Unfortunately, I could 
not find an appropriate time to ask this person to leave because I was already facilitating the 
group and therefore they remained in the room for the entirety of the discussion. 
6.3.3. Study setting  
I conducted all three focus group discussions in England between July and November 2019. 
I carried out the focus groups at locations where a dedicated event or group activity was 
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taking place specifically for young people with HIV. I arranged FGD1 and FGD3 with the 
voluntary sector staff so that they piggybacked existing residential events where participants 
from across the UK were staying for several nights. FGD2 was held at a voluntary sector 
organisation on the evening that their routine support group was held.  
The settings of the focus groups provided several benefits. Firstly, by carrying out the groups 
within organised HIV-related events and voluntary organisations, it was assured that 
participants’ HIV status was already known to the other participants. Secondly, pre-existing 
groups are a useful forum to explore ‘naturally occurring’ topics within the social 
context.(266)  Furthermore, safeguards were available because voluntary sector staff were 
well placed to provide support if any inadvertent distress was caused by the topics discussed. 
Finally, in all three instances, participants did not have to go out of their way to attend the 
session and were familiar with their surroundings by the time the focus group was carried 
out.  
6.3.4. Focus group discussion facilitation and data collected 
I facilitated all three focus groups, with the aid of a session plan I developed for use in the 
focus group discussions (abbreviated version shown in Appendix H). It included an overview 
of the aims of each section, resources required, content to include as well as possible 
prompts and timings. I paid attention to the order of topics to be discussed in the focus group 
to encourage people to feel relaxed in the groups, beginning with less sensitive issues. I also 
used flip charts with simple tables and spider grams to facilitate reflection and further 
exploration of specific messages. During each section, I wrote the main points raised by the 
participants on a flip chart, and read these back to the group to make sure the participants 
had accurately understood main points.  
I developed and used a PowerPoint presentation to explain the quantitative analysis. Slides 
were largely pictorial to help explain examples in an understandable, lay way. After a brief 
introduction about EIC, I carried out a warm-up game in FGD2 and FGD3 to help people feel 
comfortable in the group. In FGD1, the participants had already spent all week working 
together as a group so I did not think this warm-up activity was necessary.  
After the warm up, I gave a very brief overview of what is known about EIC in young people 
with PHIV. Then I carried out an exercise to familiarise young people with the idea of factors 
that affect EIC. I gave young people five minutes to quickly review a list of the variables 
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included in the quantitative analysis and then asked them to identify five factors from their 
experience that they thought were associated with EIC.  
Next, I gave a brief explanation of the flowcharts (using PowerPoint) to the young people to 
provide them with enough information to start the reflection and discussion about the 
quantitative analysis. To help me understand how much the participants knew about what 
factors their clinic doctors use to determine the time to their next clinic appointment, I 
facilitated an initial discussion in each focus group about what reasons clinic staff give to 
explain when their next appointment should be. I presented a list of the clinical 
measurements that I used as proxy markers for clinic visits in the flowcharts. I then explored 
these with participants to see whether these measurements were collected at every 
appointment and if there were reasons that they attended clinic appointments that might 
not be captured by the proxy markers used.   
Finally, I presented predictors of EIC from the quantitative analysis to gather participants’ 
views about whether the findings concurred with their own perceptions of factors that affect 
attendance in clinic. I introduced and defined each variable found to be associated with EIC 
in the quantitative analysis (ethnicity, adherence, viral load and self-harm), though the 
discussion did not focus on ethnicity. Only one young person from the three focus groups 
was of mixed ethnicity and none of Asian ethnicity, and it did not feel appropriate to discuss 
this finding. I presented adherence and viral loads as separate entities but together due to 
the direct biological relationship between taking medication and viral load results. I 
presented adherence and viral load first so that participants could become familiar with the 
format of the focus group before I addressed the more sensitive topic of self-harm.  
6.3.5. Audio recording and transcription 
Focus groups lasted one to two hours and were audio recorded on two devices. I wrote field 
notes at the end of each focus group, with reflections on the interactions of the group and 
the topics discussed (267). I uploaded recordings to a computer the same day that I 
conducted the focus group and the recordings were then deleted from the recording devices.  
I transcribed the focus groups verbatim to gain as much familiarity with the data as possible 
after the focus group, also to allow iterative data analysis from the start and so that I could 
explore emerging ideas and questions in subsequent focus group discussions. To protect the 
anonymity of participants, I removed personal identifiers from transcripts and gave all 
participants a study number (1-16) which I then used in combination with their focus group 
244 
 
number for all subsequent writing and documentation. I removed all locations, clinics and 
voluntary sector group names. 
6.3.6. Analysis 
I used both inductive and deductive approaches to thematically synthesise the data (263). 
Inductive analysis emerges from the data and deductive analysis starts from an a priori set 
of concepts or frameworks that is applied to the data.(268) I used inductive analysis in the 
process of coding the original data and in creating the themes. However, I did have some 
awareness of the literature before I coded the data and so I recognised some familiar 
patterns emerging from the coded data based on prior knowledge. I performed line to line 
coding to try and stay close to the data in bottom up rather than top down analysis. All 
analysis was carried out using NVIVO 12 software.(269) 
I conducted two phases of coding.  First, I coded data from the individual focus groups using 
discrete codes and organised the codes under similar descriptive themes (for example 
‘dislike of medicine’, ‘invisibility of HIV’ and ‘unquestioning attendance’).(270,271) Then I 
reviewed, refined and compared all the codes within each focus groups and then across focus 
groups.(271) Next I explored relationships between codes and grouped individual codes to 
make more meaningful themes. I continually reviewed non-coded data to see if they 
challenged or fitted into existing themes or to see if new themes were emerging.   
I wrote analytical memos throughout the analysis process to highlight key content and 
concepts and emerging ideas, which I shared with my supervisors for input and discussion 
alongside anonymised and coded focus group transcripts. Analysis continued throughout the 
process of writing up the findings as questions about the data and relationships gained more 
clarity when being explained in the text.  
 Ethical considerations 
6.4.1. Consent 
Voluntary sector staff who were familiar with the participants made decisions about who 
could be contacted to protect participants who may have been too psychologically 
vulnerable to take part. I obtained written consent from all participants at the beginning of 
each focus group. I read though the consent form (Appendix I) with the group and then gave 
them as much time as they needed to read through again and ask questions. The consent 
taking process took around 10-15 minutes in each group. I informed all participants that they 
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were free to withdraw their consent to participate in the focus group discussions at any time 
and for any reason, without it affecting their clinical treatment or involvement in the 
voluntary organisations. I encouraged participants that if they found any of the subjects in 
the focus group upsetting, they should approach staff or me from the voluntary organisation 
after the group. I informed all participants at the start of the session that the focus group 
would be audio recorded. 
6.4.2. Anonymisation of data 
Consent forms were scanned and stored in the UCL Data Safe Haven. Paper consent forms 
were shredded and emails of the scanned consent forms were  deleted from the email inbox 
and deleted folder. Participant names, demographic details and a participant number were 
also stored in the Data Safe Haven separately from all study data. Only participant numbers 
were used in the transcripts of the focus group discussions. Anonymised transcripts were 
stored in a secure location on the LSHTM server. 
 Findings 
There are three sets of findings from the focus group study. I present, firstly, a summary of 
participants’ responses to the questions posed about the flowcharts and EIC predictors 
(adherence, viral load and self-harm). Secondly, I discuss the two main themes that emerged 
inductively from the young peoples’ discussion about EIC: self-management and shared 
decision making, and responsibility and blame.  
6.5.1. Participants feedback and response on the proxy markers and predictors of 
EIC 
On viewing the model in the presentation at the start of the focus group, participants first 
commented on the proxy markers and discussed whether these clinical factors accurately 
reflected all of the reasons they attended clinic or whether there were factors that had not 
been accounted for.  
I then presented and discussed the three factors that showed evidence of an association with 
EIC in the quantitative analysis (adherence self-assessment, viral load and self-harm).  
246 
 
6.5.1.1. Feedback on the proxy markers 
All participants in the three focus groups agreed that the markers being used (viral load, CD4 
count, weight, height, ART changes) were appropriate proxies for a clinic visit because at 
least one of these clinical measurements was taken at most appointments.  
However, the participants also raised several additional reasons for attending clinic that were 
not included in the list of proxy markers. Participants in all three focus groups had been asked 
to attend clinic for mental health or psychological reasons, as one young man explained here:  
‘I remember I had a rough patch and they were like ‘we want to keep an eye on you 
for a while’. Which was also linked to viral load and just keeping, making sure it didn’t 
go too high and my CD4 didn’t drop. But a lot of it was mental health and to maintain 
stability.’ (male, 18 years old, FGD1-participant 6 (P6)) 
Participants also mentioned factors other than those included as proxies for clinic visits, such 
as wanting to obtain advice on issues such as disclosure of HIV status, help with medical and 
school forms, and sexual health check-ups.  
6.5.1.2. Adherence and viral load 
Participants confirmed the face validity of the finding that young people with better 
adherence and a supressed viral load are more likely to come to attend clinic: ‘Because if 
they are undetected it means they are OK with what they are doing. If they have an 
appointment, they will go for it. They know how to take their medicines and they do it,’ 
explained one participant (male, 21 years old, FGD2-P7). 
Participants often reported that the combination of having an undetectable viral load, taking 
ART and attending clinic meant that the young person was in a ‘good place’ in terms of their 
HIV acceptance and management.  
Conversely, several participants admitted that if they thought their viral load might be 
detectable due to recent problems taking their medication, they would avoid clinic. ‘My viral 
load was awful so I just didn’t go clinic’, explained one young man (male, 20 years old, FGD1-
P4), while another participant imagined other young people would do the same: 
‘And I was supposed to go to clinic but I didn’t because I didn’t need medication and 
like I didn’t want to go… because I was thinking my viral load is bad, and what if my 
body is all messed up. Because I felt fine, but...’ (female, 20 years old, FGD1-P3)  
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Another male participant went as far as asking: ‘what’s the point of coming to hospital if you 
are not drinking medicines?’ (male, 18 years old, FGD1-P6). This suggests that young people’s 
concerns about how their adherence might show up in their viral load shape their decisions 
to engage in care. For example, one young man used an analogy to explain why young people 
might not attend clinic if they had forgotten to take their medication: 
‘It’s a bit like you know when you spent a lot of money and then you don’t want to 
look at your bank account. It’s a bit like that. So you know you haven’t done 
something that you wanted to so you kind of don’t want to find out the results or 
check your account basically.’ (male, 25 years old, FGD2- P9) 
By contrast, three of the 16 focus group participants were surprised at the finding that better 
adherence and having a supressed viral load was associated with better EIC, since, for 
example, a low viral load might signal better health and less reason to attend clinic.  
6.5.1.3. Self-harm 
The third finding from the quantitative analysis was that young people who self-harm are 
less likely to be EIC. I presented to focus group participants a definition of self-harm as 
‘hurting yourself on purpose in any way for example by taking an overdose of pills or by 
cutting yourself’. Focus group participants seemed to understand self-harm as an indication 
of deeper psychological or psychosocial suffering that may prevent people from being able 
to seek or engage in care. One male participant explained: 
‘..a lot of people that do it like they try to keep it a secret and they don’t want anyone 
to find out. So, yeah, I think one reason is that they may not go to clinic is because 
they might get found out and have to talk about it.’ (male, 25 years old, FGD2- P9) 
Participants also voiced concerns about the consequences of clinic staff finding out that they 
self-harmed and a subsequent lack of control over both their personal information and the 
situation in general. One participant expressed concern about their parents being involved: 
‘You don’t want them to know because they might tell your parents who might not know,’ 
explained one young woman (female, 16 years old, FGD3- P16). Another young woman 
talked about an influx of additional support from other services and clinic staff:  
‘Also the fear of consequence. Like if I self-harm or do this, what is going to happen? 
Because like personally, and I don’t know if other people feel the same, they haven’t 
said anything because they are like what if I get taken away or put in the hospital and 
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I don’t want to be put in the hospital, I don’t have time to be put in the hospital.’ 
(male, 20 years old, FGD1- P4) 
Possible fear about being forcibly detained in hospital if they disclosed their self-harm was 
relayed by one participant: 
‘I feel like maybe if they do go to the doctor, like what he says, when you like take drugs, and 
they take you to like rehab. They might take them somewhere and you might not want them 
to do that.’ (male, 18 years old, FGD3- P13) 
For one female participant who disclosed a history of self-harm in the focus group, this fear 
of the clinic staff members’ reaction meant she continued to attend clinic so as not to arouse 
concern, but hid her self-harm: 
‘For me I still went to the doctor, to my appointments, I knew what I was doing was wrong 
but I still wanted to maintain the appointments maintaining like everything was OK. I feel like 
if I told them, they would want to help, and they will help in the wrong way. So I just go to 
maintain it.’ (female, 21 years old, FGD1-P2) 
Participants postulated a further relationship between the quantitative results, suggesting 
that non-attendance and non-adherence could be forms of self-harm in themselves. One 
young male participant seemed to suggest a period of time when he stopped his medicines 
was actually suicidal ideation because he knew it would eventually make him ill. Another 
participant explained:  
‘For some people, they think if the meds are keeping them alive then if they stop 
taking them they won’t stay alive.’ (male, 25 years old, FGD2-P9) 
‘So they feel they want to die?’ (facilitator) 
‘Yeah, they are suicidal and that could be a type of self-harm.’ (male, 25 years old, 
FGD2-P9)  
This, however, was not a universally held view. For example, one young woman who talked 
a lot about her problems attending clinic and taking ART, did not identify with these issues 
as a form of self-harm. 
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6.5.2. Self-management and shared decision making 
The previous findings were based specifically on participant responses to questions and 
prompts about the EIC flowcharts and quantitative findings. The next two themes were 
based on participant’s experiences and emerged inductively from the discussions. The first 
theme to emerge from the analysis based on young people’s discussions in the focus group 
was about self-management and shared decision making. The theme had three components: 
influence of age on EIC, communication and involvement in decision making and control and 
choice in attending clinic appointments.  
6.5.2.1. Influence of age on engagement in care 
During the focus groups, participants initiated a discussion about age as a factor in EIC and, 
specifically, how personal responsibility to engage in care and attend clinic increased with 
age. Participants had conflicting views however, on whether this increased responsibility 
made attending appointments harder or easier. One participant explained that ‘once you 
reached puberty, and you are living your life, then you would maybe go to clinic more’ 
(female, 20 years old, FGD1-P3), while another highlighted the challenges of motivation 
associated with young adulthood: ‘Because when you are a kid, your parents or guardian 
take you. So you just go. But when you are like 18 it is on you to go and that is a lot of effort 
to drag yourself out of bed’ (male, 20 years old, FGD1-P4). 
Participants also had contrasting experiences of support provided by their parents/carers to 
attend clinic as younger children, which may have subsequently shaped their later EIC: 
‘I say for me when I was younger I probably messed up a lot more than when I got 
older. Because when I was older, I was a lot more independent and more in charge of 
my medication and my appointments. Whereas before, it was kind of like through my 
mum. And my mum, my mum is a busy woman (laughter).’ (male, 23 years old, FGD2-
P10) 
So my experiences was the opposite. When I was young, my grandparents helped me. 
So I was taking medicines twice a day and I was always taking it on time every day 
because they always reminded me. Then as I got older, because it was my 
responsibility I kept forgetting it a lot. (male, 21 years old, FGD2-P7) 
A participant also highlighted the conflict young people face between attendance in clinic 
and attendance at school and how this becomes more challenging with age:  
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When you are like 16+ you have actually got to attend school. Before that, you can 
just go out of school for a day and it’s not a problem. But when you have got A‘levels 
and GCSEs it’s not like you can take a day off and its fine, because you can’t. (male, 
20 years old, FGD1-P4) 
6.5.2.2. Communication and involvement in decision making  
During the discussions about the information participants were given by clinical staff 
regarding the rationale for the time interval to their next appointment, a broader 
conversation emerged about the benefits of being involved in decision making about follow-
up appointments, as well as the consequences of not being involved. 
A number of the participants reported that the staff at the clinic actively updated them on 
their results and or health status and made clear links between their health status and the 
amount of time to their next appointment. As one young man relayed, ‘they show me a graph 
and say that is where your CD4 count is and your viral load and that’s when we need to see 
you’ (male, 25 years old, FGD2-P9). The participants seem to see the clear link between 
health status and timing of subsequent appointments. One participant explained:  
‘Aahh yeah. It just depends, it really depends on what you are doing next. For 
example, so if I am changing my meds they say they want you to come back, you 
know, to see like if you have any side effects. And one time when I was very ill, very 
ill, they said I needed to come back to see if you are doing well and sometimes they 
just want to check your blood test and check everything is going well.’ (male, 18 years 
old, FGD1-P6) 
In FGD2, which was the oldest group, all of the participants described being well informed 
by clinic staff about their health status. Furthermore, they were also involved in the decision 
of when their next appointment should be so that clinic appointments could fit into 
participants’ lives:  
‘Like every 4 to 6 months. They usually give me a choice of when I am seen. So like 
when I usually go they say do you want to be seen this month or next month? And 
then basically depending on what I have got planned.’ (male, 25 years old, FGD2-P9)‘I 
feel like for me, if I am undetectable (viral load <50 c/mL), it’s just like usually just say 
come in whenever my meds start finishing, but because I have been at University for 
3 or 4 years, you just try to fit in when I am back from holidays basically. And it’s just 
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worked out fine. Then if I do need to come in earlier, they will text me and say based 
on your blood results can you come back in.’ (male, 23 years old, FGD2-P10) 
One young person also talked about being offered the choice of being seen earlier, even if 
his health did not require it, which may be an intimation of the wider supportive role clinics 
can provide in addition to clinical monitoring.  
In contrast, some of the participants came away from their clinic appointment feeling unclear 
about the state their health status. One young person described times in their past when  
they used the length of time to their next appointment as an indicator to try and deduce 
their health status: 
‘When it is less time your brain kind of works it out naturally, oh OK I guess I need to 
do this sooner. But when it is more time in-between, it is like 6 months, it’s like oh OK, 
why so long?’ (male, 20 years old, FGD1-P4).  
This young person described how this lack of information led to anxiety about their health 
status: 
‘I had a weird period of time when I was there every month. So I just got into the 
routine but I was like I don’t know why I am showing up every month. And they 
jumped to four months and I was like OK I guess it was every four months now. And 
then recently, I went to a new clinic and they said come back in a month and I had 
this deep fear something was wrong again but they were like no we just need to see 
if you are on the system properly and I was like that’s the first time I was given a 
reason’. (male, 20 years old, FGD1-P4) 
6.5.2.3. Choice and control in attending clinic appointments 
Participants presented differing positions as to the amount of control they had concerning 
their health and attendance in clinic. Some participants appeared able to exercise some 
sense of control and choice in their health care whereas with some other participants there 
seemed to be less chance to be involved in decision making.  
A number of participants expressed a desire to attend clinic to stay informed about their 
health status, such as this participant: ‘Because there is a reason why I missed them (ART 
medication) and I would go there and see if everything is alright. Say I missed a week (of ART), 
I wanna go there and go and see if I am OK in my bloods.’ (male, 18 years old, FGD3-P13).  
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Another participant voiced how attending clinic helped him re-gain control after a period of 
not taking medicines: 
‘To be able to be like I have grabbed my life and I have taken control and I know that 
a few other people feel the same way with their viral load. Because if they can get it 
to undetectable then they know what they are doing OK.’  (male, 20 years old, FGD1-
P4) 
In stark contrast, one participant explicitly says that attending clinic was not a choice. They 
attend because it was a better option than being chased by clinic staff. A third group of young 
people expressed their attendance in clinic with resignation – something they have always 
done and know that they need to carry on doing. It was hard to ascertain in the focus group 
if these participants, by attending clinic, were passively behaving as expected, or if they had 
more simply accepted the role clinic played in their lives:   
‘I have never had a time when I have been stressed and don’t take my meds. I go to 
clinic because I just go to hospital. I have never had times where stuff is going on and 
I don’t want to go to clinic…So I am going to clinic, I move to adult clinic, and I just go 
there and I never miss my meds. So yeah.’ (male, 18 years old, FGD1-P1) 
‘Me like I feel like what he say. It’s the same thing. I just go to my clinic like every 
appointment and they pay for my travel and everything is just sorted. So I like just go 
and they are just like nice people.’ (male, 18 years old, FGD1-P6) 
6.5.3. Responsibility and blame 
The second theme that emerged from the data was that of responsibility and blame. There 
were a number of ways young people expressed feeling the burden of responsibility for their 
HIV:  judgement, pressure and threats from others, responsibility for others, and 
internalisation of responsibility.  
6.5.3.1. Judgement, pressure and threats from others 
Being ‘told off’ and feeling judged by health care staff was a common theme in focus group 
discussions. Participants explained that fear of scolding was a possible reason for avoiding 
clinic if they had missed doses of their medication. Participants did not anticipate 
understanding from clinic staff about their adherence problems, as one participant 
explained: ‘Because by the time you go to the hospital, they are just going to say the same 
thing like ‘Take your meds’ so why should I go if they are just going to say the same thing.’  
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(male, 18 years old, FGD1-P6). Participants expressed that there was a: ‘pressure to take your 
medication’ (female, 21 years old, FGD1-P2) and said: ‘You don’t want to be judged if you are 
doing that (missing medication)’ (female, 20 years old, FGD1-P3).  
Participants also said clinical staff tried to encourage them to take their medication by 
highlighting the risks associated with missing medication: 
‘The nurses are like, ‘If you don’t take your medication you’re are going to die the 
next time’. And you’re like, OK! I just love it when people tell me I am going to die 
soon. It really makes me feel like I want to return!’ (female, 21 years old, FGD1-P2) 
One young woman expressed a concern that there could be repercussions from missing clinic 
appointments: ‘let’s say you haven’t been to the hospital for some time, and you decide to 
go, you feel they may kind of discriminate you, there may be disadvantages and 
consequences’ (female, 16 years old, FGD3-P16). Young people seemed to perceive the 
reactions they had from clinic staff in regards to their problems taking medication as an 
attempt at discipline them into ‘behaving’.   
When asked what might make someone not come to clinic if they had been having problems 
taking their medicines, participants in in one group instantly reeled off a list of people they 
felt they  were under pressure from: the doctor, themselves and their parents. They 
expressed concerns about wasting the doctor’s time and disappointing everyone. This was 
the conversation in the focus groups to mention pressure from families in relation to 
managing HIV as well as from health care professionals.  
There seemed to be a consensus from much of the group that this approach meant clinic 
staff did not properly address the problems they were dealing with. However, one young 
man defended clinic staff arguing that HIV was linked to everything:  
‘But at the same time, I understand their point, the doctor’s point about giving 
everything to HIV. Because HIV is like you, that’s you, so everything that happens to 
you is somehow it can link to HIV. So for example, how can I say this? Getting stressed 
it links to your HIV like taking your meds, going to hospital, it all links to HIV.’ (male, 
18 years old, FGD1-P6) 
There seems to be a tension between on the one hand, the messages young people receive 
about taking individual responsibility and the message that they almost have no personal 
accountability because everything problematic is caused by HIV.  
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6.5.3.2. Responsibility towards others 
As well as fear of being disciplined for not taking their medication, participants also 
expressed a feeling that their actions had a negative effect on clinic staff and the unease 
made them not want to attend clinic. Young people regularly attend the same paediatric 
clinic for many years and had developed very close relationships with doctors and nurses in 
the clinics. They talked about not wanting to ‘disappoint your doctor’ (male, 19 years old, 
FGD3-P15), and ‘worry about wasting the doctor’s time’ (male, 16 years old, FGD3-P12). 
Another participant talked about the worry of upsetting clinic staff after a period of not 
taking medication having historically managed taken medication well:  
For me, I just don’t want to let people down who have watched me grow up. They are 
always like ‘we are so proud of you we are so proud of you and we see you grow’… 
Then all of a sudden you are not taking your meds and not doing well and it’s like you 
don’t want to burden them with your problems. (male, 20 years old, FGD1-P4) 
By being praised and labelled as a ‘good adherer’ this young person then felt pressure to 
always be a ‘good adherer’.  
Participants also recounted interactions with clinic staff in which they were told how much 
their drugs cost, which they experienced as a form of reprimand and made them feel 
responsible for the cost of their treatment. After experiencing side effects on a new ART 
combination, a young person described the clinic staff reaction prompting both agreement 
and outrage in the focus group:  
‘And eventually I went back and said can I have my old ones and she said they are 
expensive and I was like ‘I don’t care, I want my old ones’ and she was like OK!’ (male, 
20 years old, FGD1-P4) 
‘Wow.’ ‘They shouldn’t talk to you about money’. (female, 20 years old, FGD1-P5) 
‘But they do.’ (General, FGD1)  
‘But they shouldn’t because that is like a guilt thing’. (female, 20 years old, FGD1-P5) 
‘But they do.’ (female, 21 years old, FGD1-P2) 
‘Some adult clinics put the prices on the bottle so you feel grateful for having them.’ 
(male, 20 years old, FGD1-P4) 
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‘Mmmmhmm.’ (female, 20 years old, FGD1-P3) 
‘They don’t do it for cancer medications because it’s not the persons fault if they have 
cancer but it is the persons fault if they have HIV’. (male, 20 years old, FGD1-P4) 
The stigma associated to HIV adds to the existing pressure these young people have to 
adhere to their treatment and puts pressure on their relationship with clinic staff.  
6.5.3.3. Internalisation of responsibility  
It was apparent that a few of the participants saw any problems they had taking their 
medicines (and attend clinic in one case) as entirely their own fault. One young woman 
openly discussed her current problems with attending clinic as well as taking ART. She 
understood the health risks of not taking medicines, and unlike some of the other 
participants in the group, she did not feel judged by the clinic staff in the paediatric or adult 
clinics for having problems attending clinic or taking medication. In fact, she was shocked by 
some of the reports from other participants where they were scolded for non-adherence or 
told the cost of the ART by clinic staff. Although this young woman later discussed her dislike 
of what she describes as the formal nature of adult services, she never attributed any blame 
to anyone but herself:    
‘I think for me it’s a personal thing I think. So it’s like, I know I need to and I tell myself 
I need to, I just don’t. For me, I think that is something for me I am just trying to figure 
out why I don’t even though I know I need to.’ (female, 20 years old, FGD1-P5) 
Likewise, another young woman talks about the shame one might feel if they became 
immunocompromised after not taking ART: 
‘Let’s say your CD4 is really low they are going to have to keep you in the clinic for 
some time and you might feel ashamed with yourself – oh why did I miss it?’ (female, 
16 years old, FGD3-P16) 
Another young man had a long history of problems taking his medicine. He explicitly 
expressed a feeling of unconditional support from his clinic. He had no problems engaging in 
care and attended very regular appointments mainly for social and psychological support. 




‘It’s not hard! It’s not hard! No I mean, it’s the person who’s using it. Some people 
make it harder than it seems. Because there are people who are using it who have 
more than me and I am very aware of it. And that there are younger kids who are 
using it better than I can.’ Male, 18 years old, (FGD2-P11) 
These young people were very critical of themselves and did not seem to be aware that the 
difficulties they were having were widely shared among other young people with HIV.  
 Discussion 
6.6.1. Summary of findings 
In this chapter, I detailed the methods I adopted to conduct three focus groups discussions 
with 16 young people living with PHIV, aged 16-25 years old. I presented findings from the 
analysis in three parts: firstly, participants’ feedback about the use of proxy markers for clinic 
appointments, and predictors from the quantitative analysis: viral load, adherence and self-
harm. This was followed by the findings from the two themes that emerged from the data, 
namely, self-management and shared decision making and responsibility and blame.  
6.6.2. Comparison to the literature 
6.6.2.1. Reflections on the use of proxy markers and the predictors of engagement in 
care  
Participants in all of the three focus groups agreed that proxy markers were routinely 
collected at most of their clinic visits. However, participants also reported additional reasons 
for attending clinic that would be missed using this approach. For example, participants 
across all three focus groups reported attending clinic for psychological support. Mental 
health challenges are well documented in young people living with PHIV in both low- and 
high-income countries. Studies suggest that young people living with PHIV face a higher 
burden of a range of metal health problems such as anxiety and depression, (272,273) post-
traumatic stress disorder,(273) suicidality,(273) and lower self-esteem, (114). Consequently, 
mental health support is often an integrated, central part of HIV health care. When 
developing the adult algorithm on which the flowcharts in this study are based, Howarth et 
al (151) acknowledged as one of the main limitations of their study, the inability to measure 
appointment made for psychosocial wellbeing. An interesting point not captured in other EIC 
studies, is the breadth of other reasons for attending clinic that participants mentioned. 
Participants reported attending for disclosure support, help with medical and disability forms 
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as well as school forms and routine sexual health check-ups (in concurrently running sexual 
health clinics). The range of reasons participants attended clinics appointments outside of 
their clinical management calls attention to the wider support role that HIV clinic staff 
provide for many young people and their families.  
One of the reasons I sought participant’s feedback was to see if the quantitative results 
resonated with young people’s experiences. Most of the participants felt it made sense that 
young people might engage less in care if their viral load was >50 c/ml or their adherence 
self-assessment was not so good/bad, as indicated by the model discussed in chapter 5. 
Interestingly, three different explanations emerged from the discussion. Firstly, in contrast 
to the quantitative results, two young people described having a long history of problems 
taking ART, but reported that this never affected their attendance in clinic. Secondly, 
participants described that attendance in clinic was more likely if they were taking their 
medicines and managing with their HIV. They felt this meant that that young people were 
generally more in control and had taken responsibility to adhere to their medicines as well 
as attend clinic. Finally, participants described using biomarkers as a reference point to 
decide for themselves whether to attend clinic or not. If young people had a period of non-
adherence, they would actively avoid clinic because their perception was that their viral load 
would be high so they did not want to have their blood test taken. Both of these last two 
accounts are in alignment with the quantitative findings, and with other literature,(256) 
although they suggest that the relationship between viral load and EIC is not uni-directional, 
but rather dynamic and changing over time.  
The active decision-making about whether to attend clinic or not was also reported in a study 
by Taylor et al (274) of adults with HIV (n=40) in the USA. They found that irrespective of 
whether participants were attending their appointments, they conveyed high self-efficacy 
and felt in control. In the context of young people who have grown up with HIV, this 
management of appointments, actively deciding whether or not to attend, may well be an 
extension of the strategy that children adopt in relation to adherence. Kawuma et al, (257) 
interviewed 11-13 year olds (n=26) to explore their perceptions and experiences of children 
taking treatment. In their findings they noted that non-adherence was not a passive activity 
as many adults presumed but was actually a deliberate and strategic choice.(257) 
Two main points came out of discussions  in my study about why young people who self-
harm may not attend clinic. Firstly, participants felt that feelings of shame may drive this 
disengagement because young people want to avoid clinic to keep the self-harm a secret. 
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The other factor from discussions in all three focus groups was the fear of what would 
happen if clinic staff found out. These fears ranged from worry about more intense, 
unwanted clinic staff attention to being forcibly institutionalised. Both of these points about 
self-harm are in accordance with the quantitative finding, although the concerns young 
people expressed about the consequences of the discovery of self-harm broaden the 
understanding of the issues. In contrast to the quantitative findings, the one young woman 
who disclosed she had self-harmed in the past however, reported she attended all her 
appointments so as not to arouse suspicion in the health care professionals.  
6.6.2.2. Self-management and shared decision making 
Young people relayed different experiences of the increasing responsibility and self- 
management of their HIV care that came with age and how this affected their EIC. Some 
participants described finding the increased responsibility difficult and reported either not 
feeling like they wanted to attend their appointments or forgetting to attend. A second group 
of young people described that their EIC and adherence improved as they took responsibility 
and were living a more independent life.  
Studies have found young people can feel worried about the shift in responsibility for their 
health care from their parents/carers to themselves.(275) The importance of continued 
support for young people even as they increasing take on more responsibility for their own 
care has been found to be associated with better self-management.(172) Again, the 
participants’ experiences were not universal, but, interestingly, the young man who 
described how his mother was not able to support him in managing his HIV when he was 
younger reported both his adherence and attendance in clinic improved once he was able to 
be responsible for this himself.   
Across the focus groups, there were mixed reports from the participants about their 
experiences of communication in clinic and how well informed they were about their state 
of health. What transpired from the discussions was that young people who reported feeling 
well informed, also reported greater involvement in decision making about the time to their 
next appointment. Of course, this focus on time to next appointment was specifically related 
to the questions I was posing about my flowcharts. However, from the responses it seems 
clear that participants’ answers are more than just about appointments. Young people were 
actually describing being given a choice of when an appointment would fit into their lives, 
which is arguably not only shared decision making but also a recognition, by the health care 
workers, of the need for young people to manage living with HIV within the broader 
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psychosocial context of their lives. The young people who described better communication 
and shared decision making were mainly from FGD2. The young people in this group were 
older and received their HIV care in large adolescent clinics both of which may have 
contributed to this improved communication. 
In contrast, some of the younger participants described feeling less clear about their health 
status and, particularly in FGD3, the youngest of the three groups, there was no discussion 
about any shared decision making. One young person described the possible consequences 
of being left with uncertainty about one’s health. He relayed times in the past when he 
became quite anxious in his attempts to try to interpret what the status of his health was 
based on whether his next appointment was sooner or further away. 
Shared decision making in health care has been shown to improve patient autonomy, health 
satisfaction, adherence and outcomes (172,276,277) but shared decision-making is 
complicated for young people who have grown up with chronic illness. These children have 
grown up with communication about their health occurring in a triad between themselves, 
their parents/carers and the clinician. Adult input often dominates the interaction in the 
consultation leaving the child in a relatively passive role.(275,276) As young people develop 
through adolescence, this relationship needs to be modified so that shared decision making 
is between the clinician and the young person which can be difficult for all parties involved. 
This process is also complicated by the dynamic nature of adolescent development that 
means this relationship is constantly shifting as the young person matures.(275,276)  
For young people growing up with PHIV, the move to shared decision making can be further 
compounded by the stigma of living with HIV, which for many young people manifests as 
silence about HIV across most aspects of their lives. (83,256,257,265) For some young 
people, clinic is one of the only spaces where they can talk about HIV.(256) Still, having grown 
up with this silence about HIV, can make the transition to having open shared decision 
making about their health care even more complicated for some young people.  
There were three distinct responses in respect to young people’s sense of control in 
attending their clinic appointments. The first group of young people saw attending clinic as 
a choice. If the attended clinic they could and find out their viral load and this gave them a 
sense of control over the management of their HIV. This sense of control was not always a 
constant state. One young person describes a transient period of disengagement and how 
he gained a sense of control when he made the decision to start attending clinic once more. 
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Conversely, a second group, describe having no choice at all in attending clinic, they just feel 
they have to attend and also want to avoid being chased and told off by clinic staff. The third 
group seemed very indifferent to their need to attend clinic appointments, they attended 
because that is just what they do.  
For some young people, it appears that attending clinic is a way to keep on top of the 
information about their own health as part of their self-management and engagement in 
their HIV care. However, for other young people, although they report attending their clinic 
appointments, their passive experience does not seem to equate with active engagement in 
care.  
6.6.3. Responsibility and blame 
There were a number of ways young people described being told off and disciplined, mainly 
at clinic but also at home and by the voluntary sector staff. In their findings from interviews 
with 26 young people (11-13 year old) in Uganda, Kawuma et al (257) found that, similarly 
to adults, children have to navigate complex social contexts to manage their HIV medication 
long-term, but that these problems were not taken seriously by clinic staff. In their accounts 
from  10-24 year olds (n=147) from across five low and high income countries, Bernays et al 
(104) found that health care providers emphasised the need to take ART rather than how 
they might support young people to take it. Instead of offering practical support, discussion 
around adherence was largely limited to being scolded after they had missed medication or 
just a reiteration that they needed ‘perfect’ adherence. (104) 
These findings are not unique to HIV research. Renedo et al (278) found comparable patterns 
of interactions between staff and young people in their research based on interviews with 
13-21 year olds with sickle cell disease. Little or no consideration was given to the social 
context of managing living with sickle cell, and participants were likewise reminded of 
previous episodes of illness as a motivation to adhere to their treatment.  
Niehaus (279) maintains that there is far too much emphasis in biomedicine on the concept 
of ‘treatment literacy’, and an assumption that there is a direct link between HIV and ART 
knowledge and education, and therapeutic adherence and efficacy. Treatment literacy as a 
construct can obscure the multiplicity of social and economic factors that affect adherence 
to ART. These factors can be both supportive of adherence, such as the role of one’s 
community, or create barriers, such as poverty and stigma. Either way, they are essential 
issues when thinking about adherence to treatment and achieving therapeutic success. (279)  
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Young people in my study did have a clear understanding that they should take their 
medication as directed; however, managing this in their day-to-day lives remained 
challenging. If the clinic staff do not acknowledge the multiplicity of factors related to 
adherence, clinic can become a place of discipline that young people might avoid when facing 
difficulties taking their medicines, or any other problems such as conflicting priorities 
attending clinic.  
Another reason young people may have for missing clinic appointments or disengaging in 
care is the responsibility they feel towards health care workers and worries they have about 
letting them down. Many young people have had long and close relationships with the 
doctors and nurses in their clinic and are grateful to them. Interestingly, praising young 
people for being a ‘good’ adherer became a burden for young people because it made it very 
difficult for them to open up about instances of non-adherence. Bernays et al (104) found 
that young people were worried that that any imperfection in their management of ART 
could negatively affect their relationship with clinic staff. ‘Scolding and praising are 
respectively linked to the ideas of young patients as being either ‘failures’ or ‘successes’, with 
very little space in the middle and no apparent accommodation of shifts and changes in young 
people’s capacity to take their treatment.’ (p 65) Similarly, findings from focus groups with 
adults (n=43) in the USA show that this concept of a ‘good’ patient was also relevant to EIC. 
(280) Patients saw the ‘engaged’ patient within a moral framework as a ‘good’ patient. While 
this framework was a positive influence for people hopeful of being a ‘good’ patient, it also 
had the opposite effect for patients who were felt they were failing at being a ‘good’ patient. 
(280) 
In addition, there were instances where participants in my focus groups were incredibly 
critical about themselves for their perceived failures in managing their HIV. Two participants 
in particular, who both had long-term problems taking their ART and/or attending clinic, 
were very defensive of their clinic staff and very much internalised the blame for these 
‘failures’ as their own responsibility, with no reference to psychosocial or structural barriers. 
Renedo et al (278) describe this internalised narrative of needing to ‘improve’, as young 
people echoing the discourse of the adults around them which young people use as a form 
of self-discipline. Paparini & Rhodes (258) contend that the acceptance of HIV as a 
normalised chronic illness has diminished consideration of the challenges and constraints to 
individual behaviours that can be brought by the different psychosocial contexts of living 
with HIV. This dictum about the ‘manageability of HIV’ has placed the responsibility of taking 
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medicines and engaging in care completely on the individual, making them morally 
responsible for poor health.(281) This is echoed in this study in instances when staff pointed 
out the costs of treatments and reminded one participant about their risk of death if they 
did not improve their adherence.  
6.6.4. Reflections, strengths and limitations of the focus group study 
All three groups had common aspects in their dynamics. Focus groups were conducted 
alongside an existing event or, as in the case of FGD2, at the same time as a regular support 
group. This meant that all the young people were in a safe space, they were with people they 
knew to some extent and, perhaps most importantly, they had already shared their HIV 
diagnosis by being in that space. 
However, differences about the three environments and pre-existing relationships could 
have affected the dynamics of the specific groups. FGD1 took place on a Friday and the young 
people had spent the week together as camp leaders in addition to previous training 
residential weekends together and existing friendships. One of the key benefits of this 
relationship - and the strengths it added to the data collection - was that the young people 
in this group elaborated more, and by their open discussion helped each other to elaborate. 
This was the case both when young people were agreeing about things and when they had 
opposite experiences. An example of interaction in the group is displayed when they discuss 
why people who are having problems taking their medication may not attend clinic.  
Can you think of some examples, from yourself or other people you know,  if you are 
having problems taking your medicines, why would that stop you going to clinic? 
(facilitator) 
Pressure to take your medication. (female, 21 years old, FGD1-P2) 
Who puts you under pressure? (facilitator) 
The nurses. (female, 21 years old, FGD1-P2) 
You don’t want to be judged if you are doing that. (female, 20 years old, FGD1-P3) 
Or told off. Doctors are sometimes like ‘You’re gonna die’ no one wants to be told 
they are going to die. (male, 20 years old, FGD1-P4) 
Yeah they are like threatening. (female, 20 years old, FGD1-P3) 
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Every single time. (female, 21 years old, FGD1-P2) 
Who has told you this? (female, 20 years old, FGD1-P5) 
The nurses are like, ‘If you don’t take your medication you’re are going to die the next 
time’. And you’re like, OK! (female, 21 years old, FGD1-P2) 
It’s never like the main doctor. It’s sometimes the one taking your bloods and you just 
sat there like, OK! (male, 20 years old, FGD1-P4)   
Mine are so lovely. (female, 20 years old, FGD1P5) 
This is a good example of how the story is built through the interaction between participants. 
When presenting different opinions, young people started differing accounts with phrases 
such as 'for me' or 'personally' which felt like a respectful way to offer an alternative 
experience. 
In FGD2, the young people all knew each other to some extent from attending the same 
support group. However, the interaction was different to FGD1. Young people seemed happy 
to share their personal experiences even if they differed to the other member, but instead 
of the conversations being interactive, the young people in this group took turns to speak 
and often waited for me to invite them to answer a question. This group had five members, 
and after answering two questions one member declined to speak for the rest of the session, 
so in fact there were only four young people interacting. Three of the members in this group 
were in their twenties and in their discussion of interactions with the group conveyed a lot 
of choice and autonomy in the management of their HIV that may have reflected their older 
age. They were also all receiving their HIV care in specialist adolescent clinics, which may 
have contributed to their involvement in decision-making.  
Participants in FGD3 were the youngest, and the group in which the participants seemed 
most reticent about offering their opinions. I tried to adapt the session as I went along, for 
example by repeating questions using comments young people had made, and using more 
spider grams and pictorial aids to try and stimulate conversation in a less direct way. In 
addition to this group being younger, the presence of three additional adults is likely to have 
had an effect on dynamics was. In my view, the unexpected presence of the voluntary worker 
may have been problematic for the participants of this focus group. In all of the focus groups 
I encouraged open discussion and reassured young people it would not be fed back to their 
parents/carers or NHS clinics. Having the voluntary sector worker in the room who knows 
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their parents/carers and the clinic they attend could potentially have undermined young 
people’s trust in the confidentiality of the session.  
Despite the difference between the interactions across the three focus groups, in this 
analysis I paid extreme attention to try to ensure data from all three groups shaped the 
findings as fairly as possible. 
One potential limitation of the study is that all participants were purposively selected from 
a group of young people already engaged in voluntary sector organisations, whose views are 
potentially not representative of those young people living with PHIV in the UK who are 
struggling with EIC even more. Although young people in two of the focus groups openly 
discussed periods where they had problems attending clinic or taking medication, they 
unlikely to represent the most disengaged young people in the population. In addition, the 
participants in the first group had been involved in the voluntary sector for a number of 
years, which is likely to have made them more aware of the issues discussed in the focus 
groups and more used to thinking critically about their health care. 
I am aware that reference to the broader social and structural challenges young people face 
managing their HIV on a day to day basis is missing from the focus group discussions. This is 
a gap noticeable against the literature on this group. It is possible that the emphasis of the 
focus groups on the topic of health care and clinic attendance precluded other kinds of 
discussions. It would be very interesting to find out more about what support young people 
are given from their families to attend clinic and to manage their HIV more generally. 
6.6.5. Concluding remarks 
In this chapter, I present the findings from focus groups with young people living with PHIV. 
In the focus groups, the findings from the quantitative analysis were presented to young 
people to see if they resonated with their experiences and to better contextualise the 
quantitative findings. Findings from the focus groups were presented in three parts: 
feedback on the use of proxy markers and the quantitative findings; and then from two 
themes that emerged from the data: self-management and shared decision-making.  
Young people in the focus groups reported that the results from the quantitative methods 
largely resonated with their experiences of attending clinic and engaging in care. However, 
findings from the focus group discussions revealed that young people’s experiences are 
much more nuanced than the quantitative findings can depict. Therefore, these findings 
extend the quantitative results and uncover issues not considered in the quantitative 
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analysis. In addition, these findings deepen the understanding of the tensions and 
ambiguities young people experience engaging in care. 
The findings from this focus group clearly highlighted the importance and benefit of including 
young people in health care research. Without the findings from the focus group, the range 
and dynamic nature of the different explanations for the individual predictors of EIC from 
the quantitative model would be lost. Crucially, what emerged from this work is the 
suggestion that attendance at clinic appointments for young people with PHIV does not 
necessarily equate to engagement in care. Similarly, participants’ active choice to not attend 
clinic visits suggests that there is more to non-attendance in clinic than being disengaged in 
care.   
There is an emerging body of work on young people’s experiences of adhering to HIV 
medications, but comparatively little on EIC. Further work with young people is required to 
broaden our understanding of EIC and how to improve it.  
 Key messages from this chapter 
• Participants largely agreed with the use of proxy markers in the quantitative analysis 
but highlighted visits that would be missed by using this method 
• Young people reported that the quantitative findings largely resonated with their 
experiences of EIC. However, discussions highlighted a much more nuanced and 
complex picture than suggested by the quantitative findings emphasising the 
importance of consulting young people on this work 
• Young people who reported clear communication with healthcare workers also 
reported more positive experiences of shared decision-making and better EIC 
• Communication about adherence from clinic staff was usually reactive when 
problems occurred and was in the form of being scolded and told off. Young people 
reported little acknowledgment of the wider context of managing their HIV 
treatment which can cause disengagement 
• For young people with PHIV, attendance in clinic did not necessarily equate to EIC, 
and nonattendance may not mean that young people were disengaged 
• If young people believe they will be scolded for missing ART doses, clinic can become 
a place of discipline that young people may choose to avoid, particularly when having 
problems with adherence.   
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Chapter 7. Discussion 
 Introduction 
Combined antiretroviral therapy has dramatically changed outcomes for people living with 
HIV, improving morbidity and mortality. For children and young people, this means they are 
surviving into adolescence and young adulthood. However, there are many familial, social 
and developmental complexities growing up with PHIV, which makes the required ongoing 
self-management of living with a stigmatised chronic condition complicated. These 
complexities are demonstrated by the poorer outcomes of young people living with PHIV 
compared to other age groups. EIC has been reported to be associated with improved patient 
outcomes and is thus increasingly becoming a focus of global and national targets as an 
important component to help improve outcomes for people living with HIV in the cART era. 
Studies mainly in adults living with HIV, have shown improved outcomes in people who are 
engaging in care. EIC is arguably especially important in young people with PHIV, who have 
worse outcomes compared to adults and are therefore particularly vulnerable. However, few 
studies have measured EIC in children and young people with PHIV in Europe, and none have 
looked at predictors of EIC which could be used to identify and support young people most 
at risk of disengagement. In this thesis, I developed a sensitive measure of EIC for young 
people with PHIV that could pick up changes in their health status and treatment. The 
resulting flowcharts were then applied to a dataset of young people in the AALPHI cohort 
study, and this dataset included both CHIPS national surveillance data as well as a wide range 
of other potential predictors of EIC. Finally, predictors of EIC which emerged from the 
quantitative analysis were explored in focus group discussions with young people living with 
PHIV to explore if they aligned with young people’s own experiences, and to gain a fuller 
understanding of the findings.  
In this discussion chapter, I summarise the key findings from each of my results chapters 
(chapters 3 to 6). I then offer some concluding remarks, which encompass a description of 
my findings’ relevance, the main strengths and limitations of my work and its generalisability, 
and finally I explore future possible uses for the EIC flowcharts and for improvements to EIC.  
 Summary of key findings 
In chapter 3, I adapted the Howarth et al algorithm which had measured EIC in adults, for 
use in young people with PHIV. Guidelines and clinical expertise were used to develop three 
267 
 
flowcharts that classified clinical management for this population. These flowcharts were 
then utilised to measure EIC in young people with PHIV in the AALPHI cohort. Across 3,585 
months of follow-up for the participants, 34% were months with a visit. At those visits, 61% 
of participants had an undetectable viral load (Flowchart A), 27% were on ART with a 
detectable viral load (Flowchart B) and 9% were off ART (Flowchart C). Using the flowcharts, 
participants were most frequently scheduled to have a follow-up appointment 4 months 
later. However, 37% of participants had at least one of their appointments scheduled in a 
month’s time, suggesting the changing health needs in these patients over the course of the 
year.  Overall EIC over the 12 month period of study was 87% person-months. 
European and Sub-Saharan African estimates of EIC range from 80-98%,(153–155,157–160) 
so my estimate of EIC falls in the middle of this range, and is in line with the upper end of 
estimates from the USA (56-99%).(123,161–168) Within chapter 3, I considered various 
limitations to both the development of the flowcharts and the available datasets (CHIPS and 
AALPHI). Two key limitations were that actual attended appointments were not reported in 
CHIPS, and therefore proxy visits were used for this analysis. In addition, all data in CHIPS 
measured clinical aspects of HIV management and therefore visits for psychological aspects 
of HIV care (which were also not available in AALPHI) were not captured in this analysis.  
In chapter 4, I describe how I compiled the exposures potentially related to EIC for the AALPHI 
cohort. A large number of exposures were available for consideration so these were grouped 
in “domains” of related factors. I then presented the potential exposures using descriptive 
statistics and compared my summary findings to other relevant studies and population data.  
This included comparison of a priori and HIV markers to PHIV in the wider CHIPS cohort, and 
comparison of other variables from the remaining domains (sociodemographic, risk 
behaviour practices, mental health, cognition and clinic) to HIV negative youth. Participants 
in the AALPHI cohort were broadly similar to CHIPS participants, except they had on average 
lower CD4 nadir counts, suggesting that AALPHI participants are broadly representative of 
the wider UK population of children living with PHIV. When compared to HIV negative young 
people, again AALPHI participants were broadly similar, but they were more likely to have 
experienced the death of one or both parents and had increased prevalence of mental health 
problems across the majority of the included measures. Young people with PHIV in my 
analyses also had lower cognition scores when compared to normative data. One of the main 
limitations highlighted in this chapter was the possibility of selection bias of the participants 
in the AALPHI cohort, who were recruited in NHS clinics and voluntary sector organisations. 
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Reassuringly, AALPHI participants were broadly similar to CHIPS participants, however, 
comparison was only on quite a crude level. At the end of this chapter I discussed in detail 
many potential biases that could have been introduced into my work, including potential 
measurement and data collection errors common to many cohort studies.   
In Chapter 5, I put together the exposure variables described in Chapter 4 and the flowcharts 
described in Chapter 3 to investigate predictors of EIC in the AALPHI cohort. Due to the large 
number of exposure variables included in this analysis, multiple stages of model building 
investigations were carried out to examine between-covariate associations to avoid 
introducing collinearity in the modelling stages. Then, four stages of multivariable logistic 
regression modelling were carried out (allowing for clustered data) to investigate predictors 
of EIC.  
Four factors were found to be associated with EIC in the primary stage 4 model, each from a 
different domain. Young people were less likely to be in care if they: were of Asian/mixed 
ethnicity compared to being of black or white ethnicity (a priori domain); reported having 
ever self-harmed compared to not (mental health domain); reported having not so good/bad 
adherence to ART or if they were not on ART compared to excellent/good adherence to ART 
(HIV experience and management domain); and had a viral load >50c/mL compared to 
≤50c/mL (clinical markers domain). In addition, four further exposure variables were found 
to be associated with worse EIC in sensitivity analyses: older age (a priori domain); speaking 
a language other than English at home compared to English or English and another language 
(sociodemographic domain); increased travel time to clinic and attending a paediatric clinic 
compared to an adolescent or adult/GUM clinic (both clinic domain). Older age was found to 
have an association with EIC in all three sensitivity analyses (one only marginally), which is in 
line with the literature which suggests EIC declines through older adolescence and early 
adulthood. Other studies also found similar associations between age,(151,161,162) viral 
load,(158) clinic type (possible proxy for clinic youth friendliness),(164) and travel time.(218) 
A number of studies also found an association between ethnicity and EIC although trends 
varied.(151,161,162) I found no other studies that identified self-harm, adherence or 
language spoken at home as predictors of EIC.   
I describe a number of limitations in Chapter 5. Despite the investigations, variables’ 
covariate associations may have been missed if I had placed exposure variables in the wrong 
domains. In addition, misclassification of the outcome, discussed in Chapter 3, had the 
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potential to cause dilution in the strength of effect or missed predictors. However, sensitivity 
analyses provided some reassurance due to the relative consistency of the findings.  
In Chapter 6, I used focus group discussions with young people living with HIV to explore the 
wider relevance and meaning of using of clinical markers for proxy visits (Chapter 3), and 
predictors of EIC (from the primary stage 4 model, Chapter 5). Three focus groups discussions 
were conducted with 16 young people aged 16-26 years. I facilitated all three focus groups 
and conducted them alongside existing voluntary sector events. Focus group discussion were 
recorded, transcribed and analysed using thematic analysis.  First, I explored with young 
people their reasons for clinic visits and regularity of tests and measurements, to analyse the 
strengths and limitations of using proxy markers in the flowcharts. Secondly, I presented the 
exposure variables found to be associated with EIC and discussed these with young people 
to elucidate if the predictors of EIC found in the quantitative analysis resonated with their 
experiences as patients. This helped me contextualise the overall findings and gain a deeper 
understanding of the nuances of the factors they face when engaging in HIV care.  
Findings were presented in three parts. Firstly, I described feedback on the use of proxy 
markers and the quantitative findings.  Then I presented two themes that emerged from the 
data, which were self-management and shared decision making. Young people reported that 
the quantitative findings were largely aligned with their experiences of EIC, however, 
discussion highlighted a much more nuanced and complex picture than suggested by the 
quantitative findings alone. Poor communication with health care providers left some young 
people feeling anxious due to subsequent negative assumptions they made about their 
health care status. Conversely, young people who reported clear communication with 
healthcare workers also reported more positive experiences of shared decision-making. 
Other young people described avoiding clinic appointments when they thought that their 
missed ART doses might be detected through viral load testing, and lead to in reproach from 
health care workers. I described a number of limitations in the chapter. The two main 
limitations were that ethnicity as a predictor of EIC was not discussed in the focus groups, 
resulting in less understanding of the context of this finding. In addition, all participants were 
purposively selected from pre-existing groups of young people already engaged in voluntary 
sector services, which might make their views unrepresentative of young people struggling 
with EIC. 




Table 7.1: Summary of the objectives, key findings and limitations from each of the results chapters 








• To develop a sensitive 
measure of EIC in 
order to take into 
account changes over 
time in treatment and 
health status for 
young people with 
perinatal HIV in 
England 
• To apply the measure 
to describe EIC in 
young people with 
perinatal HIV in 
England through 
quantitative analysis 
of the AALPHI cohort 
dataset 
• Development of a flexible new approach to measuring EIC 
that takes into account changing health status 
• Classifications are based on both clinical guidelines and 
clinician’s experience 
• 87% of 3,585 person months of follow-up across 306 
participants were engaged in care 
• Two thirds of clinic visits were in participants on ART with a 
viral load ≤50c/mL 
• Participants off ART accounted for led than 10% of months 
with a visit 
• Nearly half of appointments were categorised as requiring 
the next scheduled appointment after 4 months 
• Participants were most likely to attend their appointment 




• Flowcharts were complex and time consuming to develop and 
keep up-to-date 
• Time to next scheduled appointments may not be reflective of 
national practice 
• Use of clinical measures for proxy markers may not capture 
some appointments for other reasons (e.g. psychosocial issues) 
and may incorrectly classify other visits as actual clinic 
appointments (e.g. phlebotomy) 
• Less frequent monitoring of HIV markers may have resulted in 
missed visits 
• Leniency added into the model may have resulted in an 
underestimation of time out of care 
• The decision to drop patients and rows with no clinical data may 
have introduced selection bias 
• Missing data and data entry errors may have affected the 








• To describe the 
characteristics of 
AALPHI participants 
• To compare findings 
from analysis of 
AALPHI participants’ 
data to the national 





• Due to the breadth of the data collected in the AALPHI study, 
a large number of variables were available for consideration 
for inclusion in this analysis 
• Variables were justified for inclusion based on evidence 
form the literature or expert opinion 
• Participants in AALPHI were broadly similar to participants 
in CHIPS except AALPHI participants were more likely to be 
female than CHIPS participants, and have a lower CD4 nadir 
• AALPHI participants were also broadly similar to the UK 
population in many ways. Where they differed was that 
more young people in AALPHI had lost a parent and were in 
foster care or adopted. In addition, AALPHI participants had 
a lower cognitive score and had worse mental health than 
young people in the general population. 
• Risk of selection bias due to recruitment of AALPHI participants 
in the clinic and voluntary sector 
• Possible selection bias from specific young people not being 
referred by clinic staff to participants in AALPHI, for example 
young people with cognitive delay and newly diagnosed young 
people (due to AALPHI inclusion criteria) 
• A number of possible sources of measurement error could have 
been introduced by the use of self-completed questionnaires in 
the AALPHI interview, such as social desirability, recall bias and 
poorly phrased questions. In addition, there was a risk of poor 
execution of the protocol due to the multiple research nurses 
• Key exposure variables for EIC may not have been included in 
AALPHI 











• To investigate the 
relationship between 
a range of exposures 
and EIC in AALPHI 
participants, through 
quantitative analysis 
• Rigorous variable investigation was performed across eight 
domains 
• Four stages of modelling were carried out to identify 
predictors or EIC 
• In the primary stage 4 model, worse EIC was associated with 
Asian/mixed ethnicity, self-harm, not so good/bad 
adherence and viral load >50c/mL 
• Sensitivity analyses findings were similar to the primary 
stage 4 final model but also suggested there may be effects 
of age, travel time to clinic, language spoken at home and 
type of clinic attended. 
• Longitudinal outcome measures and baseline exposure 
variables many have been influenced by previous EIC 
• Between-covariate associations may have neem missed causing 
possible collinearity and model instability 
• Misclassification of the outcome variable may have caused 
dilution of effect or missed predictors of EIC 
• Choice of start date may also have caused dilution of effect or 
missed predictors of EIC 
• Poor selection of appropriate measurement tools in AALPHI 
could lead to an over or underestimation of EIC 
• Exclusion of patients with data not missing at random could 








• To explore the 
predictors of EIC 
discussed in Chapter 5 
through focus groups 
with young people in 
order to assess if they 
resonate with young 
people’s experiences 
and to enhance our 
understanding of the 
findings 
 
• Participants largely agreed with the use of proxy markers in 
the quantitative analysis but highlighted visits that would be 
missed by using this method 
• Young people reported that the quantitative findings largely 
resonated with their experiences of EIC. However, 
discussions highlighted a much more nuanced and complex 
picture than suggested by the quantitative findings 
emphasising the importance of consulting young people on 
this work 
• Young people who reported clear communication with 
healthcare workers who reported more positive experiences 
of shared decision-making and better EIC 
• Communication about adherence from clinic staff was 
usually reactive when problems occurred and was in the 
form of being scolded and told off. Young people reported 
little acknowledgment of the wider context of managing 
their HIV treatment which can cause disengagement 
• For young people with PHIV, attendance in clinic did not 
necessarily equate to EIC, and nonattendance may not mean 
that young people were disengaged 
• If young people believe they will be scolded for missing ART 
doses, clinic can become a place of discipline that young 
people may choose to avoid, particularly when having 
problems with adherence. 
• Ethnicity as a predictor was not discussed in the focus groups, 
resulting in less understanding of the context of this finding 
• All participants were purposively selected from pre-existing 
groups of young people already engaged in voluntary sector 
services and therefore may not be representative of young 
people struggling with EIC 
• Young people in the first focus group had been involved in the 
voluntary sector for a number of years and may be more used 
to critically thinking about health care than other young people. 
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 Concluding remarks 
The aim of this doctoral project was to describe engagement in HIV care in young people with 
PHIV in England and to assess whether psychosocial factors predicted EIC. In this thesis, I 
hypothesised that psychosocial issues were more important in influencing EIC than clinical 
aspects of living with HIV. To address whether my hypothesis may be correct, I will consider the 
four predictors of EIC from the primary stage four model of my analysis, which were ethnicity, 
self-harm, adherence and viral load, as well as age, which was identified in all three sensitivity 
analyses. Based on the quantitative findings alone, it could be assumed that only self-harm and 
adherence bear out the hypothesis. These variables were in mental health and HIV experience 
and management domains, while ethnicity and age were in the sociodemographic markers 
domain, and viral load in the HIV markers domain. 
However, findings from the focus groups give an insight into the psychosocial context of viral 
loads, with young people making decisions about whether or not to attend clinic based on their 
beliefs of what their viral load measurement may be; and the subsequent interaction they would 
have with clinic staff based on this. Likewise, for age, young people reported different 
experiences of the increasing responsibility and self-management of their HIV care that came 
with age and how this affected their EIC. In my analysis, young people of Asian/mixed ethnicity 
were less likely to be engaged in care. Unfortunately, ethnicity was not discussed in the focus 
groups, however, previous studies have highlighted how social contexts such as racism and 
medical distrust may account for disparities in EIC between people of different ethnicities.(161) 
However, these findings were not specific to young people of Asian or mixed ethnicity so may 
not be relevant for the findings from my analysis. I think it is therefore possible to argue that the 
hypothesis was broadly correct, even though some of the variables found to be associated with 
EIC fell in the sociodemographic and HIV markers domains.  
As discussed previously, the estimate of EIC from this study falls in the middle of the European 
estimates and at the higher end of estimates from the USA. Compared to the two other 
European studies from the UK and Italy, this study was the only one to focus on EIC (as opposed 
to the cascade of care,(155) and outcomes at transition (157)). Additionally, the Italian paper 
(157) did not define EIC and the UK study (155) required participants to have an appointment in 
the year prior to the analysis which is likely to explain the high proportion of young people found 
to be EIC.  
273 
 
Results from the Howarth et al (151) study, where the original algorithm to measure  EIC in 
adults in the UK was developed, are probably the most appropriate comparison. Howarth et al 
estimated EIC using surveillance data from the UK CHIC study, which included data from the 
largest clinics across the UK.(126) The estimate of EIC from this PhD analysis is similar to that 
found in the overall UK CHIC cohort (87% vs 84% respectively) but is substantially higher than 
the estimate in young people aged <25 years (77%). There is no stratification for perinatal 
acquisition in Howarth et al’s analysis, presumably because either the data were not available 
or the numbers too small. It is likely that young people in the <25 years age group were largely 
young people with BHIV, and studies have shown that this group are less likely to be engaged in 
care than young people with PHIV (161,168) which may account for the difference between the 
estimates. However, the other consideration is that young people in AALPHI were consented, 
and so were willing to be involved in the study, and they were also recruited from HIV clinics. 
When setting up the AALPHI study, consideration was given to how to recruit young people who 
may be less engaged in care or LTFU and was one of the key rationales for recruiting in the 
voluntary sector as well as HIV clinics. Inevitably, however, young people in AALPHI were likely 
to be a cohort of young people who have better EIC than the wider cohort of young people with 
PHIV in the UK. It is therefore plausible that my estimate of EIC is an overestimate due to the 
selection bias of this group. However, it is likely that the true number of young people engaged 
in care falls somewhere in between the estimate from this study and Howarth et al, and is 
reassuringly higher than many estimates from the USA where most of the studies in this field 
have been conducted to date.   
In many ways, the predictors of EIC found in this analysis are unsurprising because they point to 
the most vulnerable young people in this cohort. The findings from this analysis suggest a 
number of ways to potentially identify young people most at risk of future disengagement, such 
as through simple adherence, self-esteem or depression self-assessment (as a proxy for self-
harm) questionnaires. In addition, these identified predictors of EIC provide supporting evidence 
for future interventions to improve EIC in this group in the future. However, findings from my 
focus groups reveal greater nuance in factors underpinning decisions to engage in care and how 
engagement is a precursor for improved outcomes in subsequent steps of the cascade of care 
in young people living with PHIV. Findings from the focus groups, substantiated by the 
literature,(256) highlight how supportive clinic staff are key to making this engagement – 
outcome relationship work. A number of young people described a perceived lack of 
understanding from clinic staff about the difficulties of maintaining long-term ART adherence 
and clinic attendance, and reported being scolded if they had missed ART doses. These findings 
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suggest that in the post-cART era, improvements in outcomes in this complex group may be less 
about simply ensuring that young people attend clinic, but also about the communication that 
occurs once young people are in clinic, and the wider recognition of support required by young 
people in self-managing a stigmatised, complex, lifelong condition.     
7.3.1. Strengths and limitations 
The specific strengths of this thesis have been previously described in detail in each chapter and 
summarised in Table 7.1. Here I will discuss strengths and limitations that are relevant to the 
whole thesis. 
One of the major strengths of my approach is the definition used to measure EIC. The flowcharts 
allowed health care status of participants to be taken into account; I examined whether 
participants were attending clinic when they need to, based on their individual health care 
requirements as opposed generic predefined times or missed visits. The flowcharts highlight the 
heterogeneity of the young people in the AALPHI cohort and therefore the need for a sensitive 
measure of visit constancy in this cohort. In addition, my analysis benefited from measuring EIC 
longitudinally because it was possible to show how a cross sectional snapshot of time to next 
scheduled visit was quite different to the proportion of scheduled time to next visit 
classifications across the whole year. However, there was only one year of follow-up in my 
analysis, and this could be extended in future analyses.  
The second strength of my approach was in utilising the CHIPS and AALPHI datasets. Very few 
such comprehensive datasets exist globally, and access to these data allowed much broader 
examination of relevant factors that could potentially confound or predict EIC. Without access 
to these data, it would not have been possible to characterise EIC in this group in such detail.  
Finally, the use of mixed methods in my work has enhanced the understanding of the research. 
In general, the findings from the quantitative analysis were aligned with the experiences of the 
young people living with HIV who took part in the focus groups. Discussions highlighted a much 
more nuanced and complex picture than suggested by the quantitative findings, emphasising 
the importance of consulting young people on this work. While the quantitative results are 
generalisable and can be framed in context of the existing literature, the addition of the 
qualitative component provides a more complete picture of EIC and reminds us that this 
complex group are heterogeneous and have different experiences.  
There are some key limitations that need to be considered in addition to the strengths. Firstly, I 
did not have access to actual attended clinic visits for this analysis and therefore proxy clinic 
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visits were used based on clinical markers collected in clinic. The use of proxy markers is common 
in the EIC literature and nearly half of the papers in the literature review used this approach. 
Clinic visits for mental health support were also highlighted in all three focus groups as a reason 
young people attended clinic, and they were not captured in my measure.  
One of the main strengths of the flowchart approach, of taking individual health status factors 
into account, is also one of its main disadvantages. Monitoring and treatment guidelines are 
constantly evolving and therefore the flowcharts need regular updates. At the time of 
submitting this thesis, the flowcharts are already out of date because, for example, at the time 
of their development there was much less information about the use of integrase inhibitors in 
young people, and time to switch was treated the same as for NNRTIs rather than PIs as it is 
now.  
7.3.2. Generalisability 
I believe that my findings may be generalisable to other young people in living with HIV in the 
UK because young people in the AALPHI cohort were broadly similar in many characteristics to 
young people in the national CHIPS surveillance cohort. In addition, my findings may also be 
generalisable to other countries in Western Europe with patients of similar demographics (for 
example the Netherlands,(282) France,(283)). Generalisability with the USA may be more limited 
due to the very different health care and sociodemographic circumstances in that country. 
However, many of the issues highlighted in this analysis may be common across young people 
living with PHIV in high income countries and so results may be useful. Certainly, many of the 
explanations from the focus groups echo findings from other qualitative studies, especially 
around relationships between health care staff and young people, and the narratives around 
chronic disease management, suggestive of common patterns and experiences.  
In theory, the flowcharts used to measure EIC here could be extended for use in other high 
income countries. The main prerequisite for these flowcharts is that routine HIV monitoring is 
conducted at every clinic visit to allow the scheduling of the next appointment. Although the 
flowcharts would need updating for current guidelines and adapting to national practices, the 
paediatric guidelines on which they are based are the PENTA European treatment guidelines, 
and so for many European high income countries the adaptations required would be quite 
minor. The main limiting factor is the complexity of the flowcharts and the time that the 
underlying programming would take to revise and check. 
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7.3.3. Opportunities for future work 
There are a few important questions that could be investigated in future research. Firstly, from 
a methodological point of view, it would be interesting to measure engagement in care in this 
cohort using a simpler definition. The benefits of the flowcharts developed for this analysis are 
that they take an individual’s health status into account, but the downside is the complexity and 
time consuming nature of developing and adapting the measure. To justify continued use of this 
complex measure, one could produce comparative estimates of EIC in the same cohort using a 
simpler measure, to see if the findings correlate. A previous study compared three measures of 
EIC, gaps in care, visit constancy and a measure combining gaps in care and visit constancy. 
Moderate to strong correlation was found between visit constancy and gaps in care.(132) If high 
correlation was found between the flowchart and a subsequent simpler analysis, it might be 
hard to justify the additional time required to carry out this flowchart method. 
Another aspect of the flowcharts that could warrant further work is the classification of time to 
next scheduled appointment. This could be done by conducting an audit of patient notes to 
examine actual time between attended appointments and the clinical status at each 
appointment. This would need to be carried out in both a paediatric and adolescent or 
adult/GUM clinic. To address the issue of selection bias in the AALPHI study, it would also be 
interesting to apply the flowcharts to all young people aged ≥13 years of age in the CHIPS cohort 
to see how the prevalence of EIC compares. 
A possible use for the flowcharts could be to help gather evidence for HIV commissioning. NHS 
England commission all HIV services in the UK and are in the process of developing a national 
outpatient tariff system whereby all patients can be classified as new, stable or complex 
patients. Children and young people with HIV are yet to be classified and findings from this 
analysis, or from a similar analysis across the whole of the CHIPS cohort, could help classification 
in this cohort by measuring and capturing the complex and changing needs of this group. 
Finally, as already discussed, one of the key messages that came out of the focus groups was 
about the importance of effective, non-judgemental communication between young people and 
clinic staff. I had an initial meeting with a voluntary sector organisation about the possibility of 
creating a comprehensive resource for both young people and professionals to address these 
communication issues that arose in the focus groups. The voluntary sector organisation work 
closely with both professionals and young people living with HIV and so would be ideally placed 




The aim of this work was to develop a quantitative measure to estimate EIC in the AALPHI cohort. 
A wide range of predictors were investigated in a series of logistic regression models. The 
findings from the quantitative analysis were explored in focus groups discussions with young 
people with PHIV to see whether they resonated with young peoples’ own experiences of living 
with PHIV and to help enhance our understanding. Eighty seven per cent of young people were 
found to be engaged in care. Ethnicity, self-harm, adherence, viral load and age were all found 
to be associated with EIC. Focus groups discussions highlighted the much more nuanced and 
complex picture underlying these quantitative findings.  Results from both quantitative and 
qualitative aspects provide pointers to services about how they might improve engagement in 
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